Carmell Therapeutics (CTCX) S-1 7 Aug 23 IPO registration Financial data

Cover Page

Cover Page	3 Months Ended
	Mar. 31, 2023
Document Information [Line Items]
Document Type	S-1
Amendment Flag	false
Entity Registrant Name	CARMELL CORPORATION
Entity Central Index Key	0001842939
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	2403 Sidney Street
Entity Address, Address Line Two	Suite 300
Entity Address, City or Town	Pittsburgh
City Area Code	919
Local Phone Number	313-9633
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Address, State or Province	PA
Entity Tax Identification Number	86-1645738
Entity Primary SIC Number	0228
Business Contact [Member]
Document Information [Line Items]
Entity Address, Address Line One	2403 Sidney Street
Entity Address, Address Line Two	Suite 300
Entity Address, City or Town	Pittsburgh
Entity Address, Postal Zip Code	15203
City Area Code	919
Local Phone Number	313-9633
Entity Address, State or Province	PA
Contact Personnel Name	Randolph W. Hubbell

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash	$ 27,190	$ 128,149	$ 12,362
Prepaid expenses	7,243	55,069
Deferred offering cost	1,054,573	394,147	166,342
Other current assets	16,992	28,175
Total current assets	1,105,998	605,540	178,704
Property and equipment, net of accumulated depreciation	232,003	254,974	337,592
Operating lease right of use asset	823,520	859,331	1,007,589
Intangible assets, net of accumulated amortization	27,574	28,702	33,218
Total assets	2,189,095	1,748,547	1,557,103
Current liabilities:
Accounts payable	2,958,255	2,138,732	871,313
Accrued expenses and other liabilities	1,281,831	944,573	514,783
Accrued interest - related parties			226,170
Accrued interest - non-related parties	740,318	477,720	1,654,486
Promissory notes, net of debt discount of $5,409	369,591
Convertible notes payable - related parties, net of debt discount			900,000
Convertible notes payable, current, net of debt discount	2,777,778	2,777,778	7,703,432
Derivative liabilities	1,152,065	826,980	3,813,019
Lease liability, current	132,109	129,502	120,162
Total current liabilities	9,411,947	7,295,285	15,803,365
Long-term Liabilities:
Lease liability, net of current portion	793,708	827,728	961,908
Convertible notes payable, net of discount			922
Derivative liabilities			33,300
Total Long-term Liabilities		827,728	996,130
Total liabilities	10,205,655	8,123,013	16,799,495
Commitments and Contingencies
Shareholders' equity (deficit):
Common stock value	14,532	14,532	36,919
Additional paid-in capital	4,763,841	4,577,220	3,160,491
Accumulated deficit	(44,522,174)	(42,382,291)	(32,774,456)
Total shareholders' deficit	(39,743,801)	(37,790,539)	(29,577,046)
Total Liabilities and Shareholders' Deficit	2,189,095	1,748,547	1,557,103
Alpha Healthcare Acquisition Corp. III [Member]
Current assets:
Cash	16,133	187,664	774,192
Prepaid expenses	111,079	97,538	198,983
Total current assets	127,212	285,202	973,175
Marketable securities held in Trust Account	158,368,990	156,693,598	154,449,121
Total assets	158,496,202	156,978,800	155,422,296
Current liabilities:
Accrued interest - non-related parties	$ 1,817,299	1,258,337	215,247
Accrued offering costs		$ 0	$ 112,485
Other Liability, Noncurrent, Related Party, Type [Extensible Enumeration]	Related Party [Member]	Related Party [Member]	Related Party [Member]
Due to related party	$ 71,024	$ 31,979	$ 2,275
Income taxes payable	734,526	391,198	0
Total current liabilities	2,622,849	1,681,514	330,007
Long-term Liabilities:
Deferred underwriting fees payable	0	5,405,436	5,405,436
Total liabilities	2,622,849	7,086,950	5,735,443
Commitments and Contingencies
Shareholders' equity (deficit):
Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding	0	0	0
Additional paid-in capital		0	0
Accumulated deficit	(1,308,073)	(6,018,111)	(4,762,700)
Total shareholders' deficit	(1,307,641)	(6,017,679)	(4,762,268)
Total Liabilities and Shareholders' Deficit	158,496,202	156,978,800	155,422,296
Common Class A [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Mezzanine Equity
Class A common stock, $0.0001 par value; 100,000,000 shares authorized; 15,444,103 shares issued and outstanding subject to possible redemption	157,180,994	155,909,529	154,449,121
Shareholders' equity (deficit):
Common stock value	46	46	46
Common Class B [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Shareholders' equity (deficit):
Common stock value	386	386	386
Series C-1 Redeemable Convertible Preferred Stock [Member]
Mezzanine Equity
Redeemable Convertible Preferred stock	790,744	772,028
Series C-2 Redeemable Convertible Preferred Stock [Member]
Mezzanine Equity
Redeemable Convertible Preferred stock	16,121,643	15,904,275
Series B Redeemable Convertible Preferred Stock [Member]
Mezzanine Equity
Redeemable Convertible Preferred stock	7,025,434	7,025,434	6,928,245
Series A Redeemable Convertible Preferred Stock [Member]
Mezzanine Equity
Redeemable Convertible Preferred stock	$ 7,789,420	$ 7,714,336	$ 7,406,409

Condensed Consolidated Balan_2

Condensed Consolidated Balance Sheets (Parenthetical)	Mar. 31, 2023 USD ($) $ / shares shares
Common stock par or stated value per share | $ / shares	$ 0.001
Common stock shares authorized	240,000,000
Common stock shares issued	14,531,511
Common stock shares outstanding	14,531,511
Accumulated depreciation on property plant and equipment | $	$ 553,087
Finite lived intangible asset accumulated depreciation | $	43,172
Promissory Note [Member]
Unamortized debt discount current other than related parties | $	5,409
Nonrelated Party [Member] | Convertible Debt [Member]
Unamortized debt discount current other than related parties | $	$ 0
Alpha Healthcare Acquisition Corp. III [Member]
Preferred stock par or stated value per share | $ / shares	$ 0.0001
Preferred stock shares authorized	1,000,000
Preferred stock shares issued	0
Preferred stock shares outstanding	0
Common Class A [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Temporary Equity, Par or Stated Value Per Share | $ / shares	$ 0.0001
Temporary Equity, Shares Authorized	100,000,000
Temporary Equity, Shares Issued	15,444,103
Temporary Equity, Shares Outstanding	15,444,103
Common stock par or stated value per share | $ / shares	$ 0.0001
Common stock shares authorized	100,000,000
Common stock shares issued	463,882
Common stock shares outstanding	463,882
Common Class B [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Common stock par or stated value per share | $ / shares	$ 0.0001
Common stock shares authorized	10,000,000
Common stock shares issued	3,861,026
Common stock shares outstanding	3,861,026
Series C-1 Redeemable Convertible Preferred Stock [Member]
Temporary Equity, Shares Authorized	41,000,000
Temporary Equity, Shares Issued	5,090,693
Temporary Equity, Shares Outstanding	5,090,693
Series C-2 Redeemable Convertible Preferred Stock [Member]
Temporary Equity, Shares Authorized	75,500,000
Temporary Equity, Shares Issued	73,560,390
Temporary Equity, Shares Outstanding	73,560,390
Series B Redeemable Convertible Preferred Stock [Member]
Temporary Equity, Shares Authorized	34,622,470
Temporary Equity, Shares Issued	33,801,226
Temporary Equity, Shares Outstanding	33,801,226
Series A Redeemable Convertible Preferred Stock [Member]
Temporary Equity, Shares Authorized	19,968,051
Temporary Equity, Shares Issued	19,968,051
Temporary Equity, Shares Outstanding	19,968,051

Condensed Consolidated Stateme

Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended		11 Months Ended	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2022
Operating expenses:
Research and development	$ 740,325	$ 464,911		$ 2,196,063
General and administrative expenses	510,445	462,432		3,217,280
Depreciation and amortization	24,101	23,414		94,298
Total operating expenses	1,274,871	950,757		5,507,641
Loss from operations	(1,274,871)	(950,757)		(5,507,641)
Other income (expense):
Gain on the forgiveness of loans payable				0
Other income	34,541	10,822		10,922
Change in fair value of derivative liabilities	(325,085)	337,497		1,259,287
Interest expense	(262,597)	(236,200)		(555,556)
Loss on debt extinguishment				(1,064,692)
Interest expense, related party	0	(17,753)		(52,471)
Interest expense, non-related party				(1,652,498)
Amortization of debt discount	(703)	(619,622)		(2,044,241)
Total other expense	(553,844)	(507,503)		(3,543,693)
Provision for income taxes	0	0		0
Income (Loss) before income taxes	(1,828,715)	(1,458,260)		(9,051,334)
Net Income (Loss)	(1,828,715)	(1,458,260)		(9,051,334)
Dividends on Series A, Series C-1, and C-2 preferred stock	(311,168)	(76,981)		(556,501)
Net loss attributable to common stockholders	$ (2,139,883)	$ (1,535,241)		$ (9,607,835)
Weighted average shares outstanding , Basic	18,303,103	40,096,825		28,546,036
Weighted average shares outstanding , Diluted	18,303,103	40,096,825		28,546,036
Basic net income (loss) per share	$ (0.12)	$ (0.04)		$ (0.34)
Diluted net income (loss) per share	$ (0.12)	$ (0.04)		$ (0.34)
Alpha Healthcare Acquisition Corp. III [Member]
Operating expenses:
General and administrative expenses	$ 756,466	$ 535,142	$ 467,431	$ 1,651,483
Loss from operations	(756,466)	(535,142)	(467,431)	(1,651,483)
Other income (expense):
Dividend and interest income	1,675,861	7,612	8,091	2,247,678
Change in fair value of overallotment liability			2,923	0
Gain on expiration of overallotment option			127,035	0
Provision for income taxes	(343,328)	0	0	(391,198)
Income (Loss) before income taxes	919,395	(527,530)	(329,382)	596,195
Net Income (Loss)	$ 576,067	$ (527,530)	(329,382)	204,997
Common Class A [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Other income (expense):
Net Income (Loss)			$ (6,286)	$ 4,809
Weighted average shares outstanding of Class A common stock subject to possible redemption	15,444,103	15,444,103	6,973,122	15,444,103
Weighted average shares outstanding , Basic	463,882	463,882	209,549	463,882
Weighted average shares outstanding , Diluted	463,882	463,882	209,549	463,882
Basic net income (loss) per share	$ 0.03	$ (0.03)	$ (0.03)	$ 0.01
Diluted net income (loss) per share	$ 0.03	$ (0.03)	$ (0.03)	$ 0.01
Common Class B [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Other income (expense):
Net Income (Loss)			$ (113,920)	$ 40,037
Weighted average shares outstanding , Basic	3,861,026	3,861,026	3,797,628	3,861,026
Weighted average shares outstanding , Diluted	3,861,026	3,861,026	3,797,628	3,861,026
Basic net income (loss) per share	$ 0.03	$ (0.03)	$ (0.03)	$ 0.01
Diluted net income (loss) per share	0.03	(0.03)	(0.03)	0.01
Class A Common Stock Subject To Possible Redemption [Member]
Other income (expense):
Basic net income (loss) per share	0.03	(0.03)	(0.03)	0.01
Diluted net income (loss) per share	$ 0.03	$ (0.03)	$ (0.03)	$ 0.01
Class A Common Stock Subject To Possible Redemption [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Other income (expense):
Net Income (Loss)	$ 450,040	$ (412,121)	$ (209,176)	$ 160,151
Weighted average shares outstanding , Basic	15,444,103	15,144,103	6,973,122	15,444,103
Weighted average shares outstanding , Diluted	15,444,103	15,144,103	6,973,122	15,444,103
Basic net income (loss) per share	$ 0.03	$ (0.03)	$ (0.03)	$ 0.01
Diluted net income (loss) per share	$ 0.03	$ (0.03)	$ (0.03)	$ 0.01

Condensed Consolidated Statemen

Condensed Consolidated Statements of Shareholders' Equity (Deficit) - USD ($)	Total	Alpha Healthcare Acquisition Corp. III [Member]	Revision of Prior Period, Adjustment [Member]	Public Warrants [Member] Alpha Healthcare Acquisition Corp. III [Member]	Private Placement [Member] Alpha Healthcare Acquisition Corp. III [Member]	Common Stock [Member]	Common Stock [Member] Revision of Prior Period, Adjustment [Member]	Treasury Stock [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member] Alpha Healthcare Acquisition Corp. III [Member]	Additional Paid-in Capital [Member] Revision of Prior Period, Adjustment [Member]	Additional Paid-in Capital [Member] Public Warrants [Member] Alpha Healthcare Acquisition Corp. III [Member]	Additional Paid-in Capital [Member] Private Placement [Member] Alpha Healthcare Acquisition Corp. III [Member]	Accumulated Deficit [Member]	Accumulated Deficit [Member] Alpha Healthcare Acquisition Corp. III [Member]	Accumulated Deficit [Member] Revision of Prior Period, Adjustment [Member]	Class A Common Stock Subject To Possible Redemption [Member] Alpha Healthcare Acquisition Corp. III [Member]	Class A Common Stock Subject To Possible Redemption [Member] Common Stock [Member] Alpha Healthcare Acquisition Corp. III [Member]	Common Class A [Member] Alpha Healthcare Acquisition Corp. III [Member]	Common Class A [Member] Common Stock [Member] Alpha Healthcare Acquisition Corp. III [Member]	Common Class A [Member] Common Stock [Member] Private Placement [Member] Alpha Healthcare Acquisition Corp. III [Member]	Common Class B [Member] Alpha Healthcare Acquisition Corp. III [Member]	Common Class B [Member] Common Stock [Member] Alpha Healthcare Acquisition Corp. III [Member]	Series A Preferred Stock [Member]	Series A Preferred Stock [Member] Accumulated Deficit [Member]	Series C1 Preferred Stock [Member]	Series C1 Preferred Stock [Member] Additional Paid-in Capital [Member]	Series C1 Preferred Stock [Member] Accumulated Deficit [Member]	Series C 2 Preferred Stock [Member]	Series C 2 Preferred Stock [Member] Accumulated Deficit [Member]
Beginning Balance at Dec. 31, 2020	$ (23,288,229)		$ (23,274,351)			$ 2,922	$ 2,922		$ 2,539,486		$ 2,710,333			$ (25,830,637)		$ (25,987,606)
Beginning Balance (in Shares) at Dec. 31, 2020						2,922,284	2,922,284
Correction of accumulated error (Note 3)	13,878								170,847					(156,969)
Class B common stock issued to Sponsor	3,194					$ 31,940			(28,746)
Class B common stock issued to Sponsor (in Shares)						31,940,355
Issuance of private placement units (Value)	3,194					$ 31,940			(28,746)
Issuance of private placement units (Shares)						31,940,355
Stock-based compensation expense	246,799								246,799
Net Income (loss)	(6,478,923)													(6,478,923)
Temporary Equity, Accretion of Dividends																								$ (307,927)	$ (307,927)
Exercise of stock options	234,162					$ 2,057			232,105
Exercise of stock options (Shares)						2,056,243
Ending Balance at Dec. 31, 2021	(29,577,046)	$ (4,762,268)				$ 36,919			3,160,491	$ 0				(32,774,456)	$ (4,762,700)			$ 154,449,121		$ 46			$ 386
Ending Balance (in Shares) at Dec. 31, 2021						36,918,882												15,444,103		463,882			3,861,026
Beginning Balance at Jan. 20, 2021		0								0								$ 0		$ 0			$ 0
Beginning Balance (in Shares) at Jan. 20, 2021																		0		0			0
Class B common stock issued to Sponsor		25,000								24,569													$ 431
Class B common stock issued to Sponsor (in Shares)																							4,312,500
Issuance of private placement units (Value)					$ 4,638,820								$ 4,638,774								$ 46
Issuance of private placement units (Shares)																					463,882
Issuance of Class A Common stock, net of issuance costs of $9,905,857 (Value)																		$ 140,738,518
Issuance of Class A Common stock, net of issuance costs of $9,905,857 (Shares)																		15,444,103
Issuance of Warrants				$ 3,399,132								$ 3,399,132
Stock-based compensation expense		1,186,448								1,186,448
Fair value of underwriter's overallotment options exercised		28,317								28,317
Accretion to redemption value of Class A Common stock subject to possible redemption		$ (13,702,512)								(9,277,240)					(4,425,272)			$ 13,702,512
Forfeiture of Founder Shares related to unexercised portion of underwriter's overallotment option (Value)															45								$ (45)
Forfeiture of Founder Shares related to unexercised portion of underwriter's overallotment option (Shares)		451,474																				451,474	(451,474)
Change in redemption value of Class A Common stock subject to possible redemption due to dividend and interest income earned		$ (8,091)													(8,091)			8,091
Net Income (loss)		(329,382)													(329,382)		$ (209,176)		$ (6,286)			$ (113,920)
Ending Balance at Dec. 31, 2021	(29,577,046)	(4,762,268)				$ 36,919			3,160,491	0				(32,774,456)	(4,762,700)			$ 154,449,121		$ 46			$ 386
Ending Balance (in Shares) at Dec. 31, 2021						36,918,882												15,444,103		463,882			3,861,026
Class B common stock issued to Sponsor	26,477					$ 204			26,273
Class B common stock issued to Sponsor (in Shares)						203,666
Issuance of Warrants	409,483								409,483
Stock-based compensation expense	172,183								172,183
Accretion to redemption value of Class A Common stock subject to possible redemption		(7,612)													(7,612)			$ 7,612
Net Income (loss)	(1,458,260)	(527,530)												(1,458,260)	(527,530)		(412,121)			$ (12,379)			$ (103,030)
Temporary Equity, Accretion of Dividends																								(76,981)	(76,981)
Ending Balance at Mar. 31, 2022	(30,504,144)	(5,297,410)				$ 37,123			3,768,430					(34,309,697)	(5,297,842)			$ 154,456,733		$ 46			$ 386
Ending Balance (in Shares) at Mar. 31, 2022						37,122,548												15,144,103		463,882			3,861,026
Beginning Balance at Dec. 31, 2021	(29,577,046)	(4,762,268)				$ 36,919			3,160,491	0				(32,774,456)	(4,762,700)			$ 154,449,121		$ 46			$ 386
Beginning Balance (in Shares) at Dec. 31, 2021						36,918,882												15,444,103		463,882			3,861,026
Class B common stock issued to Sponsor	26,477					$ 204			26,273
Class B common stock issued to Sponsor (in Shares)						203,666																25,000
Issuance of Warrants	409,483								409,483																	$ 312,088	$ 312,088
Stock-based compensation expense	609,891								609,891
Change in redemption value of Class A Common stock subject to possible redemption due to dividend and interest income earned		(1,460,408)													(1,460,408)			$ 1,460,408
Net Income (loss)	(9,051,334)	204,997												(9,051,334)	204,997		160,151		$ 4,809			$ 40,037
Temporary Equity, Accretion of Dividends																								(307,927)	(307,927)	(9,470)		$ (9,470)	$ (239,104)	$ (239,104)
Exercise of stock options	$ 1,271					$ 9			1,262
Exercise of stock options (Shares)	9,075					9,075
Exercise of common stock purchase warrants	$ 37,426					$ 340			37,086
Exercise of common stock purchase warrants (in Shares)						340,243
Repurchase of common stock	(2,294)							$ (2,294)
Cancellation of common stock						$ (22,940)		$ 2,294	20,646
Repurchase of common stock (in Shares)								(22,940,355)
Cancellation of common stock (in Shares)						(22,940,355)		22,940,355
Ending Balance at Dec. 31, 2022	(37,790,539)	(6,017,679)				$ 14,532			4,577,220	$ 0				(42,382,291)	(6,018,111)			$ 155,909,529		$ 46			$ 386
Ending Balance (in Shares) at Dec. 31, 2022						14,531,511												15,444,103		463,882			3,861,026
Issuance of Warrants	6,112								6,112
Stock-based compensation expense	180,509								180,509
Deferred underwriting fees waiver		5,405,436													5,405,436
Change in redemption value of Class A Common stock subject to possible redemption due to dividend and interest income earned		(1,271,465)													(1,271,465)			$ 1,271,465
Net Income (loss)	(1,828,715)	576,067												(1,828,715)	576,067		$ 450,040			$ 13,517			$ 112,510
Temporary Equity, Accretion of Dividends																								$ (75,084)	$ (75,084)	$ (18,716)		$ (18,716)	$ (217,368)	$ (217,368)
Ending Balance at Mar. 31, 2023	$ (39,743,801)	$ (1,307,641)				$ 14,532			$ 4,763,841					$ (44,522,174)	$ (1,308,073)			$ 157,180,994		$ 46			$ 386
Ending Balance (in Shares) at Mar. 31, 2023						14,531,511												15,444,103		463,882			3,861,026

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Shareholders' Equity (Deficit) (Parenthetical)	11 Months Ended
	Dec. 31, 2021 USD ($) shares
Common stock shares outstanding	36,918,882
Alpha Healthcare Acquisition Corp. III [Member]
Shares Issued Share Based Payment Arrangement Shares Forfeited	451,474
Public Warrants [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Issuance costs of warrants | $	$ 239,247
Common Class A [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Temporary equity stock issuance costs | $	$ 9,905,857
Common Class B [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Common stock shares outstanding	4,312,500
Shares Issued Share Based Payment Arrangement Shares Forfeited	451,474
Over-Allotment Option [Member] | Common Class B [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Common Stock Shares Subject To Forfeiture	562,500

Condensed Consolidated State_2

Condensed Consolidated Statement of Cash Flows - USD ($)	3 Months Ended		11 Months Ended	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Cash Flows from Operating Activities:
Net income (loss)	$ (1,828,715)	$ (1,458,260)		$ (9,051,334)	$ (6,478,923)
Adjustments to reconcile net income (loss) to net cash used in operating activities
Gain on forgiveness of loans payable				0	(438,180)
Depreciation and Amortization	24,099	23,415		94,298	94,162
Amortization of debt discount	703	619,622		2,044,241	1,783,597
Amortization of ROU assets	35,811	40,711		148,258	147,962
Change in fair value of derivative liabilities	325,085	(337,497)		(1,259,287)	2,515,065
Loss on debt extinguishment				1,064,692	0
Stock-based compensation	180,509	185,421		636,368	246,799
Interest expense recognized on default	262,597	236,200		555,556
Changes in current assets and liabilities:
Prepaid expenses	47,826	(72,555)		(55,069)	9,418
Other current assets	11,183	(5,000)		(28,175)	500
Accounts payable	159,097	(768,539)		1,059,946	80,320
Accrued expenses and other liabilities	337,258	10,129		429,790	262,097
Lease liability	(31,413)	(34,268)		(124,840)	(115,132)
Accrued interest - related parties	0	17,753		52,471	72,000
Accrued interest - non-related parties	262,598	181,410		1,004,378	643,486
Net cash used in operating activities	(475,959)	(1,597,658)		(3,428,707)	(1,176,829)
Cash Flows from Investing Activities:
Purchase of property and equipment	0	(3,579)		(7,164)	(7,273)
Net cash used in investing activities	0	(3,579)		(7,164)	(7,273)
Cash Flows from Financing Activities:
Payment of offering costs				(20,332)	(166,342)
Proceeds from convertible notes	0	2,612,514		2,745,974	906,839
Proceeds from promissory notes	375,000	0
Proceeds from PPP loan					217,460
Proceeds from issuance of Series C-1 preferred stock				1,064,317
Repurchase of common stock				(2,294)
Payment of debt financing fee	0	(382,222)		(382,222)
Proceeds from issuance of common stock					3,194
Proceeds from warrant exercise				144,944
Proceeds from Stock Options Exercised				1,271	234,163
Net cash (used in) provided by financing activities	375,000	2,230,292		3,551,658	1,195,314
Net Change in Cash	(100,959)	629,055		115,787	11,212
Cash – beginning of period	128,149	12,362		12,362	1,150
Cash—end of period	27,190	641,417	$ 12,362	128,149	12,362
Supplemental Disclosure of cash flow information:
Conversion of convertible notes and accrued interest to series C-2 prefered stock				15,665,171
Warrants issued in connection with convertible notes	6,112	409,483		409,483
Warrants issued in connection with Series C-1 preferred stock				312,088
Accrued Series A preferred stock dividends	75,084	76,981		307,926	307,927
Accrued Series C-1 preferred stock dividends	18,716	0		9,470
Accrued Series C-2 preferred stock dividends	217,368	0		239,104
Initial recognition of derivative liabilities	0	1,267,860		1,321,860	258,359
Unpaid deferred offering costs	660,426	732,046		207,473
Prepaid expense from shares for services	0	13,237
Supplemental Cash Flow Information [Abstract]
Interest paid	0	37,037		92,593	0
Income tax paid	0	0		0	0
Alpha Healthcare Acquisition Corp. III [Member]
Cash Flows from Operating Activities:
Net income (loss)	576,067	(527,530)	(329,382)	204,997
Adjustments to reconcile net income (loss) to net cash used in operating activities
Interest earned in Trust Account	(1,675,392)	(7,612)	(8,091)	(2,244,477)
Change in fair value of overallotment liability			(2,923)	0
Gain on expiration of overallotment option			(127,035)	0
Changes in current assets and liabilities:
Prepaid expenses	(13,541)	37,637	(198,983)	101,445
Accrued expenses	558,962	346,993	215,247	1,028,390
Due to related party	39,045	(1,162)	0	29,704
Income taxes payable	343,328	0
Net cash used in operating activities	(171,531)	(151,674)	(451,167)	(488,743)
Cash Flows from Investing Activities:
Investment of cash into Trust Account			(154,441,030)	0
Cash Flows from Financing Activities:
Proceeds from related party			56,922	0
Payment to related party			(54,647)	0
Proceeds from issuance of Public Units			154,441,030	0
Proceeds from issuance of Private Units			4,638,820	0
Payment of offering costs	0	(27,785)	(3,415,736)	(97,785)
Net cash (used in) provided by financing activities			155,666,389	(97,785)
Net Change in Cash	(171,531)	(179,459)	774,192	(586,528)
Cash – beginning of period	187,664	774,192	0	774,192
Cash—end of period	16,133	594,733	774,192	187,664	774,192
Supplemental Disclosure of cash flow information:
Offering costs paid by Sponsor in exchange for issuance of Class B common stock			25,000	0
Capital contribution by the Sponsor through transfer of Class B shares			1,186,448	0
Offering costs included in accrued offering costs	0	84,700	112,485	0
Deferred underwriting commissions			5,405,436	0
Accretion of the interest earned in Trust Account	1,271,465	7,612	$ 8,091	$ 1,460,408	$ 8,091
Deferred underwriting fees waiver	$ 5,405,436	$ 0

Nature of the Organization and

Nature of the Organization and Business	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Nature of the Organization and Business	NOTE 1 — NATURE OF THE ORGANIZATION AND BUSINESS Carmell Therapeutics Corporation (“Carmell” or the “Company”) was incorporated in the State of Delaware in November 2008. With operations in Pittsburgh, Pennsylvania, its mission is to expand and commercialize technology developed jointly at Carnegie Mellon University and Allegheny General Hospital. The proprietary technology enables the manufacture of biologically active plastics from blood plasma for treating injuries to bone and soft tissue and to promote the growth of hair and the production of collagen. These plastics are sterile, off-the-shelf, The Company is focused on products designed to enhance and accelerate healing and produce better clinical outcomes in orthopedic trauma, dental bone graft substitutes, advance wound care and aesthetic medicine. The Company is currently conducting research and development activities to operationalize certain patented technology that the Company owns and licenses. The Company is in the process of initiating and assessing regulatory efforts and pathways in Europe and the United States. Risks and Uncertainties Management continues to evaluate the impact of the COVID-19 The current challenging economic climate may lead to adverse changes in cash flows, working capital levels and/or debt balances, which may also have a direct impact on the Company’s future operating results and financial position. The ultimate duration and magnitude of the impact and the efficacy of government interventions on the economy a n	NOTE 1 — NATURE OF THE ORGANIZATION AND BUSINESS Carmell Therapeutics Corporation (“Carmell” or the “Company”) was incorporated in the State of Delaware in November 2008. With operations in Pittsburgh, Pennsylvania, its mission is to expand and commercialize technology developed jointly at Carnegie Mellon University and Allegheny General Hospital. The proprietary technology enables the manufacture of biologically active plastics from blood plasma for treating injuries to bone and soft tissue and to promote the growth of hair and the production of collagen. These plastics are sterile, off-the-shelf, The Company is focused on products designed to enhance and accelerate healing and produce better clinical outcomes in orthopedic trauma, dental bone graft substitutes, advance wound care and aesthetic medicine. The Company is currently conducting research and development activities to operationalize certain patented technology that the Company owns and licenses. The Company is in the process of initiating and assessing regulatory efforts and pathways in Europe and the United States. Risks and Uncertainties Management continues to evaluate the impact of the COVID-19 The current challenging economic climate may lead to adverse changes in cash flows, working capital levels and/or debt balances, which may also have a direct impact on the Company’s future operating results and financial position. The ultimate duration and magnitude of the impact and the efficacy of government interventions on the economy and the financial effect on the Company is not known at this time. The extent of such impact will depend on future developments, which are highly uncertain and not in the Company’s control.
Alpha Healthcare Acquisition Corp. III [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Nature of the Organization and Business	Note 1 — Organization and Business Operations Alpha Healthcare Acquisition Corp. III (the “Company”) is a blank check company incorporated as a Delaware corporation and formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses that the Company has not yet identified (“Business Combination”). On January 4, 2023, the Company entered into a business combination agreement (the “Business Combination Agreement”) with Candy Merger Sub, Inc., a Delaware corporation (“Merger Sub”), and Carmell Therapeutics Corporation, a Delaware corporation (“Carmell”). The Company has selected December 31 as its fiscal year end. As of March 31, 2023, the Company has not yet commenced any operations. All activity from January 21, 2021 (inception) through March 31, 2023 relates to the Company’s formation, the IPO (as defined below), and activities necessary to identify a potential target and prepare for a Business Combination. Since our IPO, we have not generated any operating revenues, and do not expect to generate any operating revenues, until at least after completion of our initial Business Combination, if at all. The registration statement for the Company’s initial public offering (the “IPO”) was declared effective on July 26, 2021. On July 29, 2021 (“IPO Date”), the Company consummated the IPO of 15,000,000 units (the “Public Units” and, with respect to the shares of Class A common stock included in the Units sold, the “Public Shares”), at $10.00 per Public Unit, generating gross proceeds of $150,000,000, which is described in Note 3. In connection with the IPO, the Company also granted the underwriters a 45-day Simultaneously with the closing of the IPO, the Company consummated the sale of 455,000 units (each, a “Private Placement Unit” and, collectively, the “Private Placement Units”) at a price of $10.00 per Private Placement Unit in a private placement to AHAC Sponsor III LLC (the “Sponsor”), generating gross proceeds of $4,550,000, which is described in Note 4. Each Private Placement Unit contains one share of Class A common stock (the “Private Placement Share”) and one fourth of one warrant (one whole warrant, a “Private Placement Warrant”). At the IPO Date, transaction costs amounted to $3,461,151, consisting of $3,000,000 of underwriting fees and $461,151 of other offering costs. The Company also accrued underwriting fees of $5,250,000 that will be paid only if a Business Combination is entered into. In addition, cash of $1,550,000 was held outside of the Trust Account (as defined below) and was available for the payment of offering costs and for working capital purposes. At the IPO Date, the Sponsor also transferred to certain investors a total of 225,000 of Founders shares (Note 4) (“Non-Risk Non-Risk At the IPO Date, the Sponsor also transferred to certain other investors the total of 600,900 of Founders shares (“Risk Incentive Private Shares”) as a compensation for their commitment to acquire at least 9.9% of the Public Units sold in the IPO. These Risk Incentive Private Shares are subject to forfeiture if the investors sell their Public Units prior to the closing of the initial Business Combination. The fair value of these Risk Incentive Private Shares is equal to the fair value of the Non-Risk On August 3, 2021, the Underwriters partially exercised their overallotment option and purchased 444,103 additional Public Units for a total amount of $4,441,030 resulting from the partial over-allotment exercise. The Company also issued 8,882 Private Placement Units, generating additional $88,820 in gross proceeds. Transaction costs related to the Underwriters’ partial over-allotment exercise amounted to $92,070, consisting of $88,820 of underwriting fees and $3,250 of other offering costs. The Company has also accrued additional underwriting fees of $155,436 that will be paid only if a business combination is entered into. The total issuance costs of $ were allocated to the Class A common shares subject to possible redemption and the Public Warrants based on their relative fair values with $ to the Class A shares subject to possible redemption and $ to the Public Warrants. Following the closing of the IPO on July 29, 2021, an amount of $154,441,030 ($10.00 per Public Unit) from the net proceeds of the sale of the Public Units in the IPO, including the Public Units sold upon the exercise of the over-allotment option, and the sale of the Private Placement Units was placed in a trust account (the “Trust Account”), invested in U.S. government securities, within the meaning set forth in Section 2(a) (16) of the Investment Company Act, with a maturity of 185 days or less, or in any open-ended investment company that holds itself out as a money market fund meeting the conditions of Rule 2a-7 pre-initial The Company’s management has broad discretion with respect to the specific application of the net proceeds of the Public Offering, although substantially all of the net proceeds are intended to be generally applied toward consummating a Business Combination. The Company’s Business Combination must be with one or more target businesses that together have an aggregate fair market value of at least 80% of the assets held in the Trust Account (as defined below) (excluding the amount of deferred underwriting discounts held in trust and taxes payable on the interest earned on the Trust Account) at the time of the signing an agreement to enter into a Business Combination. However, the Company will only complete an initial Business Combination if the post-business combination company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act. There is no assurance that the Company will be able to successfully effect a Business Combination. The Company will provide its public shareholders with the opportunity to redeem all or a portion of their public shares upon the completion of the initial Business Combination either (i) in connection with a shareholder meeting called to approve the initial Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a proposed initial Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The shareholders will be entitled to redeem their shares at a per-share The Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 either immediately prior to or upon consummation of a Business Combination and, if the Company seeks shareholder approval, a majority of the issued and outstanding shares voted are voted in favor of the Business Combination. If the Company is unable to complete a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up; (ii) as promptly as reasonably possible, but not more than ten business days thereafter, redeem the public shares, at a per-share The Sponsor has agreed (i) to waive its redemption rights with respect to any Founder Shares, Private Placement Shares and public shares held by it in connection with the completion of the initial Business Combination, (ii) to waive its rights to liquidating distributions from the Trust Account with respect to any Founder Shares or Private Placement Shares held by it if the Company fails to complete its Business Combination within the Combination Period, although the Sponsor will be entitled to liquidating distributions from the Trust Account with respect to any public shares it holds if the Company fails to complete its Business Combination within such time period, (iii) not to propose any amendment to the Company’s amended and restated certificate of incorporation that would modify the substance or timing of its obligation to redeem 100% of the public shares if the Company does not complete its initial Business Combination within the Combination Period or with respect to any other material provisions relating to shareholders’ rights or pre-initial The Company’s Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a vendor for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amounts in the Trust Account to below the lesser of (i) $10.00 per public share and (ii) the actual amount per public share held in the Trust Account as of the date of the liquidation of the Trust Account if less than $10.00 per share due to reductions in the value of the trust assets, in each case less taxes payable, provided that such liability will not apply to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account nor will it apply to any claims under the Company’s indemnity of the underwriters of the Public Offering against certain liabilities, including liabilities under the Securities Act. In the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. However, the Company has not asked the Sponsor to reserve for such indemnification obligations, nor has it independently verified whether the Sponsor has sufficient funds to satisfy its indemnity obligations and the Company believes that the Sponsor’s only assets are securities of the Company. Therefore, the Company cannot assure you that the Sponsor would be able to satisfy those obligations. None of the Company’s officers or directors will indemnify the Company for claims by third parties including, without limitation, claims by vendors and prospective target businesses. Business Combination Agreement—Proposed Business Combination with Carmell Therapeutics Corporation On January 4, 2023, the Company entered into the Business Combination Agreement with Merger Sub and Carmell. The Business Combination Agreement provides, among other things, that on the terms and subject to the conditions set forth therein, Merger Sub will merge with and into Carmell, with Carmell surviving as a wholly-owned subsidiary of the Company (the “Carmell Business Combination”). Upon the closing of the Carmell Business Combination (the “Closing”), it is anticipated that the Company will change its name to “Carmell Therapeutics Corporation” and its ticker symbol on the Nasdaq Stock Market (“Nasdaq”) is expected to change to “CTCX” and have the Class A common stock listed for trading with such trading ticker. The below description of the Business Combination Agreement and the transactions contemplated thereby is not complete and is subject to, and qualified in its entirety by reference to, the actual agreement, a copy of which is filed with the prospectus on Form 8-K The Business Combination Agreement and the transactions contemplated thereby were approved by the boards of directors of each of the Company and Carmell. Under the Business Combination Agreement, the Company will acquire all of the outstanding equity interests of Carmell in exchange for shares of the Company’s Class A common stock, based on an implied Carmell equity value of $150,000,000, to be paid to Carmell stockholders at the effective time of the Carmell Business Combination. Pursuant to the Business Combination Agreement, at or prior to the effective time of the Business Combination, each option and warrant exercisable for Carmell equity that is outstanding immediately prior to the effective time of the Business Combination shall be assumed by the Company and continue in full force and effect on the same terms and conditions as are currently applicable to such options and warrants, subject to adjustments to exercise price and number of shares of Class A common stock issued upon exercise. The parties to the Business Combination Agreement have agreed to customary representations and warranties for transactions of this type. In addition, the parties to the Business Combination Agreement agreed to be bound by certain customary covenants for transactions of this type, including, among others, covenants with respect to the conduct of Carmell, the Company and their respective subsidiaries during the period between execution of the Business Combination Agreement and Closing. The representations, warranties, agreements and covenants of the parties set forth in the Business Combination Agreement will terminate at Closing, except for those covenants and agreements that, by their terms, contemplate performance after Closing. Each of the parties to the Business Combination Agreement has agreed to use its reasonable best efforts to take or cause to be taken all actions and things necessary to consummate and expeditiously implement the Carmell Business Combination. The Business Combination Agreement may be terminated under certain customary and limited circumstances at any time prior to the Closing, including, without limitation, (i) by the Company or Carmell, if (a) the Closing has not occurred by June 30, 2023 and (b) a breach of the covenants or obligations of the other party (Carmell, on one hand, or the Company or Merger Sub, on the other hand) seeking to terminate the Business Combination Agreement did not proximately cause the failure to consummate the Business Combination; (ii) by the Company or Carmell, in the event an applicable governmental, regulatory or administrative authority has issued a final and non-appealable S-4 If the Business Combination Agreement is validly terminated, none of the parties to the Business Combination Agreement will have any liability or any further obligation under the Business Combination Agreement other than customary confidentiality obligations, except in the case of Willful Breach or Fraud (each, as defined in the Business Combination Agreement). Liquidity and Going Concern As of March 31, 2023, the Company had cash outside the Trust Account of $16,133 available for working capital needs. All remaining cash held in the Trust Account is generally unavailable for the Company’s use, prior to an initial business combination, and is restricted for use either in a Business Combination or to redeem common stock. Up to $100,000 of interest and dividends earned in the Trust Account are available to pay dissolution expenses, if necessary, and the Company may withdraw dividend and interest income earned in the Trust Account to pay income and franchise taxes. As of March 31, 2023 and December 31, 2022, none of the principal amount in the Trust Account was withdrawn as described above. As of March 31, 2023, the Company had cash, negative working capital and an accumulated deficit of $16,133, ($2,495,637 ) The Company has until July 29, 2023 to consummate the initial Business Combination. It is uncertain whether the Company will be able to consummate the proposed Business Combination by this date. If a Business Combination is not consummated by this date, then, unless that time is extended, there will be a mandatory liquidation and subsequent dissolution of the Company. Extension of the business combination period would require an amendment to the Company’s amended and restated certificate of incorporation. Amending the amended and restated certificate of incorporation will require the approval of holders of 65% of the Company’s common stock, and, in connection with this, amending the warrant agreement will require a vote of holders of at least a majority of the public warrants (which may include public warrants acquired by the Sponsor or its affiliates in this offering or thereafter in the open market). In addition, the amended and restated certificate of incorporation requires the Company to provide its public stockholders with the opportunity to redeem their public shares for cash if the Company proposes an amendment to the amended and restated certificate of incorporation (A) to modify the substance or timing of its obligation to allow redemption in connection with the initial business combination or certain amendments to the charter prior thereto or to redeem 100% of the Company’s public shares if the Company does not complete the initial business combination within 24 months from the closing of the IPO or (B) with respect to any other provision relating to stockholders’ rights or pre-initial business combination activity. As disclosed in the Company’s Form 8-K The Notice gave the Company 45 calendar days to submit a plan to regain compliance with the Minimum Public Holders Rule. The Company submitted a plan to regain compliance with the Minimum Public Holders Rule within the required timeframe. If Nasdaq accepts the Company’s plan, Nasdaq may grant the Company an extension of up to 180 calendar days from the date of the Notice to evidence compliance with the Minimum Public Holders Rule. If Nasdaq does not accept the Company’s plan, the Company will have the opportunity to appeal the decision in front of a Nasdaq Hearings Panel. These conditions raise substantial doubt about the Company’s ability to continue as a going concern until the earlier of the consummation of the Business Combination or the date the Company is required to liquidate, no later than July, 29, 2023. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern. The Company believes that the proceeds raised in the IPO and the funds potentially available from loans from the sponsor or any of their affiliates will be sufficient to allow the Company to meet the expenditures required for operating its business. However, if the estimate of the costs of identifying a target business, undertaking in-depth	Note 1 — Organization and Business Operations Alpha Healthcare Acquisition Corp. III is a blank check company incorporated as a Delaware corporation and formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses (the “Business Combination”). On January 4, 2023, the Company entered into a business combination agreement (the “Business Combination Agreement”) with Candy Merger Sub, Inc., a Delaware corporation (“Merger Sub”), and Carmell Therapeutics Corporation, a Delaware corporation (“Carmell”). The Company has selected December 31 as its fiscal year end. As of December 31, 2022, the Company has not yet commenced any operations. All activity from January 21, 2021 (inception) through December 31, 2022, relates to the Company’s formation, the IPO (as defined below), and activities necessary to identify a potential target and prepare for a Business Combination. Since our IPO, we have not generated any operating revenues, and do not expect to generate any operating revenues, until at least after completion of our initial Business Combination, if at all. The registration statement for the Company’s initial public offering (“IPO”) was declared effective on July 26, 2021. On July 29, 2021 (“IPO Date”), the Company consummated the IPO of 15,000,000 units (the “Public Units” and, with respect to the shares of Class A common stock included in the Public Units sold, the “Public Shares”), at $10.00 per Public Unit, generating gross proceeds of $150,000,000, which is described in Note 3. In connection with the IPO, the Company also granted the underwriters a 45-day Simultaneously with the closing of the IPO, the Company consummated the sale of 455,000 units (each, a “Private Placement Unit” and, collectively, the “Private Placement Units”) at a price of $10.00 per Private Placement Unit in a private placement to AHAC Sponsor III LLC (the “Sponsor”), generating gross proceeds of $4,550,000, which is described in Note 4. At the IPO Date, transaction costs amounted to $3,461,151, consisting of $3,000,000 of underwriting fees and $461,151 of other offering costs. The Company also accrued underwriting fees of $5,250,000 that will be paid only if a Business Combination is entered into. In addition, cash of $1,550,000 was held outside of the Trust Account (as defined below) and was available for the payment of offering costs and for working capital purposes. At the IPO Date, the Sponsor also transferred to certain investors a total of 225,000 of Founders shares (Note 4) (“Non-Risk Non-Risk At the IPO Date, the Sponsor also transferred to certain other investors the total of 600,900 of Founders shares (“Risk Incentive Private Shares”) as a compensation for their commitment to acquire at least 9.9% of the Public Units sold in the IPO. These Risk Incentive Private Shares are subject to forfeiture if the investors sell their Public Units prior to the closing of the initial Business Combination. The fair value of these Risk Incentive Private Shares is equal to the fair value of the Non-Risk On August 3, 2021, the Underwriters partially exercised their overallotment option and purchased 444,103 additional Public Units for a total amount of $4,441,030 resulting from the partial over-allotment exercise. The Company also issued 8,882 Private Placement Units, generating additional $88,820 in gross proceeds. Transaction costs related to the Underwriters’ partial over-allotment exercise amounted to $92,070, consisting of $88,820 of underwriting fees and $3,250 of other offering costs. The Company has also accrued additional underwriting fees of $155,436 that will be paid only if a business combination is entered into. The total issuance costs of $10,145,105 were allocated to the Class A common shares subject to possible redemption and the Public Warrants (Note 6) based on their relative fair values with $9,905,857 to the Class A shares subject to possible redemption and $239,247 to the Public Warrants. Following the closing of the IPO on July 29, 2021, an amount of $154,441,030 ($10.00 per Public Unit) from the net proceeds of the sale of the Public Units in the IPO, including the Public Units sold upon the exercise of the over-allotment option, and the sale of the Private Placement Units was placed in a trust account (the “Trust Account”), invested in U.S. government securities, within the meaning set forth in Section 2(a) (16) of the Investment Company Act, with a maturity of 185 days or less, or in any open-ended investment company that holds itself out as a money market fund meeting the conditions of Rule 2a-7 certificate of incorporation and subject to the requirements of law and regulation, provides that none of the funds held in the Trust Account will be released from the Trust Account until the earliest of (a) the completion of the Company’s initial Business Combination, (b) the redemption of the public shares if the Company is unable to consummate an initial Business Combination within months from the closing of the Public Offering (the “Combination Period”), subject to applicable law, and (c) the redemption of the Company’s public shares properly submitted in connection with a shareholder vote to approve an amendment to the Company’s amended and restated certificate of incorporation to modify the substance or timing of the Company’s obligation to redeem % of its public shares if the Company has not consummated an initial Business Combination within the Combination Period or with respect to any other material provisions relating to shareholders’ rights or pre-initial Business Combination activity. The proceeds deposited in the Trust Account could become subject to the claims of the Company’s creditors, if any, which could have priority over the claims of the Company’s public shareholders. The Company’s management has broad discretion with respect to the specific application of the net proceeds of the Public Offering, although substantially all of the net proceeds are intended to be generally applied toward consummating a Business Combination. The Company’s Business Combination must be with one or more target businesses that together have an aggregate fair market value of at least 80% of the assets held in the Trust Account (as defined below) (excluding the amount of deferred underwriting discounts held in trust and taxes payable on the interest earned on the Trust Account) at the time of the signing an agreement to enter into a Business Combination. However, the Company will only complete an initial Business Combination if the post-business combination company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act. There is no assurance that the Company will be able to successfully effect a Business Combination. The Company will provide its public shareholders with the opportunity to redeem all or a portion of their public shares upon the completion of the initial Business Combination either (i) in connection with a shareholder meeting called to approve the initial Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a proposed initial Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The shareholders will be entitled to redeem their shares at a per-share including interest (net of taxes payable), divided by the number of then outstanding public shares. The amount in the Trust Account is initially anticipated The shares of Class A common stock subject to possible redemption were recorded at redemption value and classified as temporary equity upon the completion of the IPO, in accordance with Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” The Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 either immediately prior to or upon consummation of a Business Combination and, if the Company seeks shareholder approval, a majority of the issued and outstanding shares voted are voted in favor of the Business Combination. If the Company is unable to complete a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up; (ii) as promptly as reasonably possible, but not more than ten business days thereafter, redeem the public shares, at a per-share The Sponsor has agreed (i) to waive its redemption rights with respect to any Founder Shares, private placement shares and public shares held by it in connection with the completion of the initial Business Combination, (ii) to waive its rights to liquidating distributions from the Trust Account with respect to any Founder Shares or private placement shares held by it if the Company fails to complete its Business Combination within the Combination Period, although the Sponsor will be entitled to liquidating distributions from the Trust Account with respect to any public shares it holds if the Company fails to complete its Business Combination within such time period, (iii) not to propose any amendment to the Company’s amended and restated certificate of incorporation that would modify the substance or timing of its obligation to redeem 100% of the public shares if the Company does not complete its initial Business Combination within the Combination Period or with respect to any other material provisions relating to shareholders’ rights or pre-initial The Company’s Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a vendor for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amounts in the Trust Account to below the lesser of (i) $ per public share and (ii) the actual amount per public share held in the Trust Account as of the date of the liquidation of the Trust Account if less than $10.00 per share due to reductions in the value of the trust assets, in each case less taxes payable, provided that such liability will not apply to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account nor will it apply to any claims under the Company’s indemnity of the underwriters of the Public Offering against certain liabilities, including liabilities under the Securities Act. In the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. However, the Company has not asked the Sponsor to reserve for such indemnification obligations, nor has it independently verified whether the Sponsor has sufficient funds to satisfy its indemnity obligations and the Company believes that the Sponsor’s only assets are securities of the Company. Therefore, the Company cannot assure you that the Sponsor would be able to satisfy those obligations. None of the Company’s officers or directors will indemnify the Company for claims by third parties including, without limitation, claims by vendors and prospective target businesses. Business Combination Agreement – Proposed Business Combination with Carmell Therapeutics Corporation On January 4, 2023, the Company entered into the Business Combination Agreement with Merger Sub and Carmell. The Business Combination Agreement provides, among other things, that on the terms and subject to the conditions set forth therein, Merger Sub will merge with and into Carmell, with Carmell surviving as a wholly-owned subsidiary of the Company (the “Carmell Business Combination”). Upon the closing of the Carmell Business Combination (the “Closing”), it is anticipated that the Company will change its name to “Carmell Therapeutics Corporation” and its ticker symbol on the Nasdaq Stock Market (Nasdaq) is expected to change to “CTCX” and have the Class A common stock listed for trading with such trading ticker. The below description of the Business Combination Agreement and the transactions contemplated thereby is not complete and is subject to, and qualified in its entirety by reference to, the actual agreement, a copy of which is filed with the prospectus on Form 8-K The Business Combination Agreement and the transactions contemplated thereby were approved by the boards of directors of each of the Company and Carmell. Under the Business Combination Agreement, the Company will acquire all of the outstanding equity interests of Carmell in exchange for shares of the Company’s Class A common stock, based on an implied Carmell equity value of $150,000,000, to be paid to Carmell stockholders at the effective time of the Carmell Business Combination. Pursuant to the Business Combination Agreement, at or prior to the effective time of the Business Combination, each option and warrant exercisable for Carmell equity that is outstanding immediately prior to the effective time of the Business Combination shall be assumed by the Company and continue in full force and effect on the same terms and conditions as are currently applicable to such options and warrants, subject to adjustments to exercise price and number of shares of Class A common stock issued upon exercise. The parties to the Business Combination Agreement have agreed to customary representations and warranties for transactions of this type. In addition, the parties to the Business Combination Agreement agreed to be bound by certain customary covenants for transactions of this type, including, among others, covenants with respect to the conduct of Carmell, the Company and their respective subsidiaries during the period between execution of the Business Combination Agreement and Closing. The representations, warranties, agreements and covenants of the parties set forth in the Business Combination Agreement will terminate at Closing, except for those covenants and agreements that, by their terms, contemplate performance after Closing. Each of the parties to the Business Combination Agreement has agreed to use its reasonable best efforts to take or cause to be taken all actions and things necessary to consummate and expeditiously implement the Carmell Business Combination. Under the Business Combination Agreement, the obligations of the parties to consummate the Carmell Business Combination are subject to the satisfaction or waiver of certain customary closing conditions of the respective parties, including, without limitation: (i) the approval and adoption of the Business Combination Agreement and transactions contemplated thereby by requisite vote of the Company’s stockholders and Carmell’s stockholders; (ii) the execution of the Investor Rights Agreement by the parties thereto; (iii) the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended; (iv) the absence of a Company Material Adverse Effect or ALPA Material Adverse Effect (each, as defined in the Business Combination Agreement) since the date of the Business Combination Agreement that is continuing; (v) after giving effect to the transactions contemplated by the Business Combination Agreement, the Company has net tangible assets of at of non-compliance therewith S-4 “S-4 Registration the S-4 Registration The Business Combination Agreement may be terminated under certain customary and limited circumstances at any time prior to the Closing, including, without limitation, (i) by the Company or Carmell, if (a) the Closing has not occurred by June 30, 2023 and (b) a breach of the covenants or obligations of the other party (Carmell, on one hand, or the Company or Merger Sub, on the other hand) seeking to terminate the Business Combination Agreement did not proximately cause the failure to consummate the Business Combination; (ii) by the Company or Carmell, in the event an applicable governmental, regulatory or administrative authority has issued a final and non-appealable order having the effect of permanently restraining, enjoining or otherwise prohibiting the Carmell Business Combination; (iii) by the Company or Carmell, if Carmell or the Company or Merger Sub, as applicable, has breached any of its respective representations, warranties, agreements or covenants contained in the Business Combination Agreement, such failure or breach would render certain conditions precedent to the Closing incapable of being satisfied, and such breach or failure is not cured within 30 days of written notice thereof; (iv) by the Company or Carmell if the Company’s stockholder meeting to vote on the Carmell Business Combination has been held and the Company stockholder approval has not been obtained; (v) by the Company, if the Carmell stockholder approval is not obtained within five (5) business days following the time at which a registration statement on Form S-4 relating to the approval by the Company’s stockholders of the Carmell Business Combination filed with the SEC by the Company is declared effective under the Securities Act of 1933, as amended; or (vi) by mutual written consent of the Company and Carmell. If the Business Combination Agreement is validly terminated, none of the parties to the Business Combination Agreement will have any liability or any further obligation under the Business Combination Agreement other than customary confidentiality obligations, except in the case of Willful Breach or Fraud (each, as defined in the Business Combination Agreement). Liquidity and Going Concern As of December 31, 2022, the Company had cash outside the Trust Account of $187,664 available for working capital needs. All remaining cash held in the Trust Account is generally unavailable for the Company’s use, prior to an initial Business Combination, and is restricted for use either in a Business Combination or to redeem common stock. Up to $100,000 of interest and dividends earned in the trust account are available to pay dissolution expenses, if necessary, and the Company may withdraw dividend and interest income earned in the Trust Account to pay income and franchise taxes. As of December 31, 2022, none of the amount in the Trust Account was withdrawn as described above. Through December 31, 2022, the Company’s liquidity needs were satisfied through receipt of $25,000 from the sale of the founder shares and the remaining net proceeds from the sale of Private Placement Units held outside of the trust account, totaling $187,664 as of December 31, 2022. There were no withdrawals from the trust account through December 31, 2022 for payment of tax obligations. As of December 31, 2022, we had cash, negative working capital and an accumulated deficit of $187,664, (1,396,312) and $6,018,111, respectively. The $187,664 held outside of the Trust Account may not be sufficient to allow the Company to operate for at least the next 12 months from the issuance of the financial statements, assuming that a Business Combination is not consummated during that time. The Company may need to raise additional capital through loans or additional investments from its Sponsor, stockholders, officers, directors, or third parties. The Company’s officers, directors and Sponsor may, but are not obligated to, loan the Company funds, from time to time or at any time, in whatever amount they deem reasonable in their sole discretion, to meet the Company’s working capital needs. Accordingly, the Company may not be able to obtain additional financing. If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, curtailing operations, suspending the pursuit of a potential transaction, and reducing overhead expenses. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all. The Company has until July 29, 2023 to consummate the initial Business Combination. It is uncertain whether the Company will be able to consummate the proposed Business Combination by this date. If a Business Combination is not consummated by this date, then, unless that time is extended, there will be a mandatory liquidation and subsequent dissolution of the Company. Extension of the business combination period would require an amendment to the Company’s amended and restated certificate of incorporation. Amending the amended and restated certificate of incorporation will require the approval of holders of 65% of the Company’s common stock, and, in connection with this, amending the warrant agreement will require a vote of holders of at least a majority of the Public Warrants (which may include Public Warrants acquired by the Sponsor or its affiliates in this offering or thereafter in the open market, see Note 6). In addition, the amended and restated certificate of incorporation requires the Company to provide its public stockholders with the opportunity to redeem their public shares for cash if the Company proposes an amendment to the amended and restated certificate of incorporation (A) to modify the substance or timing of its obligation to allow redemption in connection with the initial business combination or certain amendments to the charter prior thereto or to redeem 100% of the Company’s public shares if the Company does not complete the initial business combination within 24 months from the closing of the IPO or (B) with respect to any other provision relating to stockholders’ rights or pre-initial These conditions raise substantial doubt about the Company’s ability to continue as a going concern. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern. The Company believes that the proceeds raised in the IPO and the funds potentially available from loans from the sponsor or any of their affiliates will be sufficient to allow the Company to meet the expenditures required for operating its business. However, if the estimate of the costs of identifying a target business, undertaking in-depth

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Summary of Significant Accounting Policies	NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The unaudited financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These financial statements should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2022. The accompanying unaudited condensed financial statements include all adjustments that are of a normal recurring nature and necessary for the fair presentation of the results for the interim periods presented. Results for interim periods are not necessarily indicative of results to be expected for the full year. Use of Estimates The preparation of financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity- based transactions and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one Cash The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company has no cash equivalents as of March 31, 2023 and at December 31, 2022. Property and Equipment Property and equipment are stated at cost less accumulated depreciation. Maintenance and repair charges are expensed as incurred. The assets are depreciated using the straight-line method using the following useful lives: Lab equipment—7 years Leasehold improvements—The lesser of 10 years or the remaining life of the lease Furniture and fixtures – 7 years Intangible Assets Intangible assets consist entirely of patent costs. The Company capitalizes legal costs directly associated with the submission of Company patent applications. Gross patent costs of $70,746 as of March 31, 2023 and December 31, 2022 are amortized on a straight-line basis over the patent term and are stated net of accumulated amortization of $43,172 and $42,044, respectively. No asset impairment was recognized during the three months ended March 31, 2023 and 2022. Amortization expense for the three months ended March 31, 2023 and 2022, was $1,128 and $1,114, respectively. Costs billed to the Company as reimbursement for third parties’ patent submissions are considered as license fees and expensed as incurred. Offering Costs Associated with a Public Offering The Company complies with the requirements of FASB ASC 340-10-S99-1 ASC 340-10-S99-1 S-1 S-1 Impairment of Long-Lived Assets The Company reviews long-lived assets for impairment whenever events or circumstances indicate that the carrying value of such assets may not be fully recoverable. Impairment is present when the sum of estimated undiscounted future cash flow expected to result from use of the assets is less than carrying value. If impairment is present, the carrying value of the impaired asset is reduced to its fair value. Fair value is determined based on discounted cash flow or appraised values, depending on the nature of the assets. There were no impairment losses recognized for long-lived assets for the three months ended March 31, 2023 and 2022. Income Taxes Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of March 31, 2023 and December 31, 2022. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities for tax years ended 2019 to 2022. Fair Value Measurements and Fair Value of Financial Instruments Our financial instruments consist primarily of cash, prepaid expenses, accounts payable, accrued expenses and short-term debt. The carrying value of cash, prepaid expenses, accounts payable and accrued expenses approximates fair value because of the short-term maturity of such instruments. We have categorized our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy in accordance with GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets and liabilities recorded in the balance sheet at fair value as of March 31, 2023 and at December 31, 2022 are categorized based on a hierarchy of inputs, as follows: Carrying Fair Value Measurement Using Value Level 1 Level 2 Level 3 Total Derivative liability at March 31, 2023 $ 1,152,065 $ — $ — $ 1,152,065 $ 1,152,065 Derivative liability at December 31, 2022 $ 826,980 $ — $ — $ 826,980 $ 826,980 Fair Value Measurements Using Significant Unobservable March 31, 2023 December 31, 2022 Balance, beginning of year $ 826,980 $ 3,846,319 Initial recognition of derivative liability — 1,321,860 Settled in Series C-2 — (3,081,912 ) Change in fair value of derivative liability 325,085 (1,259,287 ) Balance, end of period $ 1,152,065 $ 826,980 Level 1—Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date. Level 2—Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data. Level 3—Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information. The fair value of the embeded derivatives in the convertible notes as of March 31, 2023 and December 31, 2022, was valued using a Monte-Carlo model and were based upon the following management assumptions: March 31, 2023 December 31, 2022 Stock price $ 0.16 $ 0.16 Expected term (years) 0.50 0.04 Volatility 73.40 % 55.10 % Risk free interest rate 4.40 % 4.38 % Probability of Qualified Financing or IPO 50.00 % 50.00 % Probability of a Change in Control Event 10.00 % 10.00 % The stock price was derived from 409a valuations. The volatility was determined from the historical volatility of comparable public companies over the expected terms. The term was based on the maturity date of the note. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon Research and Development Costs The Company is currently conducting research and development activities to operationalize certain patented technology that the Company owns and licenses. The Company expenses costs related to these activities in the period incurred. Net Loss Per Share Net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the reporting period. Diluted earnings per share is computed like basic earnings per share, except the weighted average number of common shares outstanding are increased to include additional shares from the assumed exercise of share options, if dilutive. The dilutive effect, if any, of convertible instruments or warrants is calculated using the treasury stock method. There are no outstanding dilutive instruments as the outstanding convertible instruments and warrants would be anti-dilutive if converted or exercised, respectively, as of March 31, 2023 and 2022. The following table summarizes the securities that were excluded from the diluted per share calculation because the effect of including these potential shares was antidilutive due to the Company’s net loss position even though the exercise price could be less than the average market price of the common shares: Three Months Ended March 31, 2023 2022 Series A Preferred Stock (if converted) 19,968,051 19,968,051 Series B Preferred Stock (if converted) 33,801,226 32,917,690 Series C-1 5,090,693 — Series C-2 73,560,390 — Stock Options 37,370,980 35,440,469 Common Stock Warrants (penny warrants excluded) 1,536,379 1,758,975 Preferred Stock Warrants 3,758,186 1,704,759 Convertible Notes 31,982,684 17,094,017 Total 207,068,589 108,883,961 Stock-Based Compensation The Company applies the provisions of ASC 718, Compensation — Stock Compensation For stock options issued to employees and members of the Board of Directors (the “Board) for their services, the Company estimates the grant date fair value of each option using the Black-Scholes option pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. For awards subject to service-based vesting conditions, including those with a graded vesting schedule, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock options on a straight-line basis over the requisite service period, which is generally the vesting term. Forfeitures are recorded as they are incurred as opposed to being estimated at the time of grant and revised. Pursuant to Accounting Standards Update (“ASU”) 2018-07, Compensation — Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Payment Accounting non-employees Leases The Company adopted ASC Topic 842, Leases, as amended, on January 1, 2020. We elected the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allowed the Company to not separate non-lease non-lease The Company’s leases consist of leaseholds on office space. The Company determines if an arrangement contains a lease at inception as defined by ASC 842. In order to meet the definition of a lease under ASC 842 in exchange for consideration. ROU (Right of Use) assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. Recent Accounting Pronouncements On June 30, 2022, the FASB issued ASU 2022-03, 2022-03 2022-03	NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying audited financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). References to the “ASC” hereafter refer to the Accounting Standards Codification established by the Financial Accounting Standards Board (“FASB”) as the source of authoritative U.S. GAAP. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity- based transactions and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future events. Accordingly, the actual results could differ significantly from estimates included in these financial statements. Cash The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company has no cash equivalents as of December 31, 2022 and 2021. Property and Equipment Property and equipment are stated at cost less accumulated depreciation. Maintenance and repair charges are expensed as incurred. The assets are depreciated using the straight-line method using the following estimated useful lives: Lab equipment - 7 years Leasehold improvements - The lesser of 10 years or the remaining life of the lease Furniture and fixtures – 7 years Intangible Assets Intangible assets consist entirely of patent costs. The Company capitalizes legal costs directly associated with the submission of Company patent applications. Gross patent costs of $70,746 as of December 31, 2022 and 2021 are amortized on a straight-line basis over the patent term and are stated net of accumulated amortization of $42,044 and $37,528, respectively. Such assets are periodically evaluated as to the recoverability of their carrying values. No asset impairment was recognized during the years ended December 31, 2022 and 2021. Amortization expense for the years ended December 31, 2022 and 2021, was $4,516 and $4,516, respectively. Costs billed to the Company as reimbursement for third parties’ patent submissions are considered as license fees and expensed as incurred. Estimated amortization expense for each of the following five years is as follows: 2023 $ 4,516 2024 4,528 2025 4,516 2026 4,516 2027 4,090 Thereafter 6,536 Total $ 28,702 Offering Costs Associated with a Public Offering The Company complies with the requirements of FASB ASC 340-10-S99-1 ASC 340-10-S99-1 S-1 Advertising Costs Advertising costs are expensed as incurred. Advertising expense for the year ended December 31, 2022 and 2021, were $9,247 and $8,015 respectively. Impairment of Long-Lived Assets The Company reviews long-lived assets for impairment whenever events or circumstances indicate that the carrying value of such assets may not be fully recoverable. Impairment is present when the sum of estimated undiscounted future cash flow expected to result from use of the assets is less than carrying value. If impairment is present, the carrying value of the impaired asset is reduced to its fair value. Fair value is determined based on discounted cash flow or appraised values, depending on the nature of the assets. There were no impairment losses recognized for long-lived assets for the years ended December 31, 2022 and 2021. Income Taxes Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of December 31, 2022 and 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities for tax years ended 2019 to 2022. Fair Value Measurements and Fair Value of Financial Instruments Our financial instruments consist primarily of accounts payable, accrued expenses and short- and long-term debt. The carrying value of cash, prepaid expenses, other current assets, accounts payable and accrued expenses approximates fair value because of the short-term maturity of such instruments. We have categorized our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy in accordance with U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets and liabilities recorded in the balance sheet at fair value as of December 31, 2022 and 2021 are categorized based on a hierarchy of inputs, as follows: Carrying Fair Value Measurement Using Value Level 1 Level 2 Level 3 Total Derivative liability at December 31, 2022 $ 826,980 $ — $ — $ 826,980 $ 826,980 Derivative liability at December 31, 2021 $ 3,846,319 $ — $ — $ 3,846,319 $ 3,846,319 Fair Value Measurements Using Significant 2022 2021 Balance, beginning of year $ 3,846,319 $ 1,045,905 Initial recognition of derivative liability 1,321,860 285,349 Settled in Series C-2 (3,081,912 ) — Change in fair value of derivative liability (1,259,287 ) 2,515,065 Balance, end of year $ 826,980 $ 3,846,319 Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date. Level 2 - Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data. Level 3 - Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information. The fair value of the embedded derivatives in the convertible notes as of December 31, 2022 and 2021, was valued using a Monte-Carlo model and were based upon the following management assumptions: 2022 2021 Stock price $ 0.16 $0.13 Expected term (years) 0.04 0.71 - 3.48 Volatility 55.10 % 48.90% - 60.50% Risk free interest rate 4.38 % 0.44% - 0.72% Probability of Qualified Financing or IPO 50.00 % 60.00% Probability of a Change in Control Event 10.00 % 10.00% The stock price was derived from 409a valuations. The volatility was determined from the historical volatility of comparable public companies over the expected term. The term was based on the maturity date of the note. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon Research and Development Costs The Company is currently conducting research and development activities to operationalize certain patented technology that the Company owns and licenses. The Company expenses costs related to these activities in the period incurred. Net Loss Per Share Net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the reporting period. Diluted earnings per share is computed like basic earnings per share, except the weighted average number of common shares outstanding are increased to include additional shares from the assumed exercise of share options, if dilutive. The dilutive effect, if any, of convertible instruments or warrants is calculated using the treasury stock method. There are no outstanding dilutive instruments as the outstanding convertible instruments and warrants would be anti-dilutive if converted or exercised, respectively, as of December 31, 2022 and 2021. The following table summarizes the securities that were excluded from the diluted per share calculation because the effect of including these potential shares was anti-dilutive due to the Company’s net loss position even though the exercise price could be less than the average market price of the common shares: Year Ended December 31, 2022 2021 Series A Preferred Stock (if converted) 19,968,051 19,968,051 Series B Preferred Stock (if converted) 33,801,226 32,917,690 Series C-1 5,090,693 — Series C-2 73,560,390 — Stock Options 36,320,980 34,990,469 Common Stock Warrants (penny warrants excluded) 1,418,733 1,758,975 Preferred Stock Warrants 3,758,186 1,704,789 Convertible Notes 26,620,370 — Total 200,538,629 91,339,974 Stock-Based Compensation The Company applies the provisions of ASC 718, Compensation — Stock Compensation For stock options issued to employees and members of the Board of Directors (the “Board) for their services, the Company estimates the grant date fair value of each option using the Black-Scholes option pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. For awards subject to service-based vesting conditions, including those with a graded vesting schedule, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock options on a straight-line basis over the requisite service period, which is generally the vesting term. Forfeitures are recorded as they are incurred as opposed to being estimated at the time of grant and revised. Pursuant to Accounting Standards Update (“ASU”) 2018-07, Compensation — Stock Compensation (Topic 718): Improvements to Non-employee non-employees Leases The Company adopted ASC Topic 842, Leases, as amended, on January 1, 2020. We elected the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allowed the Company to not separate non-lease non-lease The Company’s leases consist of leaseholds on office space. The Company determines if an arrangement contains a lease at inception as defined by ASC 842. In order to meet the definition of a lease under ASC 842, the contractual arrangement must convey to us the right to control the use of an identifiable asset for a period of time in exchange for consideration. ROU (Right of Use) assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. Recent Accounting Pronouncements On June 30, 2022, the FASB issued ASU 2022-03, 2022-03 2022-03
Alpha Healthcare Acquisition Corp. III [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Summary of Significant Accounting Policies	Note 2 — Significant Accounting Policies Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q S-X The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto for the year ended December 31, 2022 included in the Company’s Form 10-K as filed with the SEC on March 17, 2023. The interim results for the three months ended March 31, 2023 are not necessarily indicative of the results to be expected for the year ending December 31, 2023 or for any future periods. Emerging Growth Company Status The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended, (the “Securities Act”), as modified by the Jumpstart our Business Startups Act of 2012, (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Marketable Securities Held in Trust Account At March 31, 2023 and December 31, 2022, the assets held in the Trust Account were substantially held in a money market fund which is comprised of U.S. Treasury Bills, U.S. Treasury Coupons, and U.S. Treasury Inflation-Protected Securities. Through March 31, 2023, the Company has not withdrawn any dividend and interest income from the Trust Account to pay its tax obligations. Common Stock Subject to Possible Redemption The Company accounts for its Class A common stock subject to possible redemption in accordance with the guidance in Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” Class A common stock subject to mandatory redemption (if any) are classified as a liability instrument and are measured at fair value. Conditionally redeemable common stock (including common stock that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, common stock is classified as shareholders’ equity. The Company’s common stock feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, as of March 31, 2023 and December 31, 2022, 15,444,103 shares of Class A common stock subject to possible redemption are classified in temporary equity outside of the shareholders’ equity (deficit) section of the Company’s balance sheet and were immediately accreted to redemption value at the IPO Date. Derivative Financial Instruments The Company issues warrants to its investors and accounts for warrant instruments as either equity-classified or liability-classified instruments based on an assessment of the specific terms of the warrants and applicable authoritative guidance in ASC 480 and ASC 815, “Derivatives and Hedging” (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own stock and whether the holders of the warrants could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. The Public Warrants (see Note 3) and Private Warrants (see Note 4) were accounted for as equity as these instruments meet all of the requirements for equity classification under ASC 815. Business Combination Costs Costs incurred in relation to a potential Business Combination may include legal, accounting, and other expenses. Any such costs are expensed as incurred. Net Income (Loss) per Common Stock share The Company complies with accounting and disclosure requirements of ASC Topic 260, “Earnings Per Share.” Net income (loss) per share is computed by dividing net loss by the weighted average number of Common Stock shares outstanding during the period. The Company’s condensed consolidated statements of operations include a presentation of net income (loss) per share subject to redemption in a manner similar to the two-class 480-10-S99-3A, The Company’s Public Warrants (see Note 6) and Private Placement Warrants (see Note 6) could, potentially, be exercised or converted into common shares and then share in the earnings of the Company. However, these warrants were excluded when calculating diluted income (loss) per share because such inclusion would be anti-dilutive for the periods presented. As a result, diluted income (loss) per share is the same as basic income (loss) per share for the period presented. A reconciliation of net income per share is as follows for the three months ended March 31, 2023: Class A subject to Class A Class B Allocation of undistributable income 450,040 13,517 112,510 Net income to ordinary shares $ 450,040 $ 13,517 $ 112,510 Weighted average shares outstanding, basic and diluted 15,444,103 463,882 3,861,026 Basic and diluted net income per share $ 0.03 $ 0.03 $ 0.03 A reconciliation of net income per share is as follows for the three months ended March 31, 2022: Class A subject to Class A Class B Allocation of undistributable losses (412,121 ) (12,379 ) (103,030 ) Net (loss) to Common shares $ (412,121 ) $ (12,379 ) $ (103,030 ) Weighted average shares outstanding, basic and diluted 15,144,103 463,882 3,861,026 Basic and diluted net loss per share $ (0.03 ) $ (0.03 ) $ (0.03 ) Fair Value of Financial Instruments The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC Topic 820, “Fair Value Measurement,” approximates the carrying amounts represented in the accompanying condensed consolidated balance sheet, primarily due to their short-term nature. Fair Value Measurements Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: • Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; • Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and • Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. As of March 31, 2023 and December 31, 2022, the Company held $158,368,990 and $156,693,598, respectively, of Level 1 financial instruments, which are the Company’s marketable securities held in the Trust Account. These assets are measured at fair value on a recurring basis based on quoted market prices for identical securities in the active market. The Company did not hold any assets or liabilities requiring remeasurement on a recurring or nonrecurring basis as of March 31, 2023 and December 31, 2022. Income Taxes The Company follows the asset and liability method of accounting for income taxes under ASC 740, “Income Taxes.” Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. ASC 740 prescribes recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties related to any uncertain tax benefits as of March 31, 2023 and December 31, 2022. The Company is not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception. Concentration of Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist of a cash account in a financial institution, which at times may exceed the Federal Depository Insurance Corporation coverage limit of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account. Recently Issued Accounting Standards Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.	Note 2 — Significant Accounting Policies Basis of Presentation The accompanying financial statements are presented in conformity with accounting principles generally accepted in the United States of America (“US GAAP”) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”). Emerging Growth Company Status The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended, (the “Securities Act”), as modified by the Jumpstart our Business Startups Act of 2012, (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Marketable Securities Held in Trust Account At December 31, 2022 and 2021, the assets held in the Trust Account were substantially held in a money market fund which is comprised of U.S. Treasury Bills, U.S. Treasury Coupons, and U.S Treasury Inflation-Protected Securities. During the year ended December 31, 2022, the Company did not withdraw any of interest income from the Trust Account to pay its tax obligation. Common Stock Subject to Possible Redemption The Company accounts for its Class A common stock subject to possible redemption in accordance with the guidance in ASC Topic 480 “Distinguishing Liabilities from Equity.” Class A common stock subject to mandatory redemption (if any) are classified as a liability instrument and are measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, common stock is classified as shareholders’ equity. The Company’s common stock features certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, as of December Derivative Financial Instruments The Company issues warrants to its investors and accounts for warrant instruments as either equity-classified or liability-classified The Public Warrants (see Note 3) and Private Warrants (see Note 6) were accounted for as equity as these instruments meet all of the requirements for equity classification under ASC 815. Over-Allotment Option The over-allotment option (see Note 7) was deemed to be a freestanding financial instrument indexed to the contingently redeemable shares and was accounted for as a liability pursuant to ASC 480. The fair value of the overallotment liability at the IPO Date of $158,275 was determined using the Black Scholes option pricing model based on the following assumptions: Risk-free interest rate 0.05 % Dividend rate 0 % Volatility 5.00 % Expected life (in years) 0.12 On August 3, 2021, the Underwriters partially exercised their overallotment option and purchased 444,103 Public Units (see Note 3). The fair value of the corresponding overallotment liability partially extinguished upon exercise of $28,317 was determined using the Black Scholes option pricing model based on the following assumptions: Risk-free interest rate 0.05 % Dividend rate 0 % Volatility 5.00 % Expected life (in years) 0.10 Upon the expiration of the unexercised overallotment options on September 9, 2021, the Company recorded a gain on the expiration of the overallotment option of $127,035. Business Combination Costs Costs incurred in relation to a potential Business Combination may include legal, accounting, and other expenses. Any such costs are expensed as incurred. Net Income (Loss) per Common Stock share The Company complies with accounting and disclosure requirements of ASC Topic 260, “Earnings Per Share.” Net income (loss) per share is computed by dividing net income (loss) by the weighted average number of Common Stock shares outstanding during the period. Weighted average shares for the period from January 21, 2021 (inception) through December 31, 2021 were reduced for the effect of an aggregate of 562,500 Class B Common shares that were subject to forfeiture until the over-allotment option was partially exercised by the underwriters on August 3, 2021 (see Note 5), upon which date the forfeiture provision lapsed for 111,026 Class B Common shares. Subsequent to August 3, 2021, weighted average shares were reduced for the effect of an aggregate of 451,474 Class B Common shares which were ultimately forfeited upon the expiration of the 45-day period The Company’s statements of operations include a presentation of net income (loss) per share subject to redemption in a manner similar to the two-class 480-10-S99-3A, The Company’s Public Warrants (see Note 6) and Private Warrants (see Note 6) could, potentially, be exercised or converted into common shares and then share in the earnings of the Company. However, these warrants were excluded when calculating diluted income (loss) per share because such inclusion would be anti-dilutive for the periods presented. As a result, diluted income (loss) per share is the same as basic income (loss) per share for the period presented. A reconciliation of net income per share is as follows for the year ended December 31, 2022: Year ended December 31, 2022 Class A subject to Class A Class B Allocation of undistributable income 160,151 4,809 40,037 Net income to ordinary shares $ 160,151 $ 4,809 $ 40,037 Weighted average shares outstanding, basic and diluted 15,444,103 463,882 3,861,026 Basic and diluted net income per share $ 0.01 $ 0.01 $ 0.01 A reconciliation of net loss per share is as follows for the period from January 21, (Inception) through December 31, 2021: For the period from Janaury 21, 2021 (inception) through December 31, 2021 Class A subject to Class A Class B Allocation of undistributable losses (209,176 ) (6,286 ) (113,920 ) Net loss to ordinary shares $ (209,176 ) $ (6,286 ) $ (113,920 ) Weighted average shares outstanding, basic and diluted 6,973,122 209,549 3,797,628 Basic and diluted net loss per share $ (0.03 ) $ (0.03 ) $ (0.03 ) Offering Costs Offering costs consist of underwriting, legal, accounting and other expenses incurred through the IPO that are directly related to the IPO. Offering costs are allocated to the separable financial instruments issued in the IPO based on a relative fair value basis, compared to total proceeds received. Offering costs associated with the Public Shares were charged to shareholders’ equity upon the completion of the IPO. Offering costs amounted to $9,897,599 at July 29, 2021, which were allocated between the Class A shares subject to possible redemption and the Public Warrants and charged to shareholders’ equity upon the completion of the IPO. Under the guidance in Staff Accounting Bulletin 107 Topic 5.A, Accounting for Expenses or Liabilities Paid by Principal Stockholder(s), the Company included in these offering costs amounts incurred by the Sponsor through the transfer of Non-Risk The total issuance costs of $10,145,105 were allocated to the Class A shares subject to possible redemption and the Public Warrants based on their relative fair values with $9,905,857 to the Class A shares subject to possible redemption and $239,247 to the Public Warrants. Fair Value of Financial Instruments The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC Topic 820, “Fair Value Measurement,” approximates the carrying amounts represented in the accompanying balance sheet, primarily due to their short-term nature. Fair Value Measurements Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: • Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; • Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and • Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. As of December 31, 2022 and 2021, the Company held $156,693,598 and $154,449,121, respectively, of Level 1 financial instruments, which are the Company’s marketable securities held in Trust Account. These assets are measured at fair value on a recurring basis based on quoted market prices for identical securities in the active market. The overallotment liability is measured at fair value using the Black Scholes Option Pricing Model with significant unobservable inputs. The fair value is based on the share price of the underlying shares and a number of assumptions, including expected volatility, expected life, risk-free interest rate and expected dividends. Therefore, the overallotment liability is considered to be a Level 3 financial instrument. The Company did not hold any liabilities requiring remeasurement on a recurring or non-recurring The table below presents the changes in Level 3 liabilities measured at fair value on a recurring basis during the period from January 21, 2021 (inception) through December 31, 2021: Overallotment Balance at January 21, 2021 (inception) $ — Issuance of overallotment option 158,275 Partial exercise of overallotment option (28,316 ) Change in fair value of overallotment liability (2,924 ) Expiration of overallotment option (127,035 ) Balance at December 31, 2021 $ — Income Taxes The Company follows the asset and liability method of accounting for income taxes under ASC 740, “Income Taxes.” Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. ASC 740 prescribes recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of December 31, 2022 and 2021. The Company is not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception. Concentration of Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist of a cash account in a financial institution, which at times may exceed the Federal Depository Insurance Corporation coverage limit of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account. Recently Issued Accounting Standards Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.

Business Combination Agreement

Business Combination Agreement	3 Months Ended
	Mar. 31, 2023
Business Combinations [Abstract]
Business Combination Agreement	NOTE 3 — BUSINESS COMBINATION AGREEMENT On January 4, 2023, Alpha Healthcare Acquisition Corp. III, a Delaware corporation (“Alpha”), entered into a business combination agreement (the “Business Combination Agreement”) by and among Alpha, Candy Merger Sub, Inc., a Delaware corporation (“Merger Sub”), and the Company. The Business Combination Agreement provides, among other things, that on the terms and subject to the conditions set forth therein, Merger Sub will merge with and into the Company, with the Company surviving as a wholly-owned subsidiary of Alpha (the “Business Combination”). Upon the closing of the Business Combination, it is anticipated that Alpha will change its name to “Carmell Therapeutics Corporation.” The Business Combination Agreement and the transactions contemplated thereby were approved by the Boards of Directors of each of the Company and Alpha. The agreement is still pending regulatory approval and an Alpha shareholder vote. Under the Business Combination Agreement, Alpha will acquire all of the outstanding equity interests of the Company in exchange for shares of Class A common stock of Alpha, par value $0.0001 per share (the “Class A Common Stock”), based on the Company’s implied equity value of $150,000,000, to be paid to the Company’s stockholders at the effective time of the Business Combination. Pursuant to the Business Combination Agreement, at or prior to the effective time of the Business Combination, each option and warrant exercisable for the Company’s equity that is outstanding immediately prior to the effective time of the Business Combination shall be assumed by Alpha and continue in full force and effect on the same terms and conditions as are currently applicable to such options and warrants, subject to adjustments to exercise price and number of shares of Class A Common Stock issued upon exercise.

Restatement and Correction of a

Restatement and Correction of an Error	12 Months Ended
	Dec. 31, 2022
Restatement and Correction of an Error [Abstract]
Restatement and Correction of an Error	NOTE 3 — RESTATEMENT AND CORRECTION OF AN ERROR Restatement The Company has restated its financial statements as of and for the year ended, December 31, 2021. The following tables provide the summary of restated amounts. December 31, 2021 As Previously Reclassifications Error Restated ASSETS Current Assets: Cash $ 12,362 $ 12,362 Deferred offering costs 166,342 166,342 Total Current Assets 178,704 178,704 Property and equipment, net of accumulated depreciation of $440,334 337,592 337,592 Operating lease right of use asset 1,007,589 1,007,589 Intangible assets, net of accumulated amortization of $37,528 18,506 14,712 33,218 Total Assets $ 1,542,391 — 14,712 $ 1,557,103 LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ DEFICIT Current Liabilities: Accounts payable $ 871,313 $ 871,313 Accrued expenses and other liabilities 514,783 514,783 Accrued interest— related parties — 226,170 226,170 Accrued interest— non-related 1,880,656 (226,170 ) 1,654,486 Convertible notes payable— related parties, net of debt discount of $0 — 900,000 900,000 Convertible notes payable, current, net of debt discount of $946,291 9,507,228 (900,000 ) (903,796 ) 7,703,432 Derivative liabilities — 3,813,019 3,813,019 Lease liability, current 120,162 120,162 Total Current Liabilities 12,894,142 — 2,909,223 15,803,365 Long-term Liabilities: Lease liability, net of current portion 961,908 961,908 Convertible notes payable — net of debt discount of $49,078 50,000 (49,078 ) 922 Derivative liabilities — 33,300 33,300 Total Long-term Liabilities 1,011,908 — (15,778 ) 996,130 Total Liabilities 13,906,050 — 2,893,445 16,799,495 December 31, 2021 As Previously Reclassifications Error Restated Commitments and Contingencies (Note 8) Mezzanine Equity Series A Preferred stock, 21,064,711 7,020,992 385,417 7,406,409 Series B Preferred stock, 34,772,230 shares authorized; 32,917,690 issued and outstanding as of December 31, 2021 (liquidation preference: $6,928,245) 5,970,791 957,454 6,928,245 Series C Preferred stock, 25,907,990 shares authorized; 0 shares issued and outstanding as of December 31, 2021 — Stockholders’ Deficit: Common stock, $.001 par value; 100,050,000 shares authorized; 36,918,882 shares issued and outstanding as of December 31, 2021 36,919 36,919 Additional paid-in 2,989,644 170,847 3,160,491 Accumulated deficit (28,382,005 ) (4,392,451 ) (32,774,456 ) Total Stockholders’ Deficit (25,355,442 ) — (4,221,604 ) (29,577,046 ) Total Liabilities, Mezzanine Equity and Stockholders’ Deficit $ 1,542,391 — 14,712 $ 1,557,103 For the Year Ended December 31, 2021 As Previously Reclassifications Error Restated Operating expenses: Research and development $ 982,837 $ 982,837 General and administrative 617,989 153,861 91,483 863,333 Depreciation and amortization 103,656 (9,494 ) 94,162 ROU amortization 145,846 (145,846 ) — Advertising and Marketing 8,015 (8,015 ) — Total operating expenses 1,858,343 — 81,989 1,940,332 Loss from operations (1,858,343 ) — (81,989 ) (1,940,332 ) Other income (expense): Gain on the forgiveness of loans payable 438,180 438,180 Other income 37,527 (149 ) 37,378 Change in fair value of derivative liabilities — (2,515,065 ) (2,515,065 ) Interest expense, related party — (72,000 ) (72,000 ) Interest expense, non-related (860,805 ) 125,686 91,632 (643,487 ) Amortization of debt discount — (53,686 ) (1,729,911 ) (1,783,597 ) Total other expense (385,098 ) — (4,153,493 ) (4,538,591 ) Loss before provision for income taxes (2,243,441 ) — (4,235,482 ) (6,478,923 ) Provision for income taxes — — — Net loss (2,243,441 ) — (4,235,482 ) (6,478,923 ) Dividends on Series A preferred stock (307,927 ) (307,927 ) Net loss attributable to common stockholders $ (2,243,441 ) — (4,543,409 ) $ (6,786,850 ) Net loss per common share—basic and diluted $ (0.16 ) — (0.13 ) $ (0.29 ) Weighted average shares outstanding—basic and diluted 13,698,060 — 9,441,105 23,139,165 Common Stock Additional Paid-in Accumulated Total Shares Amount As Previously Reported Balance at January 1, 2021 2,922,284 $ 2,922 $ 2,539,486 $ (25,830,637 ) $ (23,288,229 ) Accrued Series A preferred stock dividend (307,927 ) (307,927 ) Issuance of stock 31,940,355 31,940 (28,746 ) — 3,194 Exercise of stock options 2,056,243 2,057 232,105 — 234,162 Stock-based compensation expense 246,799 — 246,799 Net loss — (2,243,441 ) (2,243,441 ) Balance as of December 31, 2021 36,918,882 $ 36,919 $ 2,989,644 $ (28,382,005 ) $ (25,355,442 ) Error Correction Net loss (4,235,482 ) (4,235,482 ) As Restated Balance at January 1, 2021 2,922,284 $ 2,922 $ 2,539,486 $ (25,830,637 ) $ (23,288,229 ) Correction of accumulated error 170,847 (156,969 ) 13,878 Balance at January 1, 2021 (Restated) 2,922,284 2,922 2,710,333 (25,987,606 ) (23,274,351 ) Accrued Series A preferred stock dividend — — — (307,927 ) (307,927 ) Issuance of common stock 31,940,355 31,940 (28,746 ) 3,194 Exercise of stock options 2,056,243 2,057 232,105 — 234,162 Stock-based compensation expense — — 246,799 — 246,799 Net loss — — — (6,478,923 ) (6,478,923 ) Balance as of December 31, 2021 36,918,882 $ 36,919 $ 3,160,491 $ (32,774,456 ) $ (29,577,046 ) For the Year Ended December 31, 2021 As Previously Reclassifications Error Restated Cash flows from operating activities: Net loss $ (2,243,441 ) (4,235,482 ) $ (6,478,923 ) Adjustments to reconcile net loss to net cash used in operating activities: Gain on forgiveness of loans payable (438,180 ) (438,180 ) Depreciation and amortization 103,656 (9,494 ) 94,162 Amortization of debt discount 53,686 1,729,911 1,783,597 Amortization of ROU assets 145,846 2,116 147,962 Change in fair value of derivative liabilities 2,515,065 2,515,065 Stock-based compensation 246,799 246,799 Changes in operating assets and liabilities: Prepaid expenses and other current assets 9,918 9,918 Accounts payable 80,320 80,320 Accrued expenses and other liabilities 262,098 (1 ) 262,097 Lease liability (113,016 ) (2,116 ) (115,132 ) Accrued interest— related parties 72,000 72,000 Accrued interest -non 715,486 (72,000 ) 643,486 Net cash used in operating activities (1,176,828 ) (1 ) 0 (1,176,829 ) Cash flows from investing activities: Purchase of property and equipment (7,273 ) (7,273 ) Net cash used in investing activities (7,273 ) — — (7,273 ) Cash flows from financing activities: Proceeds from convertible notes 906,839 906,839 Proceeds from PPP loan 217,460 217,460 Payment of offering costs (166,342 ) (166,342 ) Proceeds from issuance of common stock 3,194 3,194 Proceeds from exercise of stock options 237,356 (3,193 ) 234,163 Net cash provided by financing activities 1,195,313 1 — 1,195,314 Net increase in cash 11,212 11,212 Cash — beginning of the period 1,150 1,150 Cash — end of the period $ 12,362 — — $ 12,362 Supplemental cash flow information: Interest paid $ — — — $ — Income tax paid $ — — — $ — Non-cash Accrued Series A preferred stock dividends $ 307,927 — — $ 307,927 Initial recognition of derivative liabilities $ — — 258,359 $ 258,359 Derivative liability The Company did not previously identify or account for derivatives with its convertible debt. The fair value of the derivative is recorded as a liability with an offsetting amount recorded as a debt discount, which offsets the carrying amount of the debt. The derivative is revalued at the end of each reporting period and any change in fair value is recorded as a gain or loss in the statement of operations. The debt discount is amortized through interest expense over the life of the debt. Due to the above, short and long-term derivative liabilities of $3,813,019 and $33,300, respectively, were recorded as of December 31, 2021 and the corresponding $2,515,065 loss on change in fair value of the derivative liability on the statement of operations was recorded. The debt discount recorded on the balance sheet for convertible notes and related party convertible notes increased by $995,369 as of December 31, 2021 and the corresponding amortization of debt discount on the statement of operations increased by $1,729,911. This also resulted in a correction of an error as an increase in the accumulated deficit of $1,351,531 as of January 1, 2021 for convertible notes issued prior to January 1, 2021. Series A Preferred Stock For the year ended December 31, 2011, certain convertible notes were converted into Series A preferred stock at a discount value. Since the consideration transferred should be measured at its then-current fair value, with any difference recorded as a gain or loss on the extinguishment, a loss of $425,396 at the time of conversion was reflected in the beginning accumulated deficit at January 1, 2021 with an increase in Series A preferred stock by the same amount. In addition, the dividends for Series A preferred stock issued prior to the fiscal year 2015 was overstated by the amount of $39,979 and was reflected in the beginning accumulated deficit at January 1, 2021. From the fiscal years of 2008 to 2010, the Company issued 1,096,660 warrants to purchase Series A preferred stock in connection with the conversion of certain convertible notes. As part of this extinguishment of debt, the Company did not properly value warrants issued with the conversion of the Series A shares. The fair value of the warrants was previously understated by $98,525. This correction of an error resulted in an increase in additional paid in capital and decrease in accumulated deficit of $98,325. Series B Preferred Stock For the year ended December 31, 2016, certain convertible notes were converted into Series B preferred stock at a discount value. Since the consideration transferred should be measured at its then-current fair value, with any difference recorded as a gain or loss on the extinguishment, a loss of $957,454 at the time of conversion was reflected in the beginning accumulated deficit at January 1, 2021 with an increase in Series B preferred stock by $1,029,976. As part of this extinguishment of debt, the Company did not properly value warrants issued with the issuance of the Series B shares. The fair value of the warrants was previously understated by $72,522. This correction of an error resulted in an increase in additional paid in capital and decrease in accumulated deficit of $72,522. Intangible Asset An adjustment was made to reduce the intangible assets carrying value for $78,009 and the related accumulated amortization prior to January 1, 2021. The life was adjusted from 10 years to the term of the patent which decreased accumulated deficit by $5,218 prior to January 1, 2021. For the year ended December 31, 2021, amortization expense decreased by $9,494 due to the change of the estimated useful life. Earnings per share The change in earnings per share of $0.13 is a result of the change of the net loss of $4,235,482 and the change in the weighted average shares outstanding. The weighted average shares outstanding changed from 13,698,060 to 23,139,165 due to an error in the Company’s calculation associated with the dates of stock options exercised during the year ended 2021. Correction of an Error Due to the same issues noted above, accumulated deficit at January 1, 2021 and December 31, 2021 was previously reported as $25,830,637 and $28,382,005, respectively and now is $25,987,606 and $32,774,456, respectively.

IPO

IPO	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Alpha Healthcare Acquisition Corp. III [Member]
Initial Public Offering [Line Items]
IPO	Note 3 — IPO On July 29, 2021, the Company sold 15,000,000 Public Units at $10.00 per Public Unit, generating gross proceeds of $150.0 million. Each Public Unit consists of one share of Class A common stock and one-fourth Simultaneously with the closing of the IPO, the Company consummated the sale of 455,000 Private Placement Units at a price of $10.00 per Private Placement Unit in a private placement to the Sponsor, generating gross proceeds of $4,550,000, which is described further in Note 4. On August 3, 2021, the Underwriters exercised their option to purchase 444,103 additional Public Units for the total amount of $4,441,030, received on August 6, 2021. Resulting from the partial over-allotment exercise, the Company also issued 8,882 Private Placement Units, generating additional $88,820 in gross proceeds.	Note 3 — IPO On July 29, 2021, the Company sold 15,000,000 Public Units at $10.00 per Public Unit, generating gross proceeds of $150.0 million. Each Public Unit consists of one share of Class A common stock and one-fourth Simultaneously with the closing of the IPO, the Company consummated the sale of 455,000 Private Placement Units at a price of $10.00 per Private Placement Unit in a private placement to the Sponsor, generating gross proceeds of $4,550,000, which is described further in Note 4. On August 3, 2021, the Underwriters exercised their option to purchase 444,103 additional Public Units for the total amount of $4,441,030, received on August 6, 2021. Resulting from the partial over-allotment exercise, the Company also issued 8,882 Private Placement Units, generating additional $88,820 in gross proceeds.

Going Concern and Management's

Going Concern and Management's Liquidity Plans	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Substantial Doubt About Going Concern [Abstract]
Going Concern and Management's Liquidity Plans	NOTE 4 — GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS At March 31, 2023 and December 31, 2022, the Company had cash of $27,190 and $128,149, respectively, and an accumulated deficit of $44,522,174 and $42,382,291, respectively. The Company’s liquidity needs up to March 31, 2023 have been satisfied through debt and equity financings. For the three months ended March 31, 2023 and 2022, the Company had a loss from operations of $1,274,871 and $950,757, respectively, and negative cash flows from operations of $475,959 and $1,597,658, respectively. The Company’s operating activities consume the majority of its cash resources, and management anticipates that the Company will continue to incur operating losses as it executes its plans through 2024. In addition, the Company has had and expects to have negative cash flows from operations, at least into the near future. On July 19, 2022, the Company defaulted on the January 2022 convertible notes. Pursuant to the terms of the note, upon an event of default there would be a 25% increase to the outstanding principal in addition to the interest rate increasing from 10% to 18%. The accompanying financial statements have been prepared on the basis that the Company will continue as a going concern, which assumes the realization of assets and the satisfaction of liabilities in the normal course of business. Based on the Company’s cash balance as of the date of this filing and projected cash needs for a year from the date of this filing, management estimates that it will need to raise additional capital to cover operating and capital requirements. The Company will seek additional funding either through an initial public offering or through debt financings and other arrangements. Although management has been successful to date in raising necessary funding, there is no assurance the Company will be successful in obtaining such additional financing on terms acceptable to it, if at all, and it may not be able to enter other arrangements. If the Company is unable to obtain funding, it could be forced to delay, reduce or eliminate the Company’s research and development programs, expansion or commercialization efforts, which could adversely affect its business prospects and ability to continue operations. These conditions raise substantial doubt as to whether the Company will continue as a going concern for the next twelve months from the issuance of these financial statements. The accompanying financial statements have been prepared in conformity with GAAP, which contemplates continuation of the Company as a going concern and the realization of assets and the satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.	NOTE 4 —GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS At December 31, 2022 and 2021, the Company had cash of $128,149 and $12,362, respectively, and an accumulated deficit of $42,382,291 and $32,774,456, respectively. The Company’s liquidity needs up to December 31, 2022 have been satisfied through debt and equity financings. For the years ended December 31, 2022 and 2021, the Company had a loss from operations of $5,507,641 and $1,940,332, respectively, and negative cash flows from operations of $3,428,707 and $1,176,829, respectively. The Company’s operating activities consume the majority of its cash resources, and management anticipates that the Company will continue to incur operating losses as it executes its plans through 2023. In addition, the Company has had and expects to have negative cash flows from operations, at least into the near future. As of December 31, 2022 and as of the date of issuance, the Company is in default of its convertible notes (see Note 8). The accompanying financial statements have been prepared on the basis that the Company will continue as a going concern, which assumes the realization of assets and the satisfaction of liabilities in the normal course of business. Based on the Company’s cash balance as of December 31, 2022, and projected cash needs for 2023 and subsequent fiscal periods, management estimates that it will need to raise additional capital to cover operating and capital requirements. The Company will seek additional funding either through an initial public offering or through debt financings and other arrangements. Although management has been successful to date in raising necessary funding, there is no assurance the Company will be successful in obtaining such additional financing on terms acceptable to it, if at all, and it may not be able to enter other arrangements. If the Company is unable to obtain funding, it could be forced to delay, reduce or eliminate the Company’s research and development programs, expansion or commercialization efforts, which could adversely affect its business prospects and ability to continue operations. These conditions raise substantial doubt as to whether the Company will continue as a going concern for the next twelve months from the issuance of these financial statements. The accompanying financial statements have been prepared in conformity with U.S. GAAP, which contemplates continuation of the Company as a going concern and the realization of assets and the satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Property and Equipment

Property and Equipment	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Property and Equipment	NOTE 5 — PROPERTY AND EQUIPMENT Property and equipment consist of the following: March 31, December 31, Lab equipment $ 666,178 $ 666,178 Leasehold improvements 115,333 115,333 Furniture and fixtures 3,579 3,579 785,090 785,090 Less: accumulated depreciation (553,087 ) (530,116 ) Property and equipment, net $ 232,003 $ 254,974 Depreciation expense was $22,971 and $22,301 for the three months ended March 31, 2023 and 2022, respectively.	NOTE 5 —PROPERTY AND EQUIPMENT Property and equipment consist of the following: December 31, December 31, Lab equipment $ 666,178 $ 662,593 Leasehold improvements 115,333 115,333 Furniture and fixtures 3,579 — 785,090 777,926 Less: accumulated depreciation (530,116 ) (440,334 ) Property and equipment, net $ 254,974 $ 337,592 Depreciation expense was $89,782 and $89,646 for the years ended December 31, 2022 and 2021, respectively.

Accrued Expenses and Other Liab

Accrued Expenses and Other Liabilities	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Accrued Liabilities and Other Liabilities [Abstract]
Accrued Expenses and Other Liabilities	NOTE 6 — ACCRUED EXPENSES AND OTHER LIABILITIES Accrued expenses and other liabilities consist of the following amounts: March 31, December 31, Accrued compensation $ 1,234,660 $ 916,934 Other 47,171 27,639 Accrued expenses and other liabilities $ 1,281,831 $ 944,573 Accrued compensation is a noninterest-bearing liability for employee payroll that was outstanding at March 31, 2023 and December 31, 2022. This includes compensation earned during years 2019 to 2023.	NOTE 6 —ACCRUED EXPENSES AND OTHER LIABILITIES Accrued expenses and other liabilities consist of the following amounts: December 31, December 31, Accrued compensation $ 916,934 $ 489,794 Other 27,639 24,989 Accrued expenses and other liabilities $ 944,573 $ 514,783 Accrued compensation is a noninterest-bearing liability for employee payroll that was outstanding at December 31, 2022 and 2021. This relates to compensation earned during years 2019 to 2022.

Leases

Leases	12 Months Ended
	Dec. 31, 2022
Lessee Disclosure [Abstract]
Leases	NOTE 7 —LEASES The Company is a party to two office leases which expire on December 31, 2028. As of December 31, 2022, the weighted average remaining term is 6 years. The Company elected to not recognize ROU assets and lease liabilities arising from short-term leases (leases with initial terms of twelve months or less, which are deemed immaterial) on its balance sheets. When measuring lease liabilities for leases that were classified as operating leases, the Company discounted lease payments using its estimated incremental borrowing rate at the later of lease inception or January 1, 2020 (the date of adoption). The weighted average incremental borrowing rate applied was 8%. The following table presents net lease cost and other supplemental lease information: Years Ended December 31, December 31, Lease cost Operating lease cost (cost resulting from lease payments) $ 201,400 $ 204,499 Short term lease cost — 31,500 Net lease cost 201,400 235,999 Operating lease – operating cash flows (fixed payments) $ 200,980 $ 197,565 As of December 31, 2022, the estimated future minimum lease payments, excluding non-lease Operating Fiscal Year 2023 $ 204,930 2024 204,930 2025 204,930 2026 204,930 2027 204,930 Thereafter 204,930 Total future minimum annual lease payments 1,229,580 Less: Imputed interest (272,350 ) Present value of lease liabilities $ 957,230

Convertible Notes and Promissor

Convertible Notes and Promissory Notes	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Debt Disclosure [Abstract]
Convertible Notes and Promissory Notes	NOTE 7 — CONVERTIBLE NOTES AND PROMISSORY NOTES Convertible Notes Series 1 Convertible Notes These convertible notes have been issued between July 9, 2018 (the first initial closing) and September 13, 2019. All of the notes were issued with the same maturity date which was July 8, 2021 (three years from the initial closing). The notes bear interest at 8%, have no monthly payments, and are due in full with a balloon payment on the maturity date. The notes contain an embedded conversion feature whereby the outstanding principal and accrued and unpaid interest are automatically convertible upon a Qualified Financing, which is defined as new series of preferred stock whose rights, preferences or privileges are senior to the existing Series B preferred stock, with gross proceeds of at least $5,000,000, into the same shares (preferred stock) as issued in the offering. The conversion price is the lessor of (i) the price per share for the new preferred stock purchased in the Qualified Financing, multiplied by eighty percent (80%) and (ii) the price per share equal to the quotient of $20,000,000, divided by, the number of outstanding shares of the Company’s common stock and preferred stock, plus any outstanding warrants for capital stock of Company, outstanding stock options to purchase common stock and any shares of common stock reserved for issuance under the Company’s stock incentive plan. The outstanding principal and all accrued and unpaid interest are also convertible into the same series of stock issued at the holders’ option if there is a non-qualified C-2 Series 2 Convertible Notes These convertible notes have been issued between September 25, 2019 (the first initial closing) and December 31, 2021. All of the notes were issued with the same maturity date which was September 24, 2022 (three years from the initial closing). The notes bear interest at 8%, have no monthly payments, and are due in full with a balloon payment on the maturity date. The notes contain an embedded conversion feature whereby the outstanding principal and accrued and unpaid interest are automatically convertible upon a Qualified Financing, which is defined as new series of preferred stock whose rights, preferences or privileges are senior to the existing Series B preferred stock, with gross proceeds of at least $5,000,000, into the same shares (preferred stock) as issued in the offering. The conversion price is the lessor of (i) the price per share for the new preferred stock purchased in the Qualified Financing, multiplied by eighty percent (80%) and (ii) the price per share equal to the quotient of $20,000,000, divided by, the number of outstanding shares of the Company’s common stock and preferred stock, plus any outstanding warrants for capital stock of Company, outstanding stock options to purchase common stock and any shares of common stock reserved for issuance under the Company’s stock incentive plan. The outstanding principal and all accrued and unpaid interest are also convertible into the same series of stock issued at the holders’ option if there is a non-qualified occurred at which point all outstanding principal and accrued and unpaid interest was converted in Preferred Series C-2 Other Convertible Note The Company issued a convertible note to an economic development fund for $50,000 on June 24, 2020. The note is non-interest C-2 January 2022 Convertible Notes On January 19, 2022, the Company issued two senior secured convertible notes (the “Convertible Notes”) of $1,111,111 each to two investors (“Holders”), due on January 19, 2023. The notes bear interest at 10% (18% default). The Company is required to make monthly interest payments for the interest incurred and require monthly principal payments of $158,730 beginning on July 19, 2022. The notes are collateralized by all assets (including current and future intellectual property) of the Company. These two notes were issued with a 10% discount and were subject to an 8% commission due to the underwriter. These fees were recorded as debt discount. In addition, the Holders received from the Company a warrant to subscribe for and purchase up to 1,885,796 shares (3,771,592 shares in total) of common stock of the Company. Each warrant is exercisable at a price of $0.01 per warrant share, vests immediately upon closing (the “Initial Exercise Date”) and a term of 5 years. The fair value of the warrants was $409,483 which was recorded as debt discount. The senior secured convertible notes shall be convertible at the option of the Holders into shares of common stock at a fixed conversion price equal to the lesser of $0.22 per share and a 25% discount to the price of the common stock in a Qualified Offering (as adjusted hereunder, the “Conversion Price”). In the event that units consisting of common stock and warrants are issued in a Qualified Offering, the senior secured convertible notes shall be convertible into common stock and warrants. If, at any time while the Convertible Note is outstanding, the Company sells or grants any option to purchase or sells or grants any right to reprice, or otherwise disposes of or issues (or announces any sale, grant or any option to purchase or other disposition), any common stock or common stock equivalents entitling any Person to acquire shares of common stock at an effective price per share that is lower than the then Conversion Price (such lower price, the “Base Conversion Price”), then the Conversion Price shall be reduced to equal the Base Conversion Price. Such adjustment shall be made whenever such common stock or common stock equivalents are issued. There were multiple events during the year ended December 31, 2022 that triggered the downround feature of the base conversion price. As of March 31, 2023 and December 31, 2022, the Base Conversion Price was $0.11. The conversion feature within these convertible notes meets the requirements to be treated as a derivative. Accordingly, the Company estimated the fair value of the convertible notes derivative using the Monte Carlo Method as of the date of issuance. The fair value of the derivative was determined to be $1,110,459 at the time of issuance and was recorded as a liability with an offsetting amount recorded as a debt discount. The derivative is revalued at the end of each reporting period and any change in fair value is recorded as a gain or loss in the statement of operations. Proceeds from the sales of the Convertible Notes with stock purchase warrants were allocated to the two elements based on the relative fair value of the notes without the warrants and of the warrants themselves at time of issuance. The total amounts allocated to warrants were $409,483 and accounted for as paid-in On July 19, 2022, the Company defaulted on the debt. Pursuant to the terms of the note, upon an event of default there would be a 25% increase to the outstanding principal in addition to the interest rate increasing from 10% to 18%. Upon the event of default, the unamortized debt discount of $958,899 was accelerated and expensed. The outstanding principal balance of the notes was $2,777,778 at March 31, 2023 and December 31, 2022. During the three months ended March 31, 2023, interest expense for these notes was $262,597, which consists of $125,000 of interest and $137,597 of late fees and penalties. Amortization of debt discount expense for these notes was $703 for the three months ended March 31, 2023. During the three months ended March 31, 2022, interest expense for these notes was $40,123. Amortization of debt discount expense for these notes was $314,954 for the three months ended March 31, 2022. On November 2, 2022, the Company received a letter (“Notice of Acceleration”) from one of the Holders, notifying an Event of Default. As of the date of issuance, the Company is currently in default on these notes. An Agreement Subsequent to the Notice of Acceleration The Company entered an agreement with one of the Holders (“Puritan”) in connection with the Notice of Acceleration on December 19, 2022, Pursuant to the agreement, Alpha Healthcare Acquisition Corp. III (“Alpha”) and the Company each hereby represent and warrant to Puritan that (i) it intends to enter into a business combination agreement (“the Business Combination Agreement”) among Alpha, the Company and Merger Sub ( as defined in the Business Combination Agreement, (ii) there will be no conditions to closing relating to Alpha or its affiliates delivering a certain amount of cash to the Company at closing of the Business Combination (the “Closing”), (iii) the only conditions to Closing of the merger are as set forth in Sections 6.1 through Section 6.3 of the Business Combination Agreement, (iv) upon entering into such Business Combination Agreement, such parties shall have a commitment letter from a third party to provide capital in an amount sufficient to the surviving company to the Business Combination to, among other things, repay all amounts due and owing at such time to Puritan at the Closing, (v) the equity valuation ascribed to the Company in the Business Combination Agreement is $150 million, and (vi) such Business Combination Agreement shall not place any restrictions on Puritan’s ability to transfer any of its securities, including, without limitation, the shares underlying the Puritan Warrant. The Company agrees that it will not make any payment to any other debtholder on account of interest or principal during the forbearance period hereunder. Based on the representations and warranties and agreements above and in consideration of the Company’s agreement to pay Puritan at the Closing; (i) the outstanding principal amount, plus accrued interest, late fees and all other amounts then owed as specified in the 2022 Note, including without limitation, Sections 8(b) and 2(c) of the 2022 Note (the “2022 Note Payoff Amount”)—as of the date hereof, the parties acknowledge that $1,610,413 is due ($1,627,749 as of December 31, 2022) and owed under the 2022 Note and (ii) 25,000 freely tradable shares of Alpha (not subject to lock-up non-payment Notwithstanding the foregoing, the Notice of Acceleration shall automatically be reinstated with an effective date of November 2, 2022, upon the earliest to occur of: (i) June 30, 2023, if the Closing has not occurred prior to such date, (ii) the Company and/or Alpha provide notice to Puritan that they have mutually agreed not pursue a business combination transaction, or (iii) Alpha or the Company publicly announce that the Business Combination Agreement has been terminated by either party (the first occurrence of (i), (ii) or (iii), the “Outside Date”) 2023 Promissory Notes During the three months ended March 31, 2023, the Company has received $375,000 from five zero coupon Promissory Notes (the “Notes”). The Notes have a 12-month 10-day Proceeds from the sales of the Convertible Notes with stock purchase warrants were allocated to the two elements based on the relative fair value of the notes without the warrants and of the warrants themselves at time of issuance. The total amounts allocated to warrants were $6,112 and accounted for as paid-in	NOTE 8 —LOANS PAYABLE AND CONVERTIBLE NOTES PPP Loans On April 8, 2020, under the U.S. Small Business Administration’s (“SBA”) Paycheck Protection Program (“PPP”), the Company entered into a note payable with a financial institution for $220,720 at an interest rate of 0.98% per annum and a maturity date of April 8, 2022. Pursuant to the note, principal and interest payments are deferred for six months, during which time the Company may apply for loan forgiveness. On April 23, 2021, the Company applied for loan forgiveness for the full loan amount. On June 22, 2021, the loan was forgiven in full. The forgiveness of the PPP loan was reported as gain on the forgiveness of loans payable in the statement of operations during the year ended December 31, 2021. On February 10, 2021, the Company entered into a second note payable with a financial institution under the PPP of $217,460 at an interest rate of 0.98% per annum and a maturity date of February 10, 2026. Pursuant to the note, principal and interest payments are deferred for a period no less than 10 months. On December 7, 2021, the loan was forgiven in full. The forgiveness of the PPP loan was reported as gain on the forgiveness of loans payable in the statement of operations during the year ended December 31, 2021. Convertible Notes Series 1 Convertible Notes These convertible notes have been issued between July 9, 2018 (the first initial closing) and September 13, 2019. All of the notes were issued with the same maturity date which was July 8, 2021 (three years from the initial closing). The notes bear interest at 8%, have no monthly payments, and are due in full with a balloon payment on the maturity date. The notes contain an embedded conversion feature whereby the outstanding principal and accrued and unpaid interest are automatically convertible upon a Qualified Financing, which is defined as new series of preferred stock whose rights, preferences or privileges are senior to the existing Series B preferred stock, with gross proceeds of at least $5,000,000, into the same shares (preferred stock) as issued in the offering. The conversion price is the lessor of (i) the price per share for the new preferred stock purchased in the Qualified Financing, multiplied by eighty percent (80%) and (ii) the price per share equal to the quotient of $20,000,000, divided by, the number of outstanding shares of the Company’s common stock and preferred stock, plus any outstanding warrants for capital stock of Company, outstanding stock options to purchase common stock and any shares of common stock reserved for issuance under the Company’s stock incentive plan. The outstanding principal and all accrued and unpaid interest are also convertible into the same series of stock issued at the holders’ option if there is a non-qualified C-2 Series 2 Convertible Notes These convertible notes have been issued between September 25, 2019 (the first initial closing) and December 31, 2021. All of the notes were issued with the same maturity date which was September 24, 2022 (three years from the initial closing). The notes bear interest at 8%, have no monthly payments, and are due in full with a balloon payment on the maturity date. The notes contain an embedded conversion feature whereby the outstanding principal and accrued and unpaid interest are automatically convertible upon a Qualified Financing, which is defined as new series of preferred stock whose rights, preferences or privileges are senior to the existing Series B preferred stock, with gross proceeds of at least $5,000,000, into the same shares (preferred stock) as issued in the offering. The conversion price is the lessor of (i) the price per share for the new preferred stock purchased in the Qualified Financing, multiplied by eighty percent (80%) and (ii) the price per share equal to the quotient of $20,000,000, divided by, the number of outstanding shares of the Company’s common stock and preferred stock, plus any outstanding warrants for capital stock of Company, outstanding stock options to purchase common stock and any shares of common stock reserved for issuance under the Company’s stock incentive plan. The outstanding principal and all accrued and unpaid interest are also convertible into the same series of stock issued at the holders’ option if there is a Non-Qualified C-2 Other Convertible Note The Company issued a convertible note to an economic development fund for $50,000 on June 24, 2020. The note is non-interest C-2 January 2022 Convertible Notes On January 19, 2022, the Company issued two senior secured convertible notes (the “Convertible Notes”) of $1,111,111 each to two investors (“Holders”), due on January 19, 2023. The notes bear interest at 10% (18% default). The Company is required to make monthly interest payments for the interest incurred and require monthly principal payments of $158,730 beginning on July 19, 2022. The notes are collateralized by all assets (including current and future intellectual property) of the Company. These two notes were issued with a 10% discount and were subject to an 8% commission due to the underwriter. These fees were recorded as debt discount. In addition, the Holders received from the Company a warrant to subscribe for and purchase up to 1,885,796 shares (3,771,592 shares in total) of common stock of the Company. Each warrant is exercisable at a price of $0.01 per warrant share, vests immediately upon closing (the “Initial Exercise Date”) and a term of 5 years. The fair value of the warrants was $409,483 which was recorded as debt discount. The senior secured convertible notes shall be convertible at the option of the Holders into shares of common stock at a fixed conversion price equal to the lesser of $0.22 per share and a 25% discount to the price of the common stock in a Qualified Offering (as adjusted hereunder, the “Conversion Price”). In the event that units consisting of common stock and warrants are issued in a Qualified Offering, the senior secured convertible notes shall be convertible into common stock and warrants. If, at any time while the Convertible Note is outstanding, the Company sells or grants any option to purchase or sells or grants any right to reprice, or otherwise disposes of or issues (or announces any sale, grant or any option to purchase or other disposition), any common stock or common stock equivalents entitling any Person to acquire shares of common stock at an effective price per share that is lower than the then Conversion Price (such lower price, the “Base Conversion Price”), then the Conversion Price shall be reduced to equal the Base Conversion Price. Such adjustment shall be made whenever such common stock or common stock equivalents are issued. There were multiple events during the year ended December 31, 2022 that triggered the downround feature of the base conversion price. As of December 31, 2022, the Base Conversion Price was $0.11. The conversion feature within these convertible notes meets the requirements to be treated as a derivative. Accordingly, the Company estimated the fair value of the convertible notes derivative using the Monte Carlo Method as of the date of issuance. The fair value of the derivative was determined to be $1,110,459 at the time of issuance and was recorded as a liability with an offsetting amount recorded as a debt discount. The derivative is revalued at the end of each reporting period and any change in fair value is recorded as a gain or loss in the statement of operations. Proceeds from the sales of the Convertible Notes with stock purchase warrants were allocated to the two elements based on the relative fair value of the notes without the warrants and of the warrants themselves at time of issuance. The total amounts allocated to warrants were $409,483 and accounted for as paid-in On July 19, 2022, the Company defaulted on the debt. Pursuant to the terms of the note, upon an event of default there would be a 25% increase to the outstanding principal in addition to the interest rate increasing from 10% to 18%. Upon the event of default the unamortized debt discount of $958,899 was accelerated and expensed through Loss on Extinguishment of Debt in the statement of operations. The outstanding principal balance of the notes was $2,777,778 at December 31, 2022. During the year ended December 31, 2022, interest expense for these notes was $1,125,868, which consists of $332,253 of interest, $238,059 of late fees and penalties, and $555,556 for the 25% increase in outstanding principal upon the event of default. Amortization of debt discount expense for these notes was $943,265 for the year ended December 31, 2022. On November 2, 2022, the Company received a letter (“Notice of Acceleration”) from one of the Holders, notifying an Event of Default (See below for an agreement subsequent to the notice of acceleration). As of the date of issuance, the Company is currently in default on these notes. An Agreement Subsequent to the Notice of Acceleration The Company entered an agreement with one of the Holders (“Puritan”) in connection with the Notice of Acceleration on December 19, 2022, Pursuant to the agreement, Alpha Healthcare Acquisition Corp. III (“Alpha”) and the Company each hereby represent and warrant to Puritan that (i) it intends to enter into a business combination agreement (“the Business Combination Agreement”) among Alpha, the Company and Merger Sub ( as defined in the Business Combination Agreement, (ii) there will be no conditions to closing relating to Alpha or its affiliates delivering a certain amount of cash to the Company at closing of the Business Combination (the “Closing”), (iii) the only conditions to Closing of the merger are as set forth in Sections 6.1 through Section 6.3 of the Business Combination Agreement, (iv) upon entering into such Business Combination Agreement, such parties shall have a commitment letter from a third party to provide capital in an amount sufficient to the surviving company to the Business Combination to, among other things, repay all amounts due and owing at such time to Puritan at the Closing, (v) the equity valuation ascribed to the Company in the Business Combination Agreement is $150 million, and (vi) such Business Combination Agreement shall not place any restrictions on Puritan’s ability to transfer any of its securities, including, without limitation, the shares underlying the Puritan Warrant. The Company agrees that it will not make any payment to any other debtholder on account of interest or principal during the forbearance period hereunder. Based on the representations and warranties and agreements above and in consideration of the Company’s agreement to pay Puritan at the Closing; (i) the outstanding principal amount, plus accrued interest, late fees and all other amounts then owed as specified in the 2022 Note, including without limitation, Sections 8(b) and 2(c) of the 2022 Note (the “2022 Note Payoff Amount”)—as of the date hereof, the parties acknowledge that $1,610,413 is due ($1,627,749 as of December 31, 2022) and owed under the 2022 Note and (ii) 25,000 freely tradable shares of Alpha (not subject to lock-up non-payment Notwithstanding the foregoing, the Notice of Acceleration shall automatically be reinstated with an effective date of November 2, 2022, upon the earliest to occur of: (i) June 30, 2023, if the Closing has not occurred prior to such date, (ii) the Company and/or Alpha provide notice to Puritan that they have mutually agreed not pursue a business combination transaction, or (iii) Alpha or the Company publicly announce that the Business Combination Agreement has been terminated by either party (the first occurrence of (i), (ii) or (iii), the “Outside Date”)

Commitments & Contingencies

Commitments & Contingencies	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Commitments And Contingencies [Line Items]
Commitments & Contingencies	NOTE 8 — COMMITMENTS AND CONTINGENCIES On January 30, 2008, the Company and Carnegie Mellon University (“CMU”) entered into a License Agreement, as amended by that certain Amendment No. 1 to the Amended Exclusive License Agreement, dated as of July 19, 2011, as further amended by that certain Amendment No. 2 to the Amended Exclusive License Agreement, dated as of February 8, 2016, as further amended by that certain Amendment No. 3 to the Amended Exclusive License Agreement, dated as of February 27, 2020 and as further amended by that certain Amendment No. 4 to the Amended Exclusive License Agreement, dated November 23, 2021 (collectively, the “Amended Exclusive License Agreement”). This License Agreement provides the Company an exclusive world-wide right to use certain technology of CMU relating to biocompatible plasma-based plastics to make, have made, use, and otherwise dispose of licensed products and to create derivatives for the field of use. The Company is required to use its best efforts to effect introduction of the licensed technology into the commercial market as soon as possible and meet certain milestones as stipulated within the agreement. CMU retains the right to use any derivative technology developed by the Company as a result of its use of this technology and retains the intellectual property rights to the licensed technology including patents, copyrights, and trademarks. This agreement is effective until January 30, 2028, or until the expiration of the last-to-expire 30 exercised the warrant in full and the Company issued 1,607,705 shares of Common Stock. Prior to a qualified initial public offering or a qualified sale, CMU has the right to subscribe for additional equity securities so as to maintain its then percentage of ownership in the Company. Royalties payable by the Company to CMU are 2.07% of net sales, as defined in the License Agreement. No royalties are due or payable for a period of three (3) years following the effective date or until the closing of a change in control event, whichever occurs sooner. The Company shall also pay CMU 25% of any sublicense fees received, due and payable upon receipt of the sublicense fees by the Company. All payments due to CMU are due within sixty (60) days after the end of each fiscal quarter. All overdue payments bear interest at a rate equal to the Prime rate in effect at the date such amounts are due plus 4%. Royalties accrued and paid during the three months ended March 31, 2023 and 2022, were $0. The Company is obligated to reimburse CMU for all patent expenses and fees incurred to date by CMU for the licensed technology at the earlier of (1) three years from the effective date; (2) the closing date of a change in control event; (3) for international patents, from the start of expenses for patenting outside of the United States of America. There were no reimbursed expenses and no owed related to reimbursable expenses for the three months ended March 31, 2023 and 2022, respectively.	NOTE 9 —COMMITMENTS AND CONTINGENCIES On January 30, 2008, the Company and Carnegie Mellon University (“CMU”) entered into a License Agreement, as amended by that certain Amendment No. 1 to the Amended Exclusive License Agreement, dated as of July 19, 2011, as further amended by that certain Amendment No. 2 to the Amended Exclusive License Agreement, dated as of February 8, 2016, as further amended by that certain Amendment No. 3 to the Amended Exclusive License Agreement, dated as of February 27, 2020 and as further amended by that certain Amendment No. 4 to the Amended Exclusive License Agreement, dated November 23, 2021 (collectively, the “Amended Exclusive License Agreement”). This License Agreement provides the Company an exclusive world-wide right to use certain technology of CMU relating to biocompatible plasma-based plastics to make, have made, use, and otherwise dispose of licensed products and to create derivatives for the field of use. The Company is required to use its best efforts to effect introduction of the licensed technology into the commercial market as soon as possible and meet certain milestones as stipulated within the agreement. CMU retains the right to use any derivative technology developed by the Company as a result of its use of this technology and retains the intellectual property rights to the licensed technology including patents, copyrights, and trademarks. This agreement is effective until January 30, 2028, or until the expiration of the last-to-expire Royalties payable by the Company to CMU are 2.07% of net sales, as defined in the License Agreement. No royalties are due or payable for a period of three The Company is obligated to reimburse CMU for all patent expenses and fees incurred to date by CMU for the licensed technology at the earlier of (1) three years from the effective date; (2) the closing date of a change in control event; (3) for international patents, from the start of expenses for patenting outside of the United States of America. There were no reimbursed expenses and no owed related to reimbursable expenses for the years ended December 31, 2022 and 2021, respectively.
Alpha Healthcare Acquisition Corp. III [Member]
Commitments And Contingencies [Line Items]
Commitments & Contingencies	Note 5 — Commitments & Contingencies Registration Rights The holders of the Founder Shares, Private Placement Units, Private Placement Warrants, Class A common stock underlying the Private Placement Warrants and Private Placement Units that may be issued upon conversion of Working Capital Loans (and any shares or Class A common stock issuable upon the exercise of the Private Placement Warrants and Private Placement Units that may be issued upon conversion of Working Capital Loans) are entitled to registration rights pursuant to a registration rights agreement dated July 26, 2021. The holders of these securities are entitled to make unlimited demands that the Company registers such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the completion of the initial Business Combination. However, the registration rights agreement provides that the Company will not permit any registration statement filed under the Securities Act to become effective until termination of the applicable lock-up Underwriters Agreement The Company granted the underwriters a 45-day The underwriters received a cash underwriting discount of two percent ( ( In addition to the cash underwriting discounts, under the original agreement, the underwriters were entitled to a deferred underwriting fee of three and a half percent ( On March 20, 2023, the Company received a letter providing notice from the representative of the underwriters, waiving any entitlement to their portion of the $5,405,436 deferred underwriting fee that accrued from their participation as the underwriters of the IPO as they have not been involved in the Business Combination process. This deferred underwriting discount, which previously increased the accumulated deficit due to the accretion of the Class A Common stock subject to possible redemption, was recorded as a recovery in the accumulated deficit during the three months ended March 31, 2023. Subscription Agreements In conjunction with the IPO activities, on July 14, 2021 (the “Inception Date”), the Company and its Sponsor entered into the Subscription Agreements with certain investors. Under these Subscription Agreements, the investors, who received the At Risk Incentive Private Shares, received the right but not the obligation to subscribe, at their sole discretion, to any equity financing associated with the Closing of the initial Business Combination subject to a maximum of 10% of such offerings’ proceeds, and the right but not the obligation to subscribe, at their sole discretion, at the same terms in the next special purpose acquisition company or other similar entity sponsored by Constellation Alpha Holdings. The investors who received the Non Risk Incentive Private Shares also received the right but not the obligation to subscribe, at their sole discretion, to any equity financing associated with the Closing of the SPAC’s initial Business Combination subject to a maximum of 10% of such offerings’ proceeds if the Investor still holds their Public Shares at the business combination date. Since the number of shares or other instruments to be purchase by the investors is unknown, these rights to participate in future offerings do not meet definition of an equity contract. Risks and Uncertainties Results of operations and the Company’s ability to complete an Initial Business Combination may be adversely affected by various factors that could cause economic uncertainty and volatility in the financial markets, many of which are beyond its control. The business could be impacted by, among other things, downturns in the financial markets or in economic conditions, inflation, and increases in interest rates. The Company cannot at this time fully predict the likelihood of one or more of the above events, their duration or magnitude or the extent to which they may negatively impact our business and our ability to complete an Initial Business Combination. The unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.	Note 5 — Commitments & Contingencies Registration Rights The holders of the Founder Shares, Private Placement Units, Private Placement Warrants, Class A common stock underlying the Private Placement Warrants and Private Placement Units that may be issued upon conversion of Working Capital Loans (and any shares or Class A common stock issuable upon the exercise of the Private Placement Warrants and Private Placement Units that may be issued upon conversion of Working Capital Loans) are entitled to registration rights pursuant to a registration rights agreement dated July 26, 2021. The holders of these securities are entitled to make unlimited demands that the Company registers such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the completion of the initial Business Combination. However, the registration rights agreement provides that the Company will not permit any registration statement filed under the Securities Act to become effective until termination of the applicable lock-up Underwriters Agreement The Company granted the underwriters a 45-day The underwriters received a cash underwriting discount of two percent (2.0%) of the gross proceeds of the Public Offering, or $3,000,000, paid on July 29, 2021. Additionally, in connection with the partial over-allotment exercise, the underwriters received a cash underwriting discount of two percent (2.0%) of the gross proceeds, or $88,820, paid on August 6, 2021. In addition to the cash underwriting discounts, the underwriters will be entitled to a deferred underwriting fee of three and a half percent (3.5%), or $5,405,436 of the gross proceeds of the Public Offering and the underwriters’ partial over-allotment exercise upon the completion of the Company’s initial Business Combination. Subscription Agreements In conjunction with the IPO activities, on July 14, 2021 (the “Inception Date”), the Company and its Sponsor entered into the Subscription Agreements with certain investors. Under these Subscription Agreements, the investors, who received the At Risk Incentive Private Shares, received the right but not the obligation to subscribe, at their sole discretion, to any equity financing associated with the Closing of the initial Business Combination subject to a maximu Risks and Uncertainties Results of operations and the Company’s ability to complete an Initial Business Combination may be adversely affected by various factors that could cause economic uncertainty and volatility in the financial markets, many of which are beyond its control. The business could be impacted by, among other things, downturns in the financial markets or in economic conditions, inflation, increases in interest rates, the ongoing effects of the COVID-19

Shareholder's Equity

Shareholder's Equity	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Alpha Healthcare Acquisition Corp. III [Member]
Class of Stock [Line Items]
Shareholder's Equity	Note 6 — Shareholder’s Equity Common Stock of common stock that were subject to forfeiture, to the Company by the initial shareholders On March 1, 2021, the Company amended its charter to authorize issuance of 100,000,000 Class A common stock, with a par value of $0.0001 per share, 10,000,000 Class B common stock, with a par value of $0.0001 per share, and 1,000,000 preferred stock, with a par value of $0.0001 per share, and effected a 1:1.2 stock split of its common stock which resulted in an aggregate of 4,312,500 shares of Class B common stock outstanding All shares and per share amounts have been retroactively restated to reflect the stock split. On July 29, 2021, the Company sold 15,000,000 Units, each unit consists of one share of Class A common stock and one-fourth On August 3, 2021, the Underwriters exercised their option to purchase 444,103 additional Units out of the total 2,250,000 available under the over-allotments and the forfeiture term lapsed for 111,026 Founder Shares. The remaining 451,464 Founder Shares were forfeited upon the expiration of the 45-day Both Class A and B shareholders vote together as a single class on all matters submitted to a vote of the Company shareholders, with each share of common stock entitling the holder to one vote. The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the initial Business Combination on a one-for-one as-converted of the sum of the total number of all shares of common stock outstanding upon completion of the Proposed Public Offering plus all shares of Class A common stock and equity-linked securities issued or deemed issued in connection with the Business Combination (after giving effect to any redemptions of shares of Class A common stock by Public Stockholders) (excluding any shares or equity-linked securities issued, or to be issued, to any seller in the Business Combination and any Private Placement Units issued to our Sponsor, officers or directors upon conversion of Working Capital Loans). The Sponsor may also elect to convert their shares of Class B common stock into an equal number of shares of Class A common stock, subject to adjustment as provided above, at any time. Preferred Stock Warrants issuable upon exercise of the warrants and to maintain a current prospectus relating to those shares of Class A common stock until the warrants expire or are redeemed. If a registration statement covering the issuance of the Class A common stock issuable upon exercise of the warrants is not effective by the 60th business day after the closing of the initial Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act or another exemption. The warrants have an exercise price of $11.50 per share, subject to adjustments, and will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation. In addition, if (x) the Company issues additional shares of Class A common stock or equity- linked securities for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $9.20 per share of Class A common stock (with such issue price or effective issue price to be determined in good faith by the board of directors and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Sponsor or such affiliates, as applicable, prior to such issuance), or the Newly Issued Price, (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the initial Business Combination on the date of the consummation of the initial Business Combination (net of redemptions), and (z) the volume weighted average trading price of the common stock during the 20 trading day period starting on the trading day prior to the day on which the Company consummates its initial Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger price described below under “Redemption of warrants when the price per share of Class A common stock equals or exceeds $18.00” will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price, respectively. The Private Placement Warrants are identical to the Public Warrants, except that the Private Placement Warrants and the shares of Class A common stock issuable upon exercise of the Private Placement Warrants will not be transferable, assignable or salable until 30 days after the completion of a Business Combination, subject to certain limited exceptions. Redemption of warrants when the price per share of Class A common stock equals or exceeds $18.00 • in whole and not in part; • at a price of $0.01 per warrant; • upon a minimum of 30 days’ prior written notice of redemption; and • if, and only if, the closing price of the common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock capitalizations, reorganizations, recapitalizations and the like and for certain issuances of Class A common stock and equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination) for any 20 trading days within a 30-trading The Company will not redeem the warrants unless an effective registration statement under the Securities Act covering the issuance of the shares of Class A common stock issuable upon exercise of the warrants is effective and a current prospectus relating to those shares of Class A common stock is available throughout the 30-day In no event will the Company be required to net cash settle any warrant. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless.	Note 6 — Shareholder’s Equity Common Stock On March 1, 2021, the Company amended its charter to authorize issuance of 100,000,000 Class A common stock, with a par value of $0.0001 per share, 10,000,000 Class B common stock, with a par value of $0.0001 per share, and 1,000,000 preferred stock, with a par value of $0.0001 per share, and effected a 1:1.2 stock split of its common stock which resulted in an aggregate of 4,312,500 shares of Class B common stock outstanding. All shares and per share amounts have been retroactively restated to reflect the stock split. On July 29, 2021, the Company sold 15,000,000 Public Units, each Public Unit consists of one share of Class A common stock and one-fourth On August 3, 2021, the Underwriters exercised their option to purchase 444,103 additional Public Units out of the total 2,250,000 available under the over-allotments and the forfeiture term lapsed for 111,026 Founder Shares. The remaining 451,464 Founder Shares were forfeited upon the expiration of the 45-day Both Class A and B shareholders vote together as a single class on all matters submitted to a vote of the Company shareholders, with each share of common stock entitling the holder to one vote. The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the initial Business Combination on a one-for-one basis (subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like), and subject to further adjustment as provided herein. In the case that additional shares of Class A common stock, or equity-linked securities, are issued or deemed issued in excess of the amounts offered in the Proposed Public Offering and related to the closing of the Business Combination, including pursuant to a specified future issuance, the ratio at which shares of Class B common stock shall convert into shares of Class A common stock will be adjusted (unless our Sponsor agrees to waive such adjustment with respect to any such issuance or deemed issuance, including a specified future issuance) so that the number of shares of Class A common stock issuable upon conversion of all shares of Class B common stock will equal, in the aggregate, on an as-converted Preferred Stock Warrants The warrants have an exercise price of $11.50 per share, subject to adjustments, and will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation. In addition, if (x) the Company issues additional shares of Class A common stock or equity- linked securities for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $9.20 per share of Class A common stock (with such issue price or effective issue price to be determined in good faith by the board of directors and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Sponsor or such affiliates, as applicable, prior to such issuance), or the Newly Issued Price, (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the initial Business Combination on the date of the consummation of the initial Business Combination (net of redemptions), and (z) the volume weighted average trading price of the common stock during the 20 trading day period starting on the trading day prior to the day on which the Company consummates its initial Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger price described below under “Redemption of warrants when the price per share of Class A common stock equals or exceeds The Private Placement Warrants are identical to the Public Warrants, except that the Private Placement Warrants and the shares of Class A common stock issuable upon exercise of the Private Placement Warrants will not be transferable, assignable or salable until 30 days after the completion of a Business Combination, subject to certain limited exceptions (the “Private Placement Warrants”). Redemption of warrants when the price per share of Class A common stock equals or exceeds $18.00 • in whole and not in part; • at a price of $0.01 per warrant; • upon a minimum of 30 days’ prior written notice of redemption; and • if, and only if, the closing price of the common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock capitalizations, reorganizations, recapitalizations and the like and for certain issuances of Class A common stock and equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination) for any 20 trading days within a 30-trading The Company will not redeem the warrants unless an effective registration statement under the Securities Act covering the issuance of the shares of Class A common stock issuable upon exercise of the warrants is effective and a current prospectus relating to those shares of Class A common stock is available throughout the 30-day In no event will the Company be required to net cash settle any warrant. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless.

Profit-Sharing Plan

Profit-Sharing Plan	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Defined Benefit Plan [Abstract]
Profit-Sharing Plan	NOTE 9 — PROFIT-SHARING PLAN The Company has a 401(k) profit-sharing plan covering substantially all employees. The Company’s discretionary profit-sharing contributions are determined annually by the Board. No discretionary profit-sharing contributions were made to the plan during the three months ended March 31, 2023 and 2022.	NOTE 10 —PROFIT-SHARING PLAN The Company has a 401(k) profit-sharing plan covering substantially all employees. The Company’s discretionary profit-sharing contributions are determined annually by the Board. No discretionary profit-sharing contributions were made to the plan during the years ended December 31, 2022 and 2021.

Mezzanine Equity And Stockholde

Mezzanine Equity And Stockholders' Deficit	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Temporary Equity And Permanent Equity [Abstract]
Mezzanine Equity And Stockholders' Deficit	NOTE 10 — MEZZANINE EQUITY AND STOCKHOLDERS’ DEFICIT Authorized Capital In September 2022, the Company filed the Fourth Amended and Restated Certificate of Incorporation (the “Restated Certificate”). Such Restated Certificate shall, among other things: (i) terminate the Series C Convertible Preferred Stock, par value $0.001 per share, (ii) create a new Series C-1 C-2 C-1 C-1 C-2 C-2 Common Stock Each share of common stock is entitled to one vote at all meetings of stockholders provided that, except as otherwise required by law, holders of common stock shall not be entitled to vote on any amendment to the Certificate of Incorporation that relates solely to the terms of one or more outstanding series of preferred stock if the holders of such affected series are entitled, either separately or together with the holders of one or more other such series, to vote thereon pursuant to the Certificate of Incorporation. Preferred Stock Since the preferred stock may be redeemed at the option of the holder, but is not mandatorily redeemable, the redeemable preferred stock has been classified as mezzanine equity and initially recognized at fair value of the proceeds on the date of issuance less issuance costs. Series A Preferred Stock, Series C-1 C-2 C-1 C-2 C-1 C-2 C-1 C-2 Each share of preferred stock is convertible into one share of common stock at any time, at the holder’s option, subject to adjustments for stock dividends, splits, combinations, certain issuances at prices below the issue price of preferred stock, and certain other events. Holders of preferred stock are entitled to cast the number of votes equal to the number of shares of common stock into which shares are convertible. The holders of Series A Preferred Shares, exclusively and as a separate class, are entitled to elect one director of the Company. The holders of common stock, exclusively and as a separate class, are entitled to elect one director of the Company who must be the then-sitting Chief Executive Officer of the Company and one director shall be selected and nominated by the then-sitting directors of the Company. In the event of any distributions in cash or other property prior to a Deemed Liquidation Event as defined in the Restated Certificate, 70% of the distributions shall be paid ratably to the holders of Series B Preferred Stock, before any payment made to the holders of Series C-1 C-2 In the event of the liquidation or dissolution of the Company, the holders of Series C-1 C-2 pro-rata 2009 Stock Incentive Plan The Company has authorized the issuance of 45,072,120 shares under its 2009 Stock Incentive Plan (the “Plan”). Under the Plan, the Board may grant incentive and nonqualified stock options to purchase shares of the Company’s common stock to employees and other recipients as determined by the Board. The exercise price per share for an option granted to employees owning stock representing more than 10% of the Company at the time of the grant cannot be less than 110% of the fair market value. Incentive and nonqualified stock options granted to all persons shall be granted at a price no less than 100% of the fair market value and any price determined by the Board, respectively. Options expire no more than ten years after the date of grant. Incentive stock options to employees owning more than 10% of the Company expire no more than five years after the date of grant. The vesting of stock options is determined by the Board. Generally, the options vest over a four-year period at a rate of 25% one year following the date of grant, with the remaining shares vesting equally on a monthly basis over the subsequent thirty-six Warrant and Option Valuation The Company has computed the fair value of warrants and options granted using the Black-Scholes option pricing model. The expected term used for warrants and options issued to non-employees zero-coupon Warrants Outstanding The following table presents information related to common stock warrants for the three months ended March 31, 2023: Number of Weighted Weighted Outstanding and exercisable, December 31, 2022 5,190,325 $ 0.13 3.32 Warrants issued 117,646 0.88 — Warrants exercised — — — Warrants expired/cancelled — — — Outstanding and exercisable, March 31, 2023 5,307,971 $ 0.14 3.12 The intrinsic value of the common stock warrants as of March 31, 2023 was $565,739. The following table presents information related to Series B preferred stock warrants for the year ended March 31, 2023: Number of Weighted Weighted Outstanding and exercisable, December 31, 2022 821,253 $ 0.22 4.16 Warrants issued — — — Warrants exercised — — — Warrants expired/cancelled — — — Outstanding and exercisable, March 31, 2023 821,253 $ 0.22 3.92 The intrinsic value of the Series B warrants as of March 31, 2023 was $0. The following table presents information related to Series C-1 Number of Weighted Weighted Outstanding and exercisable, December 31, 2022 2,936,933 $ 0.16 9.73 Warrants issued — — — Warrants exercised — — — Warrants expired/cancelled — — — Outstanding and exercisable, March 31, 2023 2,936,933 $ 0.16 9.49 The intrinsic value of the Series C-1 Option Activity and Summary A summary of the option activity during the three months ended March 31, 2023 is presented below: Number of Weighted Weighted Aggregate Outstanding, December 31, 2022 36,320,980 $ 0.13 8.07 $ 1,083,492 Granted 1,250,000 0.16 Exercised — — Expired/Cancelled (200,000 ) 0.11 Outstanding, March 31, 2023 37,370,980 $ 0.13 7.91 $ 1,073,492 Vested/Exercisable, March 31, 2023 16,163,949 $ 0.12 6.88 $ 569,604 The weighted average fair value of the options granted during the three months ended March 31, 2023 was $0.12 per share, based on a Black Scholes option pricing model using the following assumptions: Expected volatility 76.3% Expected term of option 6 years Range of risk-free interest rate 3.55% -3.75% Dividend yield — During the three months ended March 31, 2023 and 2002, the Company recorded stock-based compensation expense for options in the amount of $180,509 and $172,183, respectively. As of March 31, 2023, there was approximately $1.93 million of total unrecognized compensation expense related to unvested stock options, which will be recognized over the weighted-average remaining vesting period of 2.2 years.	NOTE 11 —MEZZANINE EQUITY AND STOCKHOLDERS’ DEFICIT Authorized Capital In September 2022, the Company filed the Fourth Amended and Restated Certificate of Incorporation (the “Restated Certificate”). Such Restated Certificate shall, among other things: (i) terminate the Series C Convertible Preferred Stock, par value $0.001 per share, (ii) create a new Series C-1 C-2 C-1 C-1 C-2 C-2 Common Stock Each share of common stock is entitled to one vote at all meetings of stockholders provided that, except as otherwise required by law, holders of common stock shall not be entitled to vote on any amendment to the Certificate of Incorporation that relates solely to the terms of one or more outstanding series of preferred stock if the holders of such affected series are entitled, either separately or together with the holders of one or more other such series, to vote thereon pursuant to the Certificate of Incorporation. Preferred Stock Since the preferred stock may be redeemed at the option of the holder, but is not mandatorily redeemable, the redeemable preferred stock has been classified as mezzanine equity and initially recognized at fair value of the proceeds on the date of issuance less issuance costs. Series A Preferred Stock, Series C-1 C-2 C-1 C-2 C-1 C-2 During the year ended December 31, 2022, 883,536 shares of Preferred Series B shares were issued due to the exercise of Preferred Series B warrants. The gross proceeds were $97,189. On September 23, 2022, the Company offered investors the chance to purchase Series C-1 C-1 C-1 C-1 C-1 C-1 During the year ended December 31, 2022, 93,897 shares of Preferred Series C-1 C-1 Each share of preferred stock is convertible into one share of common stock at any time, at the holder’s option, subject to adjustments for stock dividends, splits, combinations, certain issuances at prices below the issue price of preferred stock, and certain other events. Holders of preferred stock are entitled to cast the number of votes equal to the number of shares of common stock into which shares are convertible. The holders of Series A Preferred Shares, exclusively and as a separate class, are entitled to elect one director of the Company. The holders of common stock, exclusively and as a separate class, are entitled to elect one director of the Company who must be the then-sitting Chief Executive Officer of the Company and one director shall be selected and nominated by the then-sitting directors of the Company. In the event of any distributions in cash or other property prior to a Deemed Liquidation Event as defined in the Restated Certificate, 70% of the distributions shall be paid ratably to the holders of Series B Preferred Stock, before any payment made to the holders of Series C-1 C-2 In the event of the liquidation or dissolution of the Company, the holders of Series C-1 C-2 pro-rata Issuances and Repurchase of Common Stock In September of 2021, the Company entered into an agreement with two angel investors associated with pre-IPO During the year ended December 31, 2022, the Company issued 203,666 shares with a fair value of $26,477 in exchange for services. 2009 Stock Incentive Plan The Company has authorized the issuance of 45,072,120 shares under its 2009 Stock Incentive Plan (the “Plan”). Under the Plan, the Board may grant incentive and nonqualified stock options to purchase shares of the Company’s common stock to employees and other recipients as determined by the Board. The exercise price per share for an option granted to employees owning stock representing more than 10 ten 10 five four thirty-six Warrant and Option Valuation The Company has computed the fair value of warrants and options granted using the Black-Scholes option pricing model. The expected term used for warrants and options issued to non-employees zero-coupon Warrants Outstanding The following table presents information related to common stock warrants for the year ended December 31, 2022: Number of Weighted Weighted Outstanding and exercisable, December 31, 2021 1,758,975 $ 0.46 2.38 Warrants issued 3,771,592 0.01 — Warrants exercised (340,242 ) 0.11 — Warrants expired/cancelled — — — Outstanding and exercisable, December 31, 2022 5,190,325 $ 0.13 3.32 During the year ended December 31, 2022, the Company offered all holders of warrants an opportunity to exercise at $0.11 per share regardless of the contractual exercise price set forth in each warrant. In connection with this one-time 5 The following table presents information related to Series B preferred stock warrants for the year ended December 31, 2022: Number of Weighted Weighted Outstanding and exercisable, December 31, 2021 1,704,789 $ 0.22 5.07 Warrants issued — — — Warrants exercised (883,536 ) 0.11 — Warrants expired/cancelled — — — Outstanding and exercisable, December 31, 2022 821,253 $ 0.22 4.16 During the year ended December 31, 2022, the Company offered all holders of warrants an opportunity to exercise at $0.11 per share regardless of the contractual exercise price set forth in each warrant. In connection with this one-time The following table presents information related to Series C-1 Number of Warrants Weighted Exercise Price Weighted Average Remaining Contractual Life in Years Outstanding and exercisable, December 31, 2021 — $ — — Warrants issued 3,030,830 0.16 — Warrants exercised (93,897 ) 0.11 — Warrants expired/cancelled — — — Outstanding and exercisable, December 31, 2022 2,936,933 $ 0.16 9.73 During the year ended December 31, 2022, the Company offered all holders of warrants an opportunity to exercise at $0.11 per share regardless of the contractual exercise price set forth in each warrant. In connection with this one-time C-1 Option Activity and Summary A summary of the option activity during the year ended December 31, 2022 is presented below: Number of Options Weighted Average Exercise Price Weighted Average Aggregate Outstanding, December 31, 2021 34,990,469 $ 0.13 8.92 $ 106,429 Granted 4,350,000 0.15 Exercised (9,075 ) 0.14 Expired/Cancelled (3,010,414 ) 0.13 Outstanding, December 31, 2022 36,320,980 $ 0.13 8.07 $ 1,083,492 Vested/Exercisable, December 31, 2022 14,578,490 $ 0.12 6.85 $ 527,441 The weighted average fair value of the options granted during the years ended December 31, 2022 and 2021 was $0.10 and $0.09 per share, respectively, based on a Black Scholes option pricing model using the following assumptions: 2022 2021 Range of expected volatility 76.3% - 82.4% 82.4% Expected term of option 6 years 6 years Range of risk-free interest rate 1.82% - 3.04% 0.74% - 1.38% Dividend yield — — During the year ended December 31, 2022 and 2001, the Company recorded stock-based compensation expense for options in the amount of $609,891 and $246,799, respectively. As of December 31, 2022, there was approximately $2 million of total unrecognized compensation expense related to unvested stock options, which will be recognized over the weighted-average remaining vesting period of 2.35 years.

Income Taxes

Income Taxes	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Income Taxes [Line Items]
Income Taxes		NOTE 12 — INCOME TAXES The Company accounts for income taxes under ASC 740-10, The components of the Company’s tax rate for the years ended December 31, 2022 and 2021 consisted of the following: 2022 2021 U.S. federal statutory rate 21.0 % 21.0 % Effects of: State taxes, net of federal benefit 7.9 % 7.9 % Stock based compensation (0.4 %) (1.1 %) Gain on loan forgiveness (2.5 %) 1.4 % Net operating loss true-up 2.6 % R&D expenses, net 0.0 % (0.6 %) R & D Credit 0.2 % 2.2 % R & D True Up (6.6 %) (1.9 %) Other permanent differences (0.2 %) 0.0 % Stock Compensation True up 0.0 % 4.9 % Valuation allowance (22.0 %) (33.8 %) Effective rate (0.0 %) (0.0 %) Significant components of the Company’s deferred tax assets as of December 31, 2022 and 2021 are summarized below: 2022 2021 Deferred income tax assets: Net operating losses $ 7,642,000 $ 5,585,000 Accrued interest 747,000 543,000 Federal research and development tax credits 113,000 568,000 Amortization of research expense 585,000 — Right of use asset 29,000 — Non-qualified 263,000 132,000 Accrued compensation 271,000 142,000 Change in fair value of derivative liabilities 275,000 632,000 Total deferred tax asset 9,925,000 7,602,000 Valuation allowance (9,925,000 ) (7,602,000 ) Net deferred income tax assets $ — $ — As of December 31, 2022, the Company had approximately $25.7 million of federal and $29.9 million state net operating loss carry forwards. Federal and state net operating loss carryforwards were approximately $5.4 and $6.3 million, respectively for the year ended December 31, 2022. The Company’s net operating loss carry forwards consist of approximately $7.0 million of pre 2018 net operating loss carryforwards, which expire after twenty years and begin to expire starting in 2028. The Company had approximately $18.9 million of post 2017 net operating losses that carry forward indefinitely. Future utilization of the net operating loss carry forwards is subject to certain limitations under Section 382 of the Internal Revenue Code. In addition, the Company has approximately $13,000 of federal research and development credit carryovers, which expire after twenty years and begin to expire starting in 2042 The Company provides for a valuation allowance when it is more likely than not that it will not realize a portion of the deferred tax assets. The Company has established a valuation allowance against the net deferred tax asset due to the uncertainty that enough taxable income will be generated in those taxing jurisdictions to utilize the assets. Therefore, we have not reflected any benefit of such deferred tax assets in the accompanying financial statements. Our net deferred tax asset and valuation allowance increased by approximately $2,323,000 and $1,481,000 for the years ended December 31, 2022 and 2021, respectively. The Company is subject to U.S. federal income tax examinations by tax authorities for all tax years since inception due to unexpired net operating loss carryforwards originating in and after that year. The Company may be subject to income tax examinations for the various state taxing authorities which vary by jurisdiction. The Company has evaluated its income tax positions and has determined that it does not have any uncertain tax positions. The Company will recognize interest and penalties related to any uncertain tax positions through its income tax expense.
Alpha Healthcare Acquisition Corp. III [Member]
Income Taxes [Line Items]
Income Taxes	Note 7 — Income Taxes The Company’s effective tax rate (“ETR”) is calculated quarterly based upon current assumptions relating to the full year’s estimated operating results and various tax-related The 2021 and 2022 federal tax returns for the Company remain open for examination.	Note 7 — Income Taxes The Company’s general and administrative expenses are generally considered start-up The Company has no uncertain tax positions related to federal and state income taxes. The 2021 federal tax return for the Company remains open for examination. In the event that the Company is assessed interest or penalties at some point in the future, it will be classified in the financial statements as tax expense. The income tax provision consisted of the following as of December 31, 2022 and 2021: December 31, 2022 2021 Federal Current $ 391,198 $ — Deferred (265,998 ) (96,461 ) Change in valuation allowance 265,998 96,461 Income tax provision $ 391,198 $ — The Company’s net deferred tax assets consisted of the following as of December 31, 2022 and 2021: December 31, 2022 2021 Deferred tax asset Net operating loss carryforward $ — $ 33,531 Startup/Organization expenses 362,459 62,930 Total deferred tax assets 362,459 96,461 Valuation allowance (362,459 ) (96,461 ) Deferred tax asset, net of allowance $ — $ — As of December 31, 2022 and 2021, the Company has U.S. federal net operating loss carryovers of $0 and $159,673, respectively, that do not expire. In assessing the realization of the deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences representing future deductible amounts become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. After consideration of all of the information available, management believes that significant uncertainty exists with respect to future realization of the deferred tax assets and has therefore established a full valuation allowance. For the year ended December 31, 2022 and for the period from January 21, 2021 (inception) through December 31, 2021, the change in the valuation allowance was $265,998 and $96,461, respectively. There were no unrecognized tax benefits as of December 31, 2022 and 2021. No amounts were accrued for the payment of interest and penalties as of December 31, 2022 and 2021. The Company is currently not aware of any issues that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception. A reconciliation of the federal income tax rate to the Company’s effective tax rate at December 31, 2022 and 2021 is as follows: December 31, 2022 2021 Statutory federal income tax rate 21.0 % 21.0 % Change in fair value of overallotment liability — 8.3 Valuation allowance 44.0 (29.3 ) Effective tax rate 65.0 % 0.0 % The Company files U.S. federal income tax returns and is subject to examination since inception.

Stock-based Compensation

Stock-based Compensation	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Alpha Healthcare Acquisition Corp. III [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based Compensation	Note 8 — Stock-based Compensation On July 27, 2021, the Sponsor transferred 25,000 shares of Class B common stock to each of the three independent director nominees as compensation for their service on the board of directors. The awards will vest simultaneously with the closing of an initial business combination, provided the director has continuously served on the Company’s board of directors through the closing of such initial business combination. As such, the service period for these awards will start on the IPO Date. As the share awards would vest only upon the consummation on a business combination, the compensation expense in relation to these grants would be not recognized until the closing of the initial business combination. As a result, the Company recorded no compensation expense for the three months ended March 31, 2023 and 2022. The fair value of the Founder Shares on the grant date was approximately $5.26 per share. The valuation performed by the Company determined the fair value of the Founder Shares on the date of grant based on the fair value of the Class A shares discounted for a) the probability of a successful business combination, and b) the lack of marketability. The aggregate grant date fair value of the award amounted to approximately $394,000.	Note 8 — Stock-based Compensation On July 27, 2021, the Sponsor transferred 25,000 shares of Class B common stock to each of the three independent director nominees as compensation for their service on the board of directors. The awards will vest simultaneously with the closing of an initial business combination, provided the director has continuously served on the Company’s board of directors through the closing of such initial business combination. As such, the service period for these awards will start on the IPO Date. As the share awards would vest only upon the consummation on a business combination, the compensation expense in relation to these grants would not be recognized until the closing of the initial business combination. As a result, the Company recorded no compensation expense for any periods through December 31, 2022. No awards were granted, exercised or cancelled during the year ended December 31, 2022. The fair value of the Founder Shares on the grant date was approximately $5.26 per share. The valuation performed by the Company determined the fair value of the Founder Shares on the date of grant based on the fair value of the Class A shares discounted for a) the probability of a successful business combination, and b) the lack of marketability. The aggregate grant date fair value of the award related to the 75,000 unvested founder shares amounted to approximately $394,000.

Related Party Transactions

Related Party Transactions	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Related Party Transaction [Line Items]
Related Party Transactions	NOTE 11 – RELATED PARTIES A member of the Board of Directors holds investments in the Company through various venture capital firms. Certain family members of the CEO invested in Series B Preferred Shares, Series C-1 C-2 The following table summarizes the related party transactions / balances in the Company at March 31, 2023 and at December 31, 2022: March 31, 2023 December 31, 2022 Dollars Shares Dollars Shares Series A Preferred Stock and Dividends Board Member Initial Investment $ 877,054 4,222,223 $ 877,054 4,222,223 Accrued Dividends 693,891 678,694 $ 1,570,945 $ 1,555,748 Series B Preferred Stock Board Member $ 887,049 5,094,537 $ 887,049 5,094,537 Immediate Family 1 103,244 780,967 103,244 780,967 $ 990,293 5,875,504 $ 990,293 5,875,504 Series C-1 Immediate Family Member 1 Initial Investment $ 50,000 234,742 $ 50,000 234,742 Accrued Dividends 873 10 $ 50,873 $ 50,010 Series C-2 Board Member $ 1,049,381 6,129,561 $ 1,049,381 6,129,561 Immediate Family 1 64,981 379,560 64,981 379,560 Immediate Family 2 64,279 375,464 64,279 375,464 $ 1,178,641 6,884,585 $ 1,178,641 6,884,585 Series C-2 Board Member $ 38,036 $ 19,924 Immediate Family 1 2,355 1,234 Immediate Family 2 2,330 1,220 $ 42,721 $ 22,378 In 2020, the Company granted 148,854 options to Immediate Family Member 2 for a fair value of $12,925 for consulting services. For each of the three months ended March 31, 2023 and 2022, the Company incurred an expense of $796 for these stock options.	NOTE 13 — RELATED PARTIES A member of the Board of Directors holds investments in the Company through various venture capital firms. Certain family members of the CEO invested in Series B Preferred Shares, Series C-1 C-2 The following table summarizes the related party transactions / balances in the Company at December 31, 2022: December 31, 2022 Interest Expense Dollars Shares Series A Preferred Stock Board Member $ 877,054 4,222,223 Dividends Earned To Date 678,694 — $ 1,555,748 4,222,223 Series B Preferred Stock Board Member $ 887,049 5,094,537 Immediate Family 1 103,244 780,967 $ 990,293 5,875,504 Series C-1 Immediate Family 1 $ 50,000 234,742 Dividends Earned To Date 10 — $ 50,010 234,742 Series C-2 Board Member $ 1,049,381 6,129,561 Immediate Family 1 64,981 379,560 Immediate Family 2 64,279 375,464 $ 1,178,641 6,884,585 Series C-2 Board Member $ 19,924 Immediate Family 1 1,234 Immediate Family 2 1,220 $ 22,378 Series 1 Convertible Notes Board Member $ 46,641 Immediate Family 1 2,915 Immediate Family 2 2,915 $ 52,471 During the year ended December 31, 2022, Immediately Family Member 1 purchased 234,742 shares of Preferred Series C-1 C-1 During the year ended December 31, 2022, the above related parties converted principal and accrued interest of $900,000 and $278,641, respectively, into 5,257,009 and 1,627,576 shares of Preferred Series C-2, In 2020, the Company granted 148,854 options to Immediate Family Member 2 for a fair value of $12,925 for consulting services. The expense was $3,229 for each of the years ended December 31, 2022 and 2021. The following table summarizes the related party transactions / balances in the Company at December 31, 2021: December 31, 2021 Accrued Interest Interest Expense Dollars Shares Series A Preferred Stock Board Member $ 877,054 4,222,223 Dividends Earned To Date 613,583 — $ 1,490,637 4,222,223 Series B Preferred Stock Board Member $ 857,089 4,822,181 Immediate Family 1 103,244 780,967 $ 960,333 5,603,148 Series 1 Convertible Notes Board Member $ 202,740 $ 64,000 $ 800,000 Immediate Family 1 12,066 4,000 50,000 Immediate Family 2 11,364 4,000 50,000 $ 226,170 $ 72,000 $ 900,000
Alpha Healthcare Acquisition Corp. III [Member]
Related Party Transaction [Line Items]
Related Party Transactions	Note 4 — Related Party Transactions Founder Shares On January 21, 2021, the Sponsor subscribed to purchase 3,593,750 shares of the Company’s common stock, par value $0.0001 per share (the “Founder Shares”) for an aggregate price of $25,000. On January 25, 2021, the Sponsor paid $25,000, or approximately $0.00696 per share, to cover certain offering and formation costs in consideration for 3,593,750 Founder Shares. On March 1, 2021, the Company effected a 1:1.2 stock split of its common stock which resulted in an aggregate of 4,312,500 shares of Class B common stock outstanding. All shares and associated amounts have been retroactively restated to reflect the stock split. On August 3, 2021, the Underwriters exercised their option to purchase 444,103 additional Units out of the total 2,250,000 available under the over-allotments and the forfeiture provisions lapsed for 111,026 Founder Shares. The remaining 451,464 Founder Shares were forfeited upon the expiration of the 45-day On July 27, 2021, our sponsor transferred 25,000 founder shares to each of Darlene DeRemer, Eugene Podsiadlo, and William Woodward, directors of the Company. The awards will vest simultaneously with the closing of an initial business combination, provided the director has continuously served on the Company’s board of directors through the closing of such initial business combination. At the IPO Date, the Sponsor also transferred to certain investors a total of 225,000 of Founders shares (Note 4) (“Non-Risk Non-Risk At the IPO Date, the Sponsor also transferred to certain other investors the total of 600,900 of Founders shares (“Risk Incentive Private Shares”) as a compensation for their commitment to acquire at least 9.9% of the Public Units sold in the IPO. These Risk Incentive Private Shares are subject to forfeiture if the investors sell their Public Units prior to the closing of the initial Business Combination and will be, upon their forfeiture, transferred back to the Sponsor. The fair value of these Risk Incentive Private Shares is equal to the fair value of the Non-Risk The Sponsor, directors and executive officers have agreed not to transfer, assign or sell (i) any of their Founder Shares until the earliest of (A) one year after the completion of the initial Business Combination and (B) subsequent to the initial Business Combination, (x) if the closing price of the Company’s shares of Class A common stock equals or exceeds $ per share (as adjusted for share splits, share capitalizations, reorganizations, recapitalizations and the like) for any trading days within any 30-trading day period commencing at least days after the initial Business Combination, or (y) the date on which the Company completes a liquidation, merger, share exchange, reorganization or other similar transaction that results in all of its public shareholders having the right to exchange their common stock for cash, securities or other property, and (ii) any of their Private Placement Units, Private Placement Shares, Private Placement Warrants and Class A common stock issued upon conversion or exercise thereof until 30 days after the completion of the initial Business Combination (the “Lock-up”). Any permitted transferees will be subject to the same restrictions and other agreements of the Sponsor and directors and executive officers with respect to any Founder Shares, Private Placement Units, Private Placement Shares, Private Placement Warrants and Class A common stock issued upon conversion or exercise thereof. Private Placement Simultaneously with the closing of the IPO, the Sponsor purchased 455,000 placement units, at a purchase price of $4,550,000, in a private placement. Each Private Placement Unit is identical to the Public Units sold in the IPO except as described below. A portion of the proceeds from the Private Placement Units was added to the proceeds from the Public Offering to be held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Units will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law). As a result of the partial over-allotment exercise on August 3, 2021, the Company also issued 8,882 Private Placement Units, generating an additional $88,820 in gross proceeds. The Private Placement Units (including the Private Placement Shares, the Private Placement Warrants and Class A common stock issuable upon exercise of such Private Placement Warrants) will not be transferable or salable until 30 days after the completion of our Business Combination (except, among other limited exceptions, to our officers and directors and other persons or entities affiliated with our Sponsor). Due to Related Party The balances of $71,024 and $31,979 as of March 31, 2023 and December 31, 2022, respectively, represents $11,024 and $1,979, respectively, of general and administrative costs paid by an executive employee and affiliate of the Sponsor on behalf of the Company and $60,000 and $30,000, respectively, of unpaid monthly administrative services fees (as described below). Administrative Service Fee The Company has agreed, commencing on the date that the Company’s securities are first listed on the Nasdaq, to pay an affiliate of the Sponsor a monthly fee of an aggregate of $10,000 for office space, administrative and support services. For each of the three months ended March 31, 2023 and 2022, administrative fees incurred totaled $30,000, included in general and administrative expenses in the accompanying condensed consolidated statement of operations. During the three months ended March 31, 2023 and 2022, administrative service fees incurred totaled $30,000, and $0, respectively. As of March 31, 2023 and December 31, 2022, $60,000 and $30,000, respectively, is owed to the affiliate of the Sponsor for the administrative service fees, included in “due to related party” on the accompanying unaudited condensed consolidated balance sheets. Upon completion of the initial Business Combination or the Company’s liquidation, the Company will cease paying these monthly fees. Related Party Loans In order to finance transaction costs in connection with a Business Combination, the Company’s Sponsor, an affiliate of the Sponsor, or the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (the “Working Capital Loans”). Such Working Capital Loans would be evidenced by promissory notes. The notes would either be repaid upon consummation of a Business Combination, without interest, or, at the lender’s discretion, up to $1,500,000 of notes may be converted upon consummation of a Business Combination into warrants at a price of $1.50 per warrant. The warrants will be identical to the Private Placement Warrants. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans, but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. As of March 31, 2023 and December 31, 2022, there were no written agreements in place for the Working Capital Loans, nor were any amounts loaned to the Company by the Sponsor. In conjunction with the IPO activities, on July 14, 2021 (the “Inception Date”), the Company and its Sponsor entered into the Subscription Agreements with certain investors (see Note 5). Forward Purchase Agreement The Company granted to the direct anchor investors an option, in their sole discretion, to subscribe to a forward purchase agreement for up to an aggregate of 60% (up to 10% per direct anchor investor) of the securities sold in one or multiple private placements to close prior to or concurrently with the closing of the initial Business Combination. The aggregate proceeds from the sale of any securities pursuant to these forward purchase agreements will be used for purposes related to the initial Business Combination. Since the issuance of the securities to the investors is contingent upon the closing of an equity financing in relation to the initial Business Combination, and the number of shares to be purchased by the investors is undefined, the terms of the forward purchase agreement will not create an obligation for the Company until such financing occurs.	Note 4 — Related Party Transactions Founder Shares On January 21, 2021, the Sponsor subscribed to purchase 3,593,750 shares of the Company’s common stock, par value $0.0001 per share (the “Founder Shares”) for an aggregate price of $25,000. On January 25, 2021, the Sponsor paid $25,000, or approximately $0.00696 per share, to cover for certain offering and formation costs in consideration for 3,593,750 Founder Shares. On March 1, 2021, the Company effected a 1:1.2 stock split of its common stock which resulted in an aggregate of 4,312,500 shares of Class B common stock outstanding. All shares and associated amounts have been retroactively restated to reflect the stock split. On August 3, 2021, the Underwriters exercised their option to purchase 444,103 additional Public Units out of the total 2,250,000 available under the over-allotments and the forfeiture provisions lapsed for 111,026 Founder Shares. The remaining 451,464 Founder Shares were forfeited upon the expiration of the 45-day On July 27, 2021, our sponsor transferred 25,000 founder shares to each of Darlene DeRemer, Eugene Podsiadlo, and William Woodward, directors of the Company. The awards will vest simultaneously with the closing of an initial business combination, provided the director has continuously served on the Company’s board of directors through the closing of such initial business combination. At the IPO Date, the Sponsor also transferred to certain investors a total of 225,000 of Founders shares (Note 4) (“Non-Risk Non-Risk At the IPO Date, the Sponsor also transferred to certain other investors the total of 600,900 of Founders shares (“Risk Incentive Private Shares”) as a compensation for their commitment to acquire at least 9.9% of the Public Units sold in the IPO. These Risk Incentive Private Shares are subject to forfeiture if the investors sell their Public Units prior to the closing of the initial Business Combination. The fair value of these Risk Incentive Private Shares is equal to the fair value of the Non-Risk The Sponsor, directors and executive officers have agreed not to transfer, assign or sell (i) any of their Founder Shares until the earliest of (A) one year after the completion of the initial Business Combination and (B) subsequent to the initial Business Combination, (x) if the closing price of the Company’s shares of Class A common stock equals or exceeds $12.00 per share (as adjusted for share splits, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading days after the initial Business Combination, or (y) the date on which the Company completes a liquidation, merger, share exchange, reorganization or other similar transaction that results in all of its public shareholders having the right to exchange their common stock for cash, securities or other property, and (ii) any of their Private Placement Units, Private Placement Shares, Private Placement Warrants and Class A common stock issued upon conversion or exercise thereof until 30 days after the completion of the initial Business Combination (the “Lock-up”). Private Placement Simultaneously with the closing of the IPO, the Sponsor purchased 455,000 placement units, at a purchase price of $4,550,000, in a private placement. Each Private Placement Unit is identical to the Public Units sold in the IPO except as described below. A portion of the proceeds from the Private Placement Units was added to the proceeds from the Public Offering to be held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Units will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law). As a result of the partial over-allotment exercise on August 3, 2021, the Company also issued 8,882 Private Placement Units, generating additional $88,820 in gross proceeds. The Private Placement Units (including the Private Placement Shares, the Private Placement Warrants and Class A common stock issuable upon exercise of such Private Placement Warrants) will not be transferable or salable until 30 days after the completion of our Business Combination (except, among other limited exceptions, to our officers and directors and other persons or entities affiliated with our Sponsor). Due to Related Party The balance of $31,979 as of December 31, 2022 represents $1,979 of general and administrative costs paid by an affiliate of the Sponsor on behalf of the Company and $30,000 of unpaid monthly administrative service fees (described below). The balance of $2,275 as of December 31, 2021, represents general and administrative costs paid by an affiliate of the Sponsor on behalf of the Company. Administrative Service Fee The Company has agreed, commencing on the date that the Company’s securities are first listed on the Nasdaq, to pay an affiliate of the Sponsor a monthly fee of an aggregate of $10,000 for office space, administrative and support services. Upon completion of the initial Business Combination or the Company’s liquidation, the Company will cease paying these monthly fees. For the year ended December 31, 2022, and for the period from January 21, 2021 (inception) through December 31, 2021, administrative service fees incurred totaled $120,000 and $51,000, respectively, included in general and administrative expenses in the accompanying statements of operations. As of December 31, 2022 and 2021, $30,000 and $0 is owed to the affiliate of the Sponsor for the administrative service fees, included in “due to related party” on the accompanying balance sheets. Related Party Loans In order to finance transaction costs in connection with a Business Combination, the Company’s Sponsor, an affiliate of the Sponsor, or the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (the “Working Capital Loans”). Such Working Capital Loans would be evidenced by promissory notes. The notes would either be repaid upon consummation of a Business Combination, without interest, or, at the lender’s discretion, up to $1,500,000 of notes may be converted upon consummation of a Business Combination into warrants at a price of $1.50 per warrant. The warrants will be identical to the Private Placement Warrants. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans, but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. As of December 31, 2022 and 2021, there were no written agreements in place for the Working Capital Loans. In conjunction with the IPO activities, on July 14, 2021 (the “Inception Date”), the Company and its Sponsor entered into the Subscription Agreements with certain investors (see Note 6). Forward Purchase Agreement The Company granted to the direct anchor investors an option, in their sole discretion, to subscribe to a forward purchase agreement for up to an aggregate of 60% (up to 10% per direct anchor investor) of the securities sold in one or multiple private placements to close prior to or concurrently with the closing of the initial Business Combination. The aggregate proceeds from the sale of any securities pursuant to these forward purchase agreements will be used for purposes related to the initial Business Combination. Since the issuance of the securities to the investors is contingent upon the closing of an equity financing in relation to the initial Business Combination, and the number of shares to be purchased by the investors is undefined, the terms of the forward purchase agreement will not create an obligation for the Company until such financing occurs.

Subsequent Events

Subsequent Events	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Subsequent Event [Line Items]
Subsequent Events	NOTE 12 – SUBSEQUENT EVENTS 2023 Promissory Notes Subsequent to March 31, 2023, the Company has received $283,500 from 14 zero coupon Promissory Notes. The Notes have a 12-month	NOTE 14 — SUBSEQUENT EVENTS Business Combination Agreement On January 4, 2023, Alpha Healthcare Acquisition Corp. III, a Delaware corporation (“Alpha”), entered into a business combination agreement (the “Business Combination Agreement”) by and among Alpha, Candy Merger Sub, Inc., a Delaware corporation (“Merger Sub”), and the Company. The Business Combination Agreement provides, among other things, that on the terms and subject to the conditions set forth therein, Merger Sub will merge with and into the Company, with the Company surviving as a wholly-owned subsidiary of Alpha (the “Business Combination”). Upon the closing of the Business Combination, it is anticipated that Alpha will change its name to “Carmell Therapeutics Corporation.” The Business Combination Agreement and the transactions contemplated thereby were approved by the boards of directors of each of the Company and Alpha. Under the Business Combination Agreement, Alpha will acquire all of the outstanding equity interests of the Company in exchange for shares of Class A common stock of Alpha, par value $0.0001 per share (the “Class A Common Stock”), based on the Company’s implied equity value of $150,000,000, to be paid to the Company’s stockholders at the effective time of the Business Combination. Pursuant to the Business Combination Agreement, at or prior to the effective time of the Business Combination, each option and warrant exercisable for the Company’s equity that is outstanding immediately prior to the effective time of the Business Combination shall be assumed by Alpha and continue in full force and effect on the same terms and conditions as are currently applicable to such options and warrants, subject to adjustments to exercise price and number of shares of Class A Common Stock issued upon exercise. 2023 Promissory Notes During 2023, the Company has received $250,000 from three zero coupon Promissory Notes. The Notes have a 12-month Issuance of Stock Options During 2023 the Company issued 950,000 stock options at an exercise price of $0.16.
Alpha Healthcare Acquisition Corp. III [Member]
Subsequent Event [Line Items]
Subsequent Events	Note 9 — Subsequent Events The Company did not identify any subsequent events that require adjustment or disclosure in the unaudited condensed consolidated financial statements other than discussed below. On May 1, 2023, Sandstone Asset Management notified the Company that it intends to stay invested in its anchor investor position in 1,020,520 shares of the Company’s common stock and 285,875 warrants through the closing of the potential Business Combination with Carmell. This commitment is expected to result in approximately $10.4 million in funds retained by the combined company after the Closing, based on the amount of funds in the Trust Account as of March 31, 2023 (excluding dividend and interest income available for payment of the Company’s taxes).	Note 9 — Subsequent Events On January 4, 2023, the Company entered into the Business Combination Agreement with Merger Sub and Carmell, which is described in Note 1. The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued. Based upon this review, the Company did not identify any further subsequent events that require adjustment or disclosure in the financial statements.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Basis of Presentation	Basis of Presentation The unaudited financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These financial statements should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2022. The accompanying unaudited condensed financial statements include all adjustments that are of a normal recurring nature and necessary for the fair presentation of the results for the interim periods presented. Results for interim periods are not necessarily indicative of results to be expected for the full year.	Basis of Presentation The accompanying audited financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). References to the “ASC” hereafter refer to the Accounting Standards Codification established by the Financial Accounting Standards Board (“FASB”) as the source of authoritative U.S. GAAP.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity- based transactions and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity- based transactions and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future events. Accordingly, the actual results could differ significantly from estimates included in these financial statements.
Cash and Cash Equivalents	Cash The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company has no cash equivalents as of March 31, 2023 and at December 31, 2022.	Cash The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company has no cash equivalents as of December 31, 2022 and 2021.
Property and Equipment	Property and Equipment Property and equipment are stated at cost less accumulated depreciation. Maintenance and repair charges are expensed as incurred. The assets are depreciated using the straight-line method using the following useful lives: Lab equipment—7 years Leasehold improvements—The lesser of 10 years or the remaining life of the lease Furniture and fixtures – 7 years	Property and Equipment Property and equipment are stated at cost less accumulated depreciation. Maintenance and repair charges are expensed as incurred. The assets are depreciated using the straight-line method using the following estimated useful lives: Lab equipment - 7 years Leasehold improvements - The lesser of 10 years or the remaining life of the lease Furniture and fixtures – 7 years
Net Income (Loss) per Common Stock share	Net Loss Per Share Net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the reporting period. Diluted earnings per share is computed like basic earnings per share, except the weighted average number of common shares outstanding are increased to include additional shares from the assumed exercise of share options, if dilutive. The dilutive effect, if any, of convertible instruments or warrants is calculated using the treasury stock method. There are no outstanding dilutive instruments as the outstanding convertible instruments and warrants would be anti-dilutive if converted or exercised, respectively, as of March 31, 2023 and 2022. The following table summarizes the securities that were excluded from the diluted per share calculation because the effect of including these potential shares was antidilutive due to the Company’s net loss position even though the exercise price could be less than the average market price of the common shares: Three Months Ended March 31, 2023 2022 Series A Preferred Stock (if converted) 19,968,051 19,968,051 Series B Preferred Stock (if converted) 33,801,226 32,917,690 Series C-1 5,090,693 — Series C-2 73,560,390 — Stock Options 37,370,980 35,440,469 Common Stock Warrants (penny warrants excluded) 1,536,379 1,758,975 Preferred Stock Warrants 3,758,186 1,704,759 Convertible Notes 31,982,684 17,094,017 Total 207,068,589 108,883,961	Net Loss Per Share Net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the reporting period. Diluted earnings per share is computed like basic earnings per share, except the weighted average number of common shares outstanding are increased to include additional shares from the assumed exercise of share options, if dilutive. The dilutive effect, if any, of convertible instruments or warrants is calculated using the treasury stock method. There are no outstanding dilutive instruments as the outstanding convertible instruments and warrants would be anti-dilutive if converted or exercised, respectively, as of December 31, 2022 and 2021. The following table summarizes the securities that were excluded from the diluted per share calculation because the effect of including these potential shares was anti-dilutive due to the Company’s net loss position even though the exercise price could be less than the average market price of the common shares: Year Ended December 31, 2022 2021 Series A Preferred Stock (if converted) 19,968,051 19,968,051 Series B Preferred Stock (if converted) 33,801,226 32,917,690 Series C-1 5,090,693 — Series C-2 73,560,390 — Stock Options 36,320,980 34,990,469 Common Stock Warrants (penny warrants excluded) 1,418,733 1,758,975 Preferred Stock Warrants 3,758,186 1,704,789 Convertible Notes 26,620,370 — Total 200,538,629 91,339,974
Offering Costs	Offering Costs Associated with a Public Offering The Company complies with the requirements of FASB ASC 340-10-S99-1 ASC 340-10-S99-1 S-1 S-1	Offering Costs Associated with a Public Offering The Company complies with the requirements of FASB ASC 340-10-S99-1 ASC 340-10-S99-1 S-1
Advertising Costs		Advertising Costs Advertising costs are expensed as incurred. Advertising expense for the year ended December 31, 2022 and 2021, were $9,247 and $8,015 respectively.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company reviews long-lived assets for impairment whenever events or circumstances indicate that the carrying value of such assets may not be fully recoverable. Impairment is present when the sum of estimated undiscounted future cash flow expected to result from use of the assets is less than carrying value. If impairment is present, the carrying value of the impaired asset is reduced to its fair value. Fair value is determined based on discounted cash flow or appraised values, depending on the nature of the assets. There were no impairment losses recognized for long-lived assets for the three months ended March 31, 2023 and 2022.	Impairment of Long-Lived Assets The Company reviews long-lived assets for impairment whenever events or circumstances indicate that the carrying value of such assets may not be fully recoverable. Impairment is present when the sum of estimated undiscounted future cash flow expected to result from use of the assets is less than carrying value. If impairment is present, the carrying value of the impaired asset is reduced to its fair value. Fair value is determined based on discounted cash flow or appraised values, depending on the nature of the assets. There were no impairment losses recognized for long-lived assets for the years ended December 31, 2022 and 2021.
Fair Value of Financial Instruments	Fair Value Measurements and Fair Value of Financial Instruments Our financial instruments consist primarily of cash, prepaid expenses, accounts payable, accrued expenses and short-term debt. The carrying value of cash, prepaid expenses, accounts payable and accrued expenses approximates fair value because of the short-term maturity of such instruments. We have categorized our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy in accordance with GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets and liabilities recorded in the balance sheet at fair value as of March 31, 2023 and at December 31, 2022 are categorized based on a hierarchy of inputs, as follows: Carrying Fair Value Measurement Using Value Level 1 Level 2 Level 3 Total Derivative liability at March 31, 2023 $ 1,152,065 $ — $ — $ 1,152,065 $ 1,152,065 Derivative liability at December 31, 2022 $ 826,980 $ — $ — $ 826,980 $ 826,980 Fair Value Measurements Using Significant Unobservable March 31, 2023 December 31, 2022 Balance, beginning of year $ 826,980 $ 3,846,319 Initial recognition of derivative liability — 1,321,860 Settled in Series C-2 — (3,081,912 ) Change in fair value of derivative liability 325,085 (1,259,287 ) Balance, end of period $ 1,152,065 $ 826,980 Level 1—Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date. Level 2—Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data. Level 3—Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information. The fair value of the embeded derivatives in the convertible notes as of March 31, 2023 and December 31, 2022, was valued using a Monte-Carlo model and were based upon the following management assumptions: March 31, 2023 December 31, 2022 Stock price $ 0.16 $ 0.16 Expected term (years) 0.50 0.04 Volatility 73.40 % 55.10 % Risk free interest rate 4.40 % 4.38 % Probability of Qualified Financing or IPO 50.00 % 50.00 % Probability of a Change in Control Event 10.00 % 10.00 % The stock price was derived from 409a valuations. The volatility was determined from the historical volatility of comparable public companies over the expected terms. The term was based on the maturity date of the note. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon	Fair Value Measurements and Fair Value of Financial Instruments Our financial instruments consist primarily of accounts payable, accrued expenses and short- and long-term debt. The carrying value of cash, prepaid expenses, other current assets, accounts payable and accrued expenses approximates fair value because of the short-term maturity of such instruments. We have categorized our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy in accordance with U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets and liabilities recorded in the balance sheet at fair value as of December 31, 2022 and 2021 are categorized based on a hierarchy of inputs, as follows: Carrying Fair Value Measurement Using Value Level 1 Level 2 Level 3 Total Derivative liability at December 31, 2022 $ 826,980 $ — $ — $ 826,980 $ 826,980 Derivative liability at December 31, 2021 $ 3,846,319 $ — $ — $ 3,846,319 $ 3,846,319 Fair Value Measurements Using Significant 2022 2021 Balance, beginning of year $ 3,846,319 $ 1,045,905 Initial recognition of derivative liability 1,321,860 285,349 Settled in Series C-2 (3,081,912 ) — Change in fair value of derivative liability (1,259,287 ) 2,515,065 Balance, end of year $ 826,980 $ 3,846,319 Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date. Level 2 - Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data. Level 3 - Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information. The fair value of the embedded derivatives in the convertible notes as of December 31, 2022 and 2021, was valued using a Monte-Carlo model and were based upon the following management assumptions: 2022 2021 Stock price $ 0.16 $0.13 Expected term (years) 0.04 0.71 - 3.48 Volatility 55.10 % 48.90% - 60.50% Risk free interest rate 4.38 % 0.44% - 0.72% Probability of Qualified Financing or IPO 50.00 % 60.00% Probability of a Change in Control Event 10.00 % 10.00% The stock price was derived from 409a valuations. The volatility was determined from the historical volatility of comparable public companies over the expected term. The term was based on the maturity date of the note. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon
Income Taxes	Income Taxes Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of March 31, 2023 and December 31, 2022. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities for tax years ended 2019 to 2022.	Income Taxes Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of December 31, 2022 and 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities for tax years ended 2019 to 2022.
Intangible Assets	Intangible Assets Intangible assets consist entirely of patent costs. The Company capitalizes legal costs directly associated with the submission of Company patent applications. Gross patent costs of $70,746 as of March 31, 2023 and December 31, 2022 are amortized on a straight-line basis over the patent term and are stated net of accumulated amortization of $43,172 and $42,044, respectively. No asset impairment was recognized during the three months ended March 31, 2023 and 2022. Amortization expense for the three months ended March 31, 2023 and 2022, was $1,128 and $1,114, respectively. Costs billed to the Company as reimbursement for third parties’ patent submissions are considered as license fees and expensed as incurred.	Intangible Assets Intangible assets consist entirely of patent costs. The Company capitalizes legal costs directly associated with the submission of Company patent applications. Gross patent costs of $70,746 as of December 31, 2022 and 2021 are amortized on a straight-line basis over the patent term and are stated net of accumulated amortization of $42,044 and $37,528, respectively. Such assets are periodically evaluated as to the recoverability of their carrying values. No asset impairment was recognized during the years ended December 31, 2022 and 2021. Amortization expense for the years ended December 31, 2022 and 2021, was $4,516 and $4,516, respectively. Costs billed to the Company as reimbursement for third parties’ patent submissions are considered as license fees and expensed as incurred. Estimated amortization expense for each of the following five years is as follows: 2023 $ 4,516 2024 4,528 2025 4,516 2026 4,516 2027 4,090 Thereafter 6,536 Total $ 28,702
Research and Development Costs	Research and Development Costs The Company is currently conducting research and development activities to operationalize certain patented technology that the Company owns and licenses. The Company expenses costs related to these activities in the period incurred.	Research and Development Costs The Company is currently conducting research and development activities to operationalize certain patented technology that the Company owns and licenses. The Company expenses costs related to these activities in the period incurred.
Stock-Based Compensation	Stock-Based Compensation The Company applies the provisions of ASC 718, Compensation — Stock Compensation For stock options issued to employees and members of the Board of Directors (the “Board) for their services, the Company estimates the grant date fair value of each option using the Black-Scholes option pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. For awards subject to service-based vesting conditions, including those with a graded vesting schedule, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock options on a straight-line basis over the requisite service period, which is generally the vesting term. Forfeitures are recorded as they are incurred as opposed to being estimated at the time of grant and revised. Pursuant to Accounting Standards Update (“ASU”) 2018-07, Compensation — Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Payment Accounting non-employees	Stock-Based Compensation The Company applies the provisions of ASC 718, Compensation — Stock Compensation For stock options issued to employees and members of the Board of Directors (the “Board) for their services, the Company estimates the grant date fair value of each option using the Black-Scholes option pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. For awards subject to service-based vesting conditions, including those with a graded vesting schedule, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock options on a straight-line basis over the requisite service period, which is generally the vesting term. Forfeitures are recorded as they are incurred as opposed to being estimated at the time of grant and revised. Pursuant to Accounting Standards Update (“ASU”) 2018-07, Compensation — Stock Compensation (Topic 718): Improvements to Non-employee non-employees
Leases	Leases The Company adopted ASC Topic 842, Leases, as amended, on January 1, 2020. We elected the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allowed the Company to not separate non-lease non-lease The Company’s leases consist of leaseholds on office space. The Company determines if an arrangement contains a lease at inception as defined by ASC 842. In order to meet the definition of a lease under ASC 842 in exchange for consideration. ROU (Right of Use) assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term.	Leases The Company adopted ASC Topic 842, Leases, as amended, on January 1, 2020. We elected the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allowed the Company to not separate non-lease non-lease The Company’s leases consist of leaseholds on office space. The Company determines if an arrangement contains a lease at inception as defined by ASC 842. In order to meet the definition of a lease under ASC 842, the contractual arrangement must convey to us the right to control the use of an identifiable asset for a period of time in exchange for consideration. ROU (Right of Use) assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term.
Recently Issued Accounting Standards	Recent Accounting Pronouncements On June 30, 2022, the FASB issued ASU 2022-03, 2022-03 2022-03	Recent Accounting Pronouncements On June 30, 2022, the FASB issued ASU 2022-03, 2022-03 2022-03
Alpha Healthcare Acquisition Corp. III [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Basis of Presentation	Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q S-X The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto for the year ended December 31, 2022 included in the Company’s Form 10-K as filed with the SEC on March 17, 2023. The interim results for the three months ended March 31, 2023 are not necessarily indicative of the results to be expected for the year ending December 31, 2023 or for any future periods.	Basis of Presentation The accompanying financial statements are presented in conformity with accounting principles generally accepted in the United States of America (“US GAAP”) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”).
Emerging Growth Company Status	Emerging Growth Company Status The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended, (the “Securities Act”), as modified by the Jumpstart our Business Startups Act of 2012, (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging	Emerging Growth Company Status The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended, (the “Securities Act”), as modified by the Jumpstart our Business Startups Act of 2012, (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
Marketable Securities Held in Trust Account	Marketable Securities Held in Trust Account At March 31, 2023 and December 31, 2022, the assets held in the Trust Account were substantially held in a money market fund which is comprised of U.S. Treasury Bills, U.S. Treasury Coupons, and U.S. Treasury Inflation-Protected Securities. Through March 31, 2023, the Company has not withdrawn any dividend and interest income from the Trust Account to pay its tax obligations.	Marketable Securities Held in Trust Account At December 31, 2022 and 2021, the assets held in the Trust Account were substantially held in a money market fund which is comprised of U.S. Treasury Bills, U.S. Treasury Coupons, and U.S Treasury Inflation-Protected Securities. During the year ended December 31, 2022, the Company did not withdraw any of interest income from the Trust Account to pay its tax obligation.
Common Stock Subject to Possible Redemption	Common Stock Subject to Possible Redemption The Company accounts for its Class A common stock subject to possible redemption in accordance with the guidance in Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” Class A common stock subject to mandatory redemption (if any) are classified as a liability instrument and are measured at fair value. Conditionally redeemable common stock (including common stock that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, common stock is classified as shareholders’ equity. The Company’s common stock feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, as of March 31, 2023 and December 31, 2022, 15,444,103 shares of Class A common stock subject to possible redemption are classified in temporary equity outside of the shareholders’ equity (deficit) section of the Company’s balance sheet and were immediately accreted to redemption value at the IPO Date.	Common Stock Subject to Possible Redemption The Company accounts for its Class A common stock subject to possible redemption in accordance with the guidance in ASC Topic 480 “Distinguishing Liabilities from Equity.” Class A common stock subject to mandatory redemption (if any) are classified as a liability instrument and are measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, common stock is classified as shareholders’ equity. The Company’s common stock features certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, as of December
Derivative Financial Instruments	Derivative Financial Instruments The Company issues warrants to its investors and accounts for warrant instruments as either equity-classified or liability-classified instruments based on an assessment of the specific terms of the warrants and applicable authoritative guidance in ASC 480 and ASC 815, “Derivatives and Hedging” (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own stock and whether the holders of the warrants could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. The Public Warrants (see Note 3) and Private Warrants (see Note 4) were accounted for as equity as these instruments meet all of the requirements for equity classification under ASC 815.	Derivative Financial Instruments The Company issues warrants to its investors and accounts for warrant instruments as either equity-classified or liability-classified The Public Warrants (see Note 3) and Private Warrants (see Note 6) were accounted for as equity as these instruments meet all of the requirements for equity classification under ASC 815.
Over-Allotment Option		Over-Allotment Option The over-allotment option (see Note 7) was deemed to be a freestanding financial instrument indexed to the contingently redeemable shares and was accounted for as a liability pursuant to ASC 480. The fair value of the overallotment liability at the IPO Date of $158,275 was determined using the Black Scholes option pricing model based on the following assumptions: Risk-free interest rate 0.05 % Dividend rate 0 % Volatility 5.00 % Expected life (in years) 0.12 On August 3, 2021, the Underwriters partially exercised their overallotment option and purchased 444,103 Public Units (see Note 3). The fair value of the corresponding overallotment liability partially extinguished upon exercise of $28,317 was determined using the Black Scholes option pricing model based on the following assumptions: Risk-free interest rate 0.05 % Dividend rate 0 % Volatility 5.00 % Expected life (in years) 0.10 Upon the expiration of the unexercised overallotment options on September 9, 2021, the Company recorded a gain on the expiration of the overallotment option of $127,035.
Business Combination Costs	Business Combination Costs Costs incurred in relation to a potential Business Combination may include legal, accounting, and other expenses. Any such costs are expensed as incurred.	Business Combination Costs Costs incurred in relation to a potential Business Combination may include legal, accounting, and other expenses. Any such costs are expensed as incurred.
Net Income (Loss) per Common Stock share	Net Income (Loss) per Common Stock share The Company complies with accounting and disclosure requirements of ASC Topic 260, “Earnings Per Share.” Net income (loss) per share is computed by dividing net loss by the weighted average number of Common Stock shares outstanding during the period. The Company’s condensed consolidated statements of operations include a presentation of net income (loss) per share subject to redemption in a manner similar to the two-class 480-10-S99-3A, The Company’s Public Warrants (see Note 6) and Private Placement Warrants (see Note 6) could, potentially, be exercised or converted into common shares and then share in the earnings of the Company. However, these warrants were excluded when calculating diluted income (loss) per share because such inclusion would be anti-dilutive for the periods presented. As a result, diluted income (loss) per share is the same as basic income (loss) per share for the period presented. A reconciliation of net income per share is as follows for the three months ended March 31, 2023: Class A subject to Class A Class B Allocation of undistributable income 450,040 13,517 112,510 Net income to ordinary shares $ 450,040 $ 13,517 $ 112,510 Weighted average shares outstanding, basic and diluted 15,444,103 463,882 3,861,026 Basic and diluted net income per share $ 0.03 $ 0.03 $ 0.03 A reconciliation of net income per share is as follows for the three months ended March 31, 2022: Class A subject to Class A Class B Allocation of undistributable losses (412,121 ) (12,379 ) (103,030 ) Net (loss) to Common shares $ (412,121 ) $ (12,379 ) $ (103,030 ) Weighted average shares outstanding, basic and diluted 15,144,103 463,882 3,861,026 Basic and diluted net loss per share $ (0.03 ) $ (0.03 ) $ (0.03 )	Net Income (Loss) per Common Stock share The Company complies with accounting and disclosure requirements of ASC Topic 260, “Earnings Per Share.” Net income (loss) per share is computed by dividing net income (loss) by the weighted average number of Common Stock shares outstanding during the period. Weighted average shares for the period from January 21, 2021 (inception) through December 31, 2021 were reduced for the effect of an aggregate of 562,500 Class B Common shares that were subject to forfeiture until the over-allotment option was partially exercised by the underwriters on August 3, 2021 (see Note 5), upon which date the forfeiture provision lapsed for 111,026 Class B Common shares. Subsequent to August 3, 2021, weighted average shares were reduced for the effect of an aggregate of 451,474 Class B Common shares which were ultimately forfeited upon the expiration of the 45-day period The Company’s statements of operations include a presentation of net income (loss) per share subject to redemption in a manner similar to the two-class 480-10-S99-3A, The Company’s Public Warrants (see Note 6) and Private Warrants (see Note 6) could, potentially, be exercised or converted into common shares and then share in the earnings of the Company. However, these warrants were excluded when calculating diluted income (loss) per share because such inclusion would be anti-dilutive for the periods presented. As a result, diluted income (loss) per share is the same as basic income (loss) per share for the period presented. A reconciliation of net income per share is as follows for the year ended December 31, 2022: Year ended December 31, 2022 Class A subject to Class A Class B Allocation of undistributable income 160,151 4,809 40,037 Net income to ordinary shares $ 160,151 $ 4,809 $ 40,037 Weighted average shares outstanding, basic and diluted 15,444,103 463,882 3,861,026 Basic and diluted net income per share $ 0.01 $ 0.01 $ 0.01 A reconciliation of net loss per share is as follows for the period from January 21, (Inception) through December 31, 2021: For the period from Janaury 21, 2021 (inception) through December 31, 2021 Class A subject to Class A Class B Allocation of undistributable losses (209,176 ) (6,286 ) (113,920 ) Net loss to ordinary shares $ (209,176 ) $ (6,286 ) $ (113,920 ) Weighted average shares outstanding, basic and diluted 6,973,122 209,549 3,797,628 Basic and diluted net loss per share $ (0.03 ) $ (0.03 ) $ (0.03 )
Offering Costs		Offering Costs Offering costs consist of underwriting, legal, accounting and other expenses incurred through the IPO that are directly related to the IPO. Offering costs are allocated to the separable financial instruments issued in the IPO based on a relative fair value basis, compared to total proceeds received. Offering costs associated with the Public Shares were charged to shareholders’ equity upon the completion of the IPO. Offering costs amounted to $9,897,599 at July 29, 2021, which were allocated between the Class A shares subject to possible redemption and the Public Warrants and charged to shareholders’ equity upon the completion of the IPO. Under the guidance in Staff Accounting Bulletin 107 Topic 5.A, Accounting for Expenses or Liabilities Paid by Principal Stockholder(s), the Company included in these offering costs amounts incurred by the Sponsor through the transfer of Non-Risk The total issuance costs of $10,145,105 were allocated to the Class A shares subject to possible redemption and the Public Warrants based on their relative fair values with $9,905,857 to the Class A shares subject to possible redemption and $239,247 to the Public Warrants.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC Topic 820, “Fair Value Measurement,” approximates the carrying amounts represented in the accompanying condensed consolidated balance sheet, primarily due to their short-term nature. Fair Value Measurements Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: • Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; • Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and • Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. As of March 31, 2023 and December 31, 2022, the Company held $158,368,990 and $156,693,598, respectively, of Level 1 financial instruments, which are the Company’s marketable securities held in the Trust Account. These assets are measured at fair value on a recurring basis based on quoted market prices for identical securities in the active market. The Company did not hold any assets or liabilities requiring remeasurement on a recurring or nonrecurring basis as of March 31, 2023 and December 31, 2022.	Fair Value of Financial Instruments The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC Topic 820, “Fair Value Measurement,” approximates the carrying amounts represented in the accompanying balance sheet, primarily due to their short-term nature. Fair Value Measurements Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: • Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; • Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and • Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. As of December 31, 2022 and 2021, the Company held $156,693,598 and $154,449,121, respectively, of Level 1 financial instruments, which are the Company’s marketable securities held in Trust Account. These assets are measured at fair value on a recurring basis based on quoted market prices for identical securities in the active market. The overallotment liability is measured at fair value using the Black Scholes Option Pricing Model with significant unobservable inputs. The fair value is based on the share price of the underlying shares and a number of assumptions, including expected volatility, expected life, risk-free interest rate and expected dividends. Therefore, the overallotment liability is considered to be a Level 3 financial instrument. The Company did not hold any liabilities requiring remeasurement on a recurring or non-recurring The table below presents the changes in Level 3 liabilities measured at fair value on a recurring basis during the period from January 21, 2021 (inception) through December 31, 2021: Overallotment Balance at January 21, 2021 (inception) $ — Issuance of overallotment option 158,275 Partial exercise of overallotment option (28,316 ) Change in fair value of overallotment liability (2,924 ) Expiration of overallotment option (127,035 ) Balance at December 31, 2021 $ —
Income Taxes	Income Taxes The Company follows the asset and liability method of accounting for income taxes under ASC 740, “Income Taxes.” Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. ASC 740 prescribes recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties related to any uncertain tax benefits as of March 31, 2023 and December 31, 2022. The Company is not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception.	Income Taxes The Company follows the asset and liability method of accounting for income taxes under ASC 740, “Income Taxes.” Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. ASC 740 prescribes recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of December 31, 2022 and 2021. The Company is not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist of a cash account in a financial institution, which at times may exceed the Federal Depository Insurance Corporation coverage limit of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.	Concentration of Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist of a cash account in a financial institution, which at times may exceed the Federal Depository Insurance Corporation coverage limit of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.
Recently Issued Accounting Standards	Recently Issued Accounting Standards Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.	Recently Issued Accounting Standards Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Schedule of Fair Value of the Overallotment Liability	The fair value of the embeded derivatives in the convertible notes as of March 31, 2023 and December 31, 2022, was valued using a Monte-Carlo model and were based upon the following management assumptions: March 31, 2023 December 31, 2022 Stock price $ 0.16 $ 0.16 Expected term (years) 0.50 0.04 Volatility 73.40 % 55.10 % Risk free interest rate 4.40 % 4.38 % Probability of Qualified Financing or IPO 50.00 % 50.00 % Probability of a Change in Control Event 10.00 % 10.00 %	The fair value of the embedded derivatives in the convertible notes as of December 31, 2022 and 2021, was valued using a Monte-Carlo model and were based upon the following management assumptions: 2022 2021 Stock price $ 0.16 $0.13 Expected term (years) 0.04 0.71 - 3.48 Volatility 55.10 % 48.90% - 60.50% Risk free interest rate 4.38 % 0.44% - 0.72% Probability of Qualified Financing or IPO 50.00 % 60.00% Probability of a Change in Control Event 10.00 % 10.00%
Schedule of Estimated Amortization Expenses		Estimated amortization expense for each of the following five years is as follows: 2023 $ 4,516 2024 4,528 2025 4,516 2026 4,516 2027 4,090 Thereafter 6,536 Total $ 28,702
Schedule of Assets and Liabilities Recorded in the Balance Sheet at Fair Value	Assets and liabilities recorded in the balance sheet at fair value as of March 31, 2023 and at December 31, 2022 are categorized based on a hierarchy of inputs, as follows: Carrying Fair Value Measurement Using Value Level 1 Level 2 Level 3 Total Derivative liability at March 31, 2023 $ 1,152,065 $ — $ — $ 1,152,065 $ 1,152,065 Derivative liability at December 31, 2022 $ 826,980 $ — $ — $ 826,980 $ 826,980 Fair Value Measurements Using Significant Unobservable March 31, 2023 December 31, 2022 Balance, beginning of year $ 826,980 $ 3,846,319 Initial recognition of derivative liability — 1,321,860 Settled in Series C-2 — (3,081,912 ) Change in fair value of derivative liability 325,085 (1,259,287 ) Balance, end of period $ 1,152,065 $ 826,980	Assets and liabilities recorded in the balance sheet at fair value as of December 31, 2022 and 2021 are categorized based on a hierarchy of inputs, as follows: Carrying Fair Value Measurement Using Value Level 1 Level 2 Level 3 Total Derivative liability at December 31, 2022 $ 826,980 $ — $ — $ 826,980 $ 826,980 Derivative liability at December 31, 2021 $ 3,846,319 $ — $ — $ 3,846,319 $ 3,846,319 Fair Value Measurements Using Significant 2022 2021 Balance, beginning of year $ 3,846,319 $ 1,045,905 Initial recognition of derivative liability 1,321,860 285,349 Settled in Series C-2 (3,081,912 ) — Change in fair value of derivative liability (1,259,287 ) 2,515,065 Balance, end of year $ 826,980 $ 3,846,319
Schedule of Securities that were Excluded from the Diluted Per Share Calculation	The following table summarizes the securities that were excluded from the diluted per share calculation because the effect of including these potential shares was antidilutive due to the Company’s net loss position even though the exercise price could be less than the average market price of the common shares: Three Months Ended March 31, 2023 2022 Series A Preferred Stock (if converted) 19,968,051 19,968,051 Series B Preferred Stock (if converted) 33,801,226 32,917,690 Series C-1 5,090,693 — Series C-2 73,560,390 — Stock Options 37,370,980 35,440,469 Common Stock Warrants (penny warrants excluded) 1,536,379 1,758,975 Preferred Stock Warrants 3,758,186 1,704,759 Convertible Notes 31,982,684 17,094,017 Total 207,068,589 108,883,961	The following table summarizes the securities that were excluded from the diluted per share calculation because the effect of including these potential shares was anti-dilutive due to the Company’s net loss position even though the exercise price could be less than the average market price of the common shares: Year Ended December 31, 2022 2021 Series A Preferred Stock (if converted) 19,968,051 19,968,051 Series B Preferred Stock (if converted) 33,801,226 32,917,690 Series C-1 5,090,693 — Series C-2 73,560,390 — Stock Options 36,320,980 34,990,469 Common Stock Warrants (penny warrants excluded) 1,418,733 1,758,975 Preferred Stock Warrants 3,758,186 1,704,789 Convertible Notes 26,620,370 — Total 200,538,629 91,339,974
Alpha Healthcare Acquisition Corp. III [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Schedule of Fair Value of the Overallotment Liability		The fair value of the overallotment liability at the IPO Date of $158,275 was determined using the Black Scholes option pricing model based on the following assumptions: Risk-free interest rate 0.05 % Dividend rate 0 % Volatility 5.00 % Expected life (in years) 0.12 Risk-free interest rate 0.05 % Dividend rate 0 % Volatility 5.00 % Expected life (in years) 0.10
Schedule of Reconciliation of Net Income (Loss) per Share	A reconciliation of net income per share is as follows for the three months ended March 31, 2023: Class A subject to Class A Class B Allocation of undistributable income 450,040 13,517 112,510 Net income to ordinary shares $ 450,040 $ 13,517 $ 112,510 Weighted average shares outstanding, basic and diluted 15,444,103 463,882 3,861,026 Basic and diluted net income per share $ 0.03 $ 0.03 $ 0.03 A reconciliation of net income per share is as follows for the three months ended March 31, 2022: Class A subject to Class A Class B Allocation of undistributable losses (412,121 ) (12,379 ) (103,030 ) Net (loss) to Common shares $ (412,121 ) $ (12,379 ) $ (103,030 ) Weighted average shares outstanding, basic and diluted 15,144,103 463,882 3,861,026 Basic and diluted net loss per share $ (0.03 ) $ (0.03 ) $ (0.03 )	A reconciliation of net income per share is as follows for the year ended December 31, 2022: Year ended December 31, 2022 Class A subject to Class A Class B Allocation of undistributable income 160,151 4,809 40,037 Net income to ordinary shares $ 160,151 $ 4,809 $ 40,037 Weighted average shares outstanding, basic and diluted 15,444,103 463,882 3,861,026 Basic and diluted net income per share $ 0.01 $ 0.01 $ 0.01 A reconciliation of net loss per share is as follows for the period from January 21, (Inception) through December 31, 2021: For the period from Janaury 21, 2021 (inception) through December 31, 2021 Class A subject to Class A Class B Allocation of undistributable losses (209,176 ) (6,286 ) (113,920 ) Net loss to ordinary shares $ (209,176 ) $ (6,286 ) $ (113,920 ) Weighted average shares outstanding, basic and diluted 6,973,122 209,549 3,797,628 Basic and diluted net loss per share $ (0.03 ) $ (0.03 ) $ (0.03 )
Schedule of Changes in Level 3 Liabilities Measured at Fair Value on a Recurring Basis		Overallotment Balance at January 21, 2021 (inception) $ — Issuance of overallotment option 158,275 Partial exercise of overallotment option (28,316 ) Change in fair value of overallotment liability (2,924 ) Expiration of overallotment option (127,035 ) Balance at December 31, 2021 $ —

Restatement and Correction of_2

Restatement and Correction of an Error (Tables)	12 Months Ended
	Dec. 31, 2022
Restatement and Correction of an Error [Abstract]
Schedule of Restated Balance Sheet	The Company has restated its financial statements as of and for the year ended, December 31, 2021. The following tables provide the summary of restated amounts. December 31, 2021 As Previously Reclassifications Error Restated ASSETS Current Assets: Cash $ 12,362 $ 12,362 Deferred offering costs 166,342 166,342 Total Current Assets 178,704 178,704 Property and equipment, net of accumulated depreciation of $440,334 337,592 337,592 Operating lease right of use asset 1,007,589 1,007,589 Intangible assets, net of accumulated amortization of $37,528 18,506 14,712 33,218 Total Assets $ 1,542,391 — 14,712 $ 1,557,103 LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ DEFICIT Current Liabilities: Accounts payable $ 871,313 $ 871,313 Accrued expenses and other liabilities 514,783 514,783 Accrued interest— related parties — 226,170 226,170 Accrued interest— non-related 1,880,656 (226,170 ) 1,654,486 Convertible notes payable— related parties, net of debt discount of $0 — 900,000 900,000 Convertible notes payable, current, net of debt discount of $946,291 9,507,228 (900,000 ) (903,796 ) 7,703,432 Derivative liabilities — 3,813,019 3,813,019 Lease liability, current 120,162 120,162 Total Current Liabilities 12,894,142 — 2,909,223 15,803,365 Long-term Liabilities: Lease liability, net of current portion 961,908 961,908 Convertible notes payable — net of debt discount of $49,078 50,000 (49,078 ) 922 Derivative liabilities — 33,300 33,300 Total Long-term Liabilities 1,011,908 — (15,778 ) 996,130 Total Liabilities 13,906,050 — 2,893,445 16,799,495 December 31, 2021 As Previously Reclassifications Error Restated Commitments and Contingencies (Note 8) Mezzanine Equity Series A Preferred stock, 21,064,711 7,020,992 385,417 7,406,409 Series B Preferred stock, 34,772,230 shares authorized; 32,917,690 issued and outstanding as of December 31, 2021 (liquidation preference: $6,928,245) 5,970,791 957,454 6,928,245 Series C Preferred stock, 25,907,990 shares authorized; 0 shares issued and outstanding as of December 31, 2021 — Stockholders’ Deficit: Common stock, $.001 par value; 100,050,000 shares authorized; 36,918,882 shares issued and outstanding as of December 31, 2021 36,919 36,919 Additional paid-in 2,989,644 170,847 3,160,491 Accumulated deficit (28,382,005 ) (4,392,451 ) (32,774,456 ) Total Stockholders’ Deficit (25,355,442 ) — (4,221,604 ) (29,577,046 ) Total Liabilities, Mezzanine Equity and Stockholders’ Deficit $ 1,542,391 — 14,712 $ 1,557,103
Schedule of Restated Operations	For the Year Ended December 31, 2021 As Previously Reclassifications Error Restated Operating expenses: Research and development $ 982,837 $ 982,837 General and administrative 617,989 153,861 91,483 863,333 Depreciation and amortization 103,656 (9,494 ) 94,162 ROU amortization 145,846 (145,846 ) — Advertising and Marketing 8,015 (8,015 ) — Total operating expenses 1,858,343 — 81,989 1,940,332 Loss from operations (1,858,343 ) — (81,989 ) (1,940,332 ) Other income (expense): Gain on the forgiveness of loans payable 438,180 438,180 Other income 37,527 (149 ) 37,378 Change in fair value of derivative liabilities — (2,515,065 ) (2,515,065 ) Interest expense, related party — (72,000 ) (72,000 ) Interest expense, non-related (860,805 ) 125,686 91,632 (643,487 ) Amortization of debt discount — (53,686 ) (1,729,911 ) (1,783,597 ) Total other expense (385,098 ) — (4,153,493 ) (4,538,591 ) Loss before provision for income taxes (2,243,441 ) — (4,235,482 ) (6,478,923 ) Provision for income taxes — — — Net loss (2,243,441 ) — (4,235,482 ) (6,478,923 ) Dividends on Series A preferred stock (307,927 ) (307,927 ) Net loss attributable to common stockholders $ (2,243,441 ) — (4,543,409 ) $ (6,786,850 ) Net loss per common share—basic and diluted $ (0.16 ) — (0.13 ) $ (0.29 ) Weighted average shares outstanding—basic and diluted 13,698,060 — 9,441,105 23,139,165
Schedule of Restated Stockholder's Equity	Common Stock Additional Paid-in Accumulated Total Shares Amount As Previously Reported Balance at January 1, 2021 2,922,284 $ 2,922 $ 2,539,486 $ (25,830,637 ) $ (23,288,229 ) Accrued Series A preferred stock dividend (307,927 ) (307,927 ) Issuance of stock 31,940,355 31,940 (28,746 ) — 3,194 Exercise of stock options 2,056,243 2,057 232,105 — 234,162 Stock-based compensation expense 246,799 — 246,799 Net loss — (2,243,441 ) (2,243,441 ) Balance as of December 31, 2021 36,918,882 $ 36,919 $ 2,989,644 $ (28,382,005 ) $ (25,355,442 ) Error Correction Net loss (4,235,482 ) (4,235,482 ) As Restated Balance at January 1, 2021 2,922,284 $ 2,922 $ 2,539,486 $ (25,830,637 ) $ (23,288,229 ) Correction of accumulated error 170,847 (156,969 ) 13,878 Balance at January 1, 2021 (Restated) 2,922,284 2,922 2,710,333 (25,987,606 ) (23,274,351 ) Accrued Series A preferred stock dividend — — — (307,927 ) (307,927 ) Issuance of common stock 31,940,355 31,940 (28,746 ) 3,194 Exercise of stock options 2,056,243 2,057 232,105 — 234,162 Stock-based compensation expense — — 246,799 — 246,799 Net loss — — — (6,478,923 ) (6,478,923 ) Balance as of December 31, 2021 36,918,882 $ 36,919 $ 3,160,491 $ (32,774,456 ) $ (29,577,046 )
Schedule of Restated Cash Flow	For the Year Ended December 31, 2021 As Previously Reclassifications Error Restated Cash flows from operating activities: Net loss $ (2,243,441 ) (4,235,482 ) $ (6,478,923 ) Adjustments to reconcile net loss to net cash used in operating activities: Gain on forgiveness of loans payable (438,180 ) (438,180 ) Depreciation and amortization 103,656 (9,494 ) 94,162 Amortization of debt discount 53,686 1,729,911 1,783,597 Amortization of ROU assets 145,846 2,116 147,962 Change in fair value of derivative liabilities 2,515,065 2,515,065 Stock-based compensation 246,799 246,799 Changes in operating assets and liabilities: Prepaid expenses and other current assets 9,918 9,918 Accounts payable 80,320 80,320 Accrued expenses and other liabilities 262,098 (1 ) 262,097 Lease liability (113,016 ) (2,116 ) (115,132 ) Accrued interest— related parties 72,000 72,000 Accrued interest -non 715,486 (72,000 ) 643,486 Net cash used in operating activities (1,176,828 ) (1 ) 0 (1,176,829 ) Cash flows from investing activities: Purchase of property and equipment (7,273 ) (7,273 ) Net cash used in investing activities (7,273 ) — — (7,273 ) Cash flows from financing activities: Proceeds from convertible notes 906,839 906,839 Proceeds from PPP loan 217,460 217,460 Payment of offering costs (166,342 ) (166,342 ) Proceeds from issuance of common stock 3,194 3,194 Proceeds from exercise of stock options 237,356 (3,193 ) 234,163 Net cash provided by financing activities 1,195,313 1 — 1,195,314 Net increase in cash 11,212 11,212 Cash — beginning of the period 1,150 1,150 Cash — end of the period $ 12,362 — — $ 12,362 Supplemental cash flow information: Interest paid $ — — — $ — Income tax paid $ — — — $ — Non-cash Accrued Series A preferred stock dividends $ 307,927 — — $ 307,927 Initial recognition of derivative liabilities $ — — 258,359 $ 258,359

Property and Equipment (Tables)

Property and Equipment (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Schedule of Property Plant and Equipment	Property and equipment consist of the following: March 31, December 31, Lab equipment $ 666,178 $ 666,178 Leasehold improvements 115,333 115,333 Furniture and fixtures 3,579 3,579 785,090 785,090 Less: accumulated depreciation (553,087 ) (530,116 ) Property and equipment, net $ 232,003 $ 254,974	Property and equipment consist of the following: December 31, December 31, Lab equipment $ 666,178 $ 662,593 Leasehold improvements 115,333 115,333 Furniture and fixtures 3,579 — 785,090 777,926 Less: accumulated depreciation (530,116 ) (440,334 ) Property and equipment, net $ 254,974 $ 337,592

Accrued Expenses and Other Li_2

Accrued Expenses and Other Liabilities (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Accrued Liabilities and Other Liabilities [Abstract]
Schedule of Accrued Expenses and Other Liabilities	Accrued expenses and other liabilities consist of the following amounts: March 31, December 31, Accrued compensation $ 1,234,660 $ 916,934 Other 47,171 27,639 Accrued expenses and other liabilities $ 1,281,831 $ 944,573	Accrued expenses and other liabilities consist of the following amounts: December 31, December 31, Accrued compensation $ 916,934 $ 489,794 Other 27,639 24,989 Accrued expenses and other liabilities $ 944,573 $ 514,783

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2022
Lessee Disclosure [Abstract]
Schedule of Net Lease Cost and Other Supplemental Lease	The following table presents net lease cost and other supplemental lease information: Years Ended December 31, December 31, Lease cost Operating lease cost (cost resulting from lease payments) $ 201,400 $ 204,499 Short term lease cost — 31,500 Net lease cost 201,400 235,999 Operating lease – operating cash flows (fixed payments) $ 200,980 $ 197,565
Schedule of Estimated Future Minimum Lease Payments, Excluding Non-lease Components	As of December 31, 2022, the estimated future minimum lease payments, excluding non-lease Operating Fiscal Year 2023 $ 204,930 2024 204,930 2025 204,930 2026 204,930 2027 204,930 Thereafter 204,930 Total future minimum annual lease payments 1,229,580 Less: Imputed interest (272,350 ) Present value of lease liabilities $ 957,230

Mezzanine Equity And Stockhol_2

Mezzanine Equity And Stockholders' Deficit (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Class of Warrant or Right [Line Items]
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	A summary of the option activity during the three months ended March 31, 2023 is presented below: Number of Weighted Weighted Aggregate Outstanding, December 31, 2022 36,320,980 $ 0.13 8.07 $ 1,083,492 Granted 1,250,000 0.16 Exercised — — Expired/Cancelled (200,000 ) 0.11 Outstanding, March 31, 2023 37,370,980 $ 0.13 7.91 $ 1,073,492 Vested/Exercisable, March 31, 2023 16,163,949 $ 0.12 6.88 $ 569,604
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The weighted average fair value of the options granted during the three months ended March 31, 2023 was $0.12 per share, based on a Black Scholes option pricing model using the following assumptions: Expected volatility 76.3% Expected term of option 6 years Range of risk-free interest rate 3.55% -3.75% Dividend yield —
Series B Redeemable Convertible Preferred Stock Warrants [Member]
Class of Warrant or Right [Line Items]
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	The following table presents information related to Series B preferred stock warrants for the year ended March 31, 2023: Number of Weighted Weighted Outstanding and exercisable, December 31, 2022 821,253 $ 0.22 4.16 Warrants issued — — — Warrants exercised — — — Warrants expired/cancelled — — — Outstanding and exercisable, March 31, 2023 821,253 $ 0.22 3.92	The following table presents information related to Series B preferred stock warrants for the year ended December 31, 2022: Number of Weighted Weighted Outstanding and exercisable, December 31, 2021 1,704,789 $ 0.22 5.07 Warrants issued — — — Warrants exercised (883,536 ) 0.11 — Warrants expired/cancelled — — — Outstanding and exercisable, December 31, 2022 821,253 $ 0.22 4.16
Common Stock Warrants [Member]
Class of Warrant or Right [Line Items]
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	The following table presents information related to common stock warrants for the three months ended March 31, 2023: Number of Weighted Weighted Outstanding and exercisable, December 31, 2022 5,190,325 $ 0.13 3.32 Warrants issued 117,646 0.88 — Warrants exercised — — — Warrants expired/cancelled — — — Outstanding and exercisable, March 31, 2023 5,307,971 $ 0.14 3.12	The following table presents information related to common stock warrants for the year ended December 31, 2022: Number of Weighted Weighted Outstanding and exercisable, December 31, 2021 1,758,975 $ 0.46 2.38 Warrants issued 3,771,592 0.01 — Warrants exercised (340,242 ) 0.11 — Warrants expired/cancelled — — — Outstanding and exercisable, December 31, 2022 5,190,325 $ 0.13 3.32
Series C One Redeemable Convertible Preferred Stock Warrants [Member]
Class of Warrant or Right [Line Items]
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	The following table presents information related to Series C-1 Number of Weighted Weighted Outstanding and exercisable, December 31, 2022 2,936,933 $ 0.16 9.73 Warrants issued — — — Warrants exercised — — — Warrants expired/cancelled — — — Outstanding and exercisable, March 31, 2023 2,936,933 $ 0.16 9.49	The following table presents information related to Series C-1 Number of Warrants Weighted Exercise Price Weighted Average Remaining Contractual Life in Years Outstanding and exercisable, December 31, 2021 — $ — — Warrants issued 3,030,830 0.16 — Warrants exercised (93,897 ) 0.11 — Warrants expired/cancelled — — — Outstanding and exercisable, December 31, 2022 2,936,933 $ 0.16 9.73

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Income Taxes [Line Items]
Schedule of Net Deferred Tax Assets	Significant components of the Company’s deferred tax assets as of December 31, 2022 and 2021 are summarized below: 2022 2021 Deferred income tax assets: Net operating losses $ 7,642,000 $ 5,585,000 Accrued interest 747,000 543,000 Federal research and development tax credits 113,000 568,000 Amortization of research expense 585,000 — Right of use asset 29,000 — Non-qualified 263,000 132,000 Accrued compensation 271,000 142,000 Change in fair value of derivative liabilities 275,000 632,000 Total deferred tax asset 9,925,000 7,602,000 Valuation allowance (9,925,000 ) (7,602,000 ) Net deferred income tax assets $ — $ —
Schedule of Reconciliation of the Federal Income Tax Rate To The Company's Effective Tax Rate	The components of the Company’s tax rate for the years ended December 31, 2022 and 2021 consisted of the following: 2022 2021 U.S. federal statutory rate 21.0 % 21.0 % Effects of: State taxes, net of federal benefit 7.9 % 7.9 % Stock based compensation (0.4 %) (1.1 %) Gain on loan forgiveness (2.5 %) 1.4 % Net operating loss true-up 2.6 % R&D expenses, net 0.0 % (0.6 %) R & D Credit 0.2 % 2.2 % R & D True Up (6.6 %) (1.9 %) Other permanent differences (0.2 %) 0.0 % Stock Compensation True up 0.0 % 4.9 % Valuation allowance (22.0 %) (33.8 %) Effective rate (0.0 %) (0.0 %)
Alpha Healthcare Acquisition Corp. III [Member]
Income Taxes [Line Items]
Schedule of Income Tax Provision	December 31, 2022 2021 Federal Current $ 391,198 $ — Deferred (265,998 ) (96,461 ) Change in valuation allowance 265,998 96,461 Income tax provision $ 391,198 $ —
Schedule of Net Deferred Tax Assets	The Company’s net deferred tax assets consisted of the following as of December 31, 2022 and 2021: December 31, 2022 2021 Deferred tax asset Net operating loss carryforward $ — $ 33,531 Startup/Organization expenses 362,459 62,930 Total deferred tax assets 362,459 96,461 Valuation allowance (362,459 ) (96,461 ) Deferred tax asset, net of allowance $ — $ —
Schedule of Reconciliation of the Federal Income Tax Rate To The Company's Effective Tax Rate	A reconciliation of the federal income tax rate to the Company’s effective tax rate at December 31, 2022 and 2021 is as follows: December 31, 2022 2021 Statutory federal income tax rate 21.0 % 21.0 % Change in fair value of overallotment liability — 8.3 Valuation allowance 44.0 (29.3 ) Effective tax rate 65.0 % 0.0 %

Related Party Transactions (Tab

Related Party Transactions (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Related Party Transaction [Line Items]
Schedule of Related Party Transactions	The following table summarizes the related party transactions / balances in the Company at March 31, 2023 and at December 31, 2022: March 31, 2023 December 31, 2022 Dollars Shares Dollars Shares Series A Preferred Stock and Dividends Board Member Initial Investment $ 877,054 4,222,223 $ 877,054 4,222,223 Accrued Dividends 693,891 678,694 $ 1,570,945 $ 1,555,748 Series B Preferred Stock Board Member $ 887,049 5,094,537 $ 887,049 5,094,537 Immediate Family 1 103,244 780,967 103,244 780,967 $ 990,293 5,875,504 $ 990,293 5,875,504 Series C-1 Immediate Family Member 1 Initial Investment $ 50,000 234,742 $ 50,000 234,742 Accrued Dividends 873 10 $ 50,873 $ 50,010 Series C-2 Board Member $ 1,049,381 6,129,561 $ 1,049,381 6,129,561 Immediate Family 1 64,981 379,560 64,981 379,560 Immediate Family 2 64,279 375,464 64,279 375,464 $ 1,178,641 6,884,585 $ 1,178,641 6,884,585 Series C-2 Board Member $ 38,036 $ 19,924 Immediate Family 1 2,355 1,234 Immediate Family 2 2,330 1,220 $ 42,721 $ 22,378	The following table summarizes the related party transactions / balances in the Company at December 31, 2022: December 31, 2022 Interest Expense Dollars Shares Series A Preferred Stock Board Member $ 877,054 4,222,223 Dividends Earned To Date 678,694 — $ 1,555,748 4,222,223 Series B Preferred Stock Board Member $ 887,049 5,094,537 Immediate Family 1 103,244 780,967 $ 990,293 5,875,504 Series C-1 Immediate Family 1 $ 50,000 234,742 Dividends Earned To Date 10 — $ 50,010 234,742 Series C-2 Board Member $ 1,049,381 6,129,561 Immediate Family 1 64,981 379,560 Immediate Family 2 64,279 375,464 $ 1,178,641 6,884,585 Series C-2 Board Member $ 19,924 Immediate Family 1 1,234 Immediate Family 2 1,220 $ 22,378 Series 1 Convertible Notes Board Member $ 46,641 Immediate Family 1 2,915 Immediate Family 2 2,915 $ 52,471 The following table summarizes the related party transactions / balances in the Company at December 31, 2021: December 31, 2021 Accrued Interest Interest Expense Dollars Shares Series A Preferred Stock Board Member $ 877,054 4,222,223 Dividends Earned To Date 613,583 — $ 1,490,637 4,222,223 Series B Preferred Stock Board Member $ 857,089 4,822,181 Immediate Family 1 103,244 780,967 $ 960,333 5,603,148 Series 1 Convertible Notes Board Member $ 202,740 $ 64,000 $ 800,000 Immediate Family 1 12,066 4,000 50,000 Immediate Family 2 11,364 4,000 50,000 $ 226,170 $ 72,000 $ 900,000

Nature of the Organization an_2

Nature of the Organization and Business - Additional Information (Detail) - USD ($)					3 Months Ended	12 Months Ended
	Jan. 04, 2023	Aug. 03, 2021	Jul. 29, 2021	Jul. 26, 2021	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Jun. 30, 2021	Jan. 01, 2021
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period						9,075
Stock Issued During Period, Value, Stock Options Exercised						$ 1,271	$ 234,162
Cash					$ 27,190	128,149	12,362
Accumulated deficit					$ 44,522,174	$ 42,382,291	32,774,456		$ 25,987,606
Entity Incorporation, Period of Incorporation					November 2008	November 2008
Alpha Healthcare Acquisition Corp. III [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Shares Issued, Price Per Share					$ 10	$ 10		$ 10
Restricted Investments Term					185 days	185 days
Lock In Period For Redemption Of Public Shares After Closing Of IPO					24 months	24 months
Percentage of public shares to be redeemed in case business combination is not consummated					100%	100%
Minimum Net Worth Required for Compliance					$ 5,000,001	$ 5,000,001
Cash					16,133	187,664	774,192
Maximum net interests to pay dissolution expenses					100,000	100,000
Negative working capital					2,495,637	(1,396,312)
Accumulated deficit					$ 1,308,073	$ 6,018,111	$ 4,762,700
Target Company [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Equity Method Investment, Ownership Percentage					50%
Initial Shareholders [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Equity Method Investment, Ownership Percentage						50%
Public Warrants [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Stock issuance cost allocation based on derivative fair value					$ 239,247	$ 239,247
Sponsor [Member] | Private Placement Warrants [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Class of warrants and rights issued during the period					455,000	455,000
Class Of Warrants and Rights Issued, Price Per Warrant					$ 10	$ 10
Proceeds from Issuance of Private Placement					$ 4,550,000	$ 4,550,000
IPO [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Shares Issued, Price Per Share			$ 10
Proceeds from Issuance Initial Public Offering			$ 154,441,030
Stock issuance costs					3,461,151	3,461,151
Payments for Underwriting Expense					3,000,000	3,000,000
Other Offering Costs					461,151	461,151
Deferred Offering Costs Current And Noncurrent					1,550,000	1,550,000
Accrued underwriting fees					5,250,000	5,250,000
Over-Allotment Option [Member] | Private Placement Warrants [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Class of warrants and rights issued during the period		8,882
Proceeds from Issuance of Private Placement		$ 88,820
Other Offering Costs		3,250
Transaction costs incurred		92,070
Underwriting fees incurred		$ 88,820
Underwriting fees payable upon the consummation of business combination					155,436	155,436
Private Placement [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Cash						$ 187,664
Common Class A [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Stock shares issued during the period shares			15,000,000
Common Class A [Member] | Carmell Therapeutics Corporation [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Equity interest acquired	$ 150,000,000
Common Class A [Member] | IPO [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Stock shares issued during the period shares			15,000,000
Shares Issued, Price Per Share			$ 10
Proceeds from Issuance Initial Public Offering			$ 150,000,000
Overallotment option vesting period			45 days
Common Class B [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Stock issued during the period shares for services						25,000
Risk Incentive Private Shares [Member] | IPO [Member] | Sponsor [Member] | Founder [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Stock shares issued during the period shares			600,900
Sale of Stock, Percentage of Ownership before Transaction			9.90%
NonRisk Incentive Private Shares [Member] | Sponsor [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Sale of Stock, Consideration Received on Transaction			$ 1,186,448
NonRisk Incentive Private Shares [Member] | IPO [Member] | Sponsor [Member] | Founder [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Stock shares issued during the period shares			225,000
Sale of Stock, Consideration Received on Transaction			$ 1,186,448
Sale of Stock, Price Per Share			$ 5.27
Class A Common Stock Subject To Possible Redemption [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Stock issuance cost allocation based on temporary equity fair value					9,905,857	$ 9,905,857
Class A Common Stock Subject To Possible Redemption [Member] | Public Warrants [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Stock issuance costs					$ 10,145,105	$ 10,145,105
Maximum [Member] | Common Class A [Member] | Over-Allotment Option [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Stock shares issued during the period shares			2,250,000
Underwriting Agreement [Member] | Over-Allotment Option [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Stock shares issued during the period shares				2,250,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		444,103
Stock Issued During Period, Value, Stock Options Exercised		$ 4,441,030
Subsequent Event [Member] | Common Class A [Member] | Carmell Therapeutics Corporation [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Equity interest acquired	$ 150,000,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)				3 Months Ended		11 Months Ended	12 Months Ended
	Sep. 09, 2021	Aug. 03, 2021	Jul. 29, 2021	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Cash Equivalents, at Carrying Value				$ 0		$ 0	$ 0	$ 0
Unrecognized Tax Benefits				0		0	0	0
Accrued for interest and penalties				0		0	$ 0	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period							9,075
Gross patent costs				70,746		70,746	$ 70,746	70,746
Accumulated amortization				43,172		37,528	42,044	37,528
Asset impairment				0	$ 0		0
Amortization expense				1,128	1,114		4,516	4,516
Impairment losses on long lived assets				0	0		0	0
Dilutive instruments				0	$ 0		0	0
Capitalized costs				$ 1,054,573		166,342	394,147	166,342
Advertising expense							$ 9,247	8,015
Equipment [Member]
Property and equipment estimated useful lives				7 years			7 years
Leasehold Improvements [Member]
Property and equipment estimated useful lives				10 years			10 years
Furniture and Fixtures [Member]
Property and equipment estimated useful lives				7 years			7 years
Alpha Healthcare Acquisition Corp. III [Member]
Unrecognized Tax Benefits						0	$ 0	0
FDIC Insured Amount				$ 250,000			250,000
Accrued for interest and penalties						$ 0	0	0
Stock issued during the period share based compensation forfeited						451,474
Offering costs incurred							92,070
Gain on expiration of overallotment option	$ 127,035					$ 127,035	0
Fair value of overallotment liability at the initial public offering date							158,275
Fair value of overallotment liability partially extinguished upon exercise of option		$ 28,317
Marketable securities held in Trust Account				158,368,990		$ 154,449,121	156,693,598	$ 154,449,121
Proceeds from Sale of Restricted Investments				0
Over-Allotment Option [Member] | Underwriting Agreement [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		444,103
IPO [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Stock issuance costs				$ 3,461,151			$ 3,461,151
Common Class A [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Temporary equity shares outstanding				15,444,103			15,444,103
Common Class A [Member] | IPO [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Offering costs incurred							$ 233,411
Class A Common Stock Subject To Possible Redemption [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Stock issuance cost allocation based on temporary equity fair value				$ 9,905,857			9,905,857
Class A Common Stock Subject To Possible Redemption [Member] | IPO [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Offering costs incurred							9,664,188
Common Class B [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Weighted average shares subject to forfeiture						562,500
Common stock shares for which the forfeiture option expired		111,026
Stock issued during the period share based compensation forfeited						451,474
NonRisk Incentive Private Shares [Member] | Sponsor [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Sale of Stock, Consideration Received on Transaction			$ 1,186,448
Public Warrants [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Stock issuance cost allocation based on derivative fair value				239,247			239,247
Public Warrants [Member] | Class A Common Stock Subject To Possible Redemption [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs							9,897,599
Stock issuance costs				$ 10,145,105			$ 10,145,105

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Fair Value of the Overallotment Liability (Detail)		12 Months Ended
	Aug. 03, 2021	Dec. 31, 2022 yr $ / shares	Mar. 31, 2023 $ / shares yr	Dec. 31, 2021 yr $ / shares
Risk-free interest rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivative liability, measurement input		4.38	4.4
Risk-free interest rate [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivative liability, measurement input				0.72
Risk-free interest rate [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivative liability, measurement input				0.44
Risk-free interest rate [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value of overallotment liability measurement input	0.05	0.05
Dividend rate [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value of overallotment liability measurement input	0	0
Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivative liability, measurement input		55.1	73.4
Volatility [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivative liability, measurement input				60.5
Volatility [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivative liability, measurement input				48.9
Volatility [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value of overallotment liability measurement input	5	5
Expected life (in years) [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivative liability, measurement input		0.04	0.5
Expected life (in years) [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivative liability, measurement input				3.48
Expected life (in years) [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivative liability, measurement input				0.71
Expected life (in years) [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value of overallotment liability term	1 month 6 days	1 month 13 days
Measurement Input, Share Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivative liability, measurement input | $ / shares		0.16	0.16	0.13
Measurement Input Probability of Qualified Financing [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivative liability, measurement input		50	50	60
Measurement Input Probability of a Change in Control Event [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivative liability, measurement input		10	10	10

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Schedule of Reconciliation of Net Income (Loss) per Share (Detail) - USD ($)	3 Months Ended		11 Months Ended	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Schedule Of Earnings Per Share Basic And Diluted [Line Items]
Allocation of undistributable income/losses Net income/loss to ordinary shares	$ (1,828,715)	$ (1,458,260)		$ (9,051,334)	$ (6,478,923)
Weighted average shares outstanding, basic	18,303,103	40,096,825		28,546,036	23,139,165
Weighted average shares outstanding, diluted	18,303,103	40,096,825		28,546,036	23,139,165
Basic net income (loss) per share	$ (0.12)	$ (0.04)		$ (0.34)	$ (0.29)
Diluted net income (loss) per share	$ (0.12)	$ (0.04)		$ (0.34)	$ (0.29)
Alpha Healthcare Acquisition Corp. III [Member]
Schedule Of Earnings Per Share Basic And Diluted [Line Items]
Allocation of undistributable income/losses Net income/loss to ordinary shares	$ 576,067	$ (527,530)	$ (329,382)	$ 204,997
Class A Common Stock Subject To Possible Redemption [Member]
Schedule Of Earnings Per Share Basic And Diluted [Line Items]
Basic net income (loss) per share	$ 0.03	$ (0.03)	$ (0.03)	$ 0.01
Diluted net income (loss) per share	$ 0.03	$ (0.03)	$ (0.03)	$ 0.01
Class A Common Stock Subject To Possible Redemption [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Schedule Of Earnings Per Share Basic And Diluted [Line Items]
Allocation of undistributable income/losses Net income/loss to ordinary shares	$ 450,040	$ (412,121)	$ (209,176)	$ 160,151
Weighted average shares outstanding, basic	15,444,103	15,144,103	6,973,122	15,444,103
Weighted average shares outstanding, diluted	15,444,103	15,144,103	6,973,122	15,444,103
Basic net income (loss) per share	$ 0.03	$ (0.03)	$ (0.03)	$ 0.01
Diluted net income (loss) per share	$ 0.03	$ (0.03)	$ (0.03)	$ 0.01
Common Class A [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Schedule Of Earnings Per Share Basic And Diluted [Line Items]
Allocation of undistributable income/losses Net income/loss to ordinary shares			$ (6,286)	$ 4,809
Weighted average shares outstanding, basic	463,882	463,882	209,549	463,882
Weighted average shares outstanding, diluted	463,882	463,882	209,549	463,882
Basic net income (loss) per share	$ 0.03	$ (0.03)	$ (0.03)	$ 0.01
Diluted net income (loss) per share	$ 0.03	$ (0.03)	$ (0.03)	$ 0.01
Common Class A [Member] | Common Stock [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Schedule Of Earnings Per Share Basic And Diluted [Line Items]
Allocation of undistributable income/losses Net income/loss to ordinary shares	$ 13,517	$ (12,379)
Weighted average shares outstanding, basic	463,882	463,882
Weighted average shares outstanding, diluted	463,882	463,882
Basic net income (loss) per share	$ 0.03	$ (0.03)
Diluted net income (loss) per share	$ 0.03	$ (0.03)
Common Class B [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Schedule Of Earnings Per Share Basic And Diluted [Line Items]
Allocation of undistributable income/losses Net income/loss to ordinary shares			$ (113,920)	$ 40,037
Weighted average shares outstanding, basic	3,861,026	3,861,026	3,797,628	3,861,026
Weighted average shares outstanding, diluted	3,861,026	3,861,026	3,797,628	3,861,026
Basic net income (loss) per share	$ 0.03	$ (0.03)	$ (0.03)	$ 0.01
Diluted net income (loss) per share	$ 0.03	$ (0.03)	$ (0.03)	$ 0.01
Common Class B [Member] | Common Stock [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Schedule Of Earnings Per Share Basic And Diluted [Line Items]
Allocation of undistributable income/losses Net income/loss to ordinary shares	$ 112,510	$ (103,030)
Weighted average shares outstanding, basic	3,861,026	3,861,026
Weighted average shares outstanding, diluted	3,861,026	3,861,026
Basic net income (loss) per share	$ 0.03	$ (0.03)
Diluted net income (loss) per share	$ 0.03	$ (0.03)

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Schedule of Changes in Level 3 Liabilities Measured at Fair Value on a Recurring Basis (Detail)	11 Months Ended
	Dec. 31, 2021 USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance, end of year	$ 3,846,319
Overallotment liability [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance, beginning of year	0
Issuance of overallotment option	158,275
Partial exercise of overallotment option	(28,316)
Change in fair value of overallotment liability	(2,924)
Expiration of overallotment option	(127,035)
Balance, end of year	$ 0

Summary of Significant Accoun_8

Summary of Significant Accounting Policies - Schedule of Estimated Amortization Expenses (Detail) - USD ($)	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]
2023		$ 4,516
2024		4,528
2025		4,516
2026		4,516
2027		4,090
Thereafter		6,536
Total	$ 27,574	$ 28,702	$ 33,218

Summary of Significant Accoun_9

Summary of Significant Accounting Policies - Schedule of Assets and Liabilities Recorded in the Balance Sheet at Fair Value (Detail) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative liability	$ 1,152,065		$ 826,980	$ 3,846,319
Balance, beginning of year	826,980	$ 3,846,319	3,846,319	1,045,905
Initial recognition of derivative liability	0		1,321,860	285,349
Settled in Series C-2 preferred stock	0		(3,081,912)	0
Change in fair value of derivative liabilities	325,085	$ (337,497)	(1,259,287)	2,515,065
Balance, end of year	1,152,065		826,980	3,846,319
Fair Value, Inputs, Level 1 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative liability	0		0	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative liability	0		0	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative liability	$ 1,152,065		$ 826,980	$ 3,846,319

Summary of Significant Accou_10

Summary of Significant Accounting Policies - Schedule of Securities that were Excluded from the Diluted Per Share Calculation (Detail) - shares	Mar. 31, 2023	Dec. 31, 2022	Mar. 31, 2022	Dec. 31, 2021
Securities That Were Excluded From The Diluted Per Share Calculation [Line Items]
Stock Options	37,370,980	36,320,980	35,440,469	34,990,469
Convertible Notes	31,982,684		17,094,017
Total	207,068,589	200,538,629	108,883,961	91,339,974
Convertible Notes Payable [Member]
Securities That Were Excluded From The Diluted Per Share Calculation [Line Items]
Convertible Notes		26,620,370		0
Series A Redeemable Convertible Preferred Stock [Member]
Securities That Were Excluded From The Diluted Per Share Calculation [Line Items]
Temporary Equity, Shares Outstanding	19,968,051	19,968,051	19,968,051	19,968,051
Series B Redeemable Convertible Preferred Stock [Member]
Securities That Were Excluded From The Diluted Per Share Calculation [Line Items]
Temporary Equity, Shares Outstanding	33,801,226	33,801,226	32,917,690	32,917,690
Series C-1 Redeemable Convertible Preferred Stock [Member]
Securities That Were Excluded From The Diluted Per Share Calculation [Line Items]
Temporary Equity, Shares Outstanding	5,090,693	5,090,693	0	0
Series C-2 Redeemable Convertible Preferred Stock [Member]
Securities That Were Excluded From The Diluted Per Share Calculation [Line Items]
Temporary Equity, Shares Outstanding	73,560,390	73,560,390	0	0
Common Stock [Member]
Securities That Were Excluded From The Diluted Per Share Calculation [Line Items]
Class of Warrants, Outstanding	1,536,379	1,418,733	1,758,975	1,758,975
Preferred Stock [Member]
Securities That Were Excluded From The Diluted Per Share Calculation [Line Items]
Class of Warrants, Outstanding	3,758,186	3,758,186	1,704,759	1,704,789

Business Combination Agreement

Business Combination Agreement - Additional Information (Detail) - USD ($)	Mar. 31, 2023	Jan. 04, 2023	Dec. 31, 2022	Sep. 30, 2022	Dec. 31, 2021
Business Acquisition [Line Items]
Common stock, par or stated value per share	$ 0.001		$ 0.001	$ 0.001	$ 0.001
Business Combination Agreement [Member] | Subsequent Event [Member]
Business Acquisition [Line Items]
Common stock, par or stated value per share		$ 0.0001
Entity equity value		$ 150,000,000

Restatement and Correction of_3

Restatement and Correction of an Error - Schedule of Restated Balance Sheet (Detail) - USD ($)	Mar. 31, 2023	Dec. 31, 2022	Mar. 31, 2022	Dec. 31, 2021	Jan. 01, 2021	Dec. 31, 2020
Current Assets:
Cash				$ 12,362
Deferred offering costs	$ 1,054,573	$ 394,147		166,342
Total current assets	1,105,998	605,540		178,704
Property and equipment, net of accumulated depreciation of $440,334	232,003	254,974		337,592
Operating lease right of use asset	823,520	859,331		1,007,589
Intangible assets, net of accumulated amortization of $37,528	27,574	28,702		33,218
Total assets	2,189,095	1,748,547		1,557,103
Current Liabilities:
Accounts payable	2,958,255	2,138,732		871,313
Accrued expenses and other liabilities	1,281,831	944,573		514,783
Accrued interest— related parties				226,170
Accrued interest— non-related parties	740,318	477,720		1,654,486
Convertible notes payable— related parties, net of debt discount of $0				900,000
Convertible notes payable, current, net of debt discount of $946,291	2,777,778	2,777,778		7,703,432
Derivative liabilities	1,152,065	826,980		3,813,019
Lease liability, current	132,109	129,502		120,162
Total current liabilities	9,411,947	7,295,285		15,803,365
Long-term Liabilities:
Lease liability, net of current portion	793,708	827,728		961,908
Convertible notes payable — net of debt discount of $49,078				922
Derivative liabilities				33,300
Total Long-term Liabilities		827,728		996,130
Total liabilities	10,205,655	8,123,013		16,799,495
Commitments and Contingencies (Note 8)
Stockholders' Deficit:
Common stock, $.001 par value; 100,050,000 shares authorized; 36,918,882 shares issued and outstanding as of December 31, 2021	14,532	14,532		36,919
Additional paid-in capital	4,763,841	4,577,220		3,160,491
Accumulated deficit	(44,522,174)	(42,382,291)		(32,774,456)	$ (25,987,606)
Total shareholders' deficit	(39,743,801)	(37,790,539)	$ (30,504,144)	(29,577,046)		$ (23,288,229)
Total Liabilities and Shareholders' Deficit	2,189,095	1,748,547		1,557,103
Series A Redeemable Convertible Preferred Stock [Member]
Mezzanine Equity
Redeemable Convertible Preferred stock	7,789,420	7,714,336		7,406,409
Series B Redeemable Convertible Preferred Stock [Member]
Mezzanine Equity
Redeemable Convertible Preferred stock	$ 7,025,434	$ 7,025,434		6,928,245
As Previously Reported [Member]
Current Assets:
Cash				12,362
Deferred offering costs				166,342
Total current assets				178,704
Property and equipment, net of accumulated depreciation of $440,334				337,592
Operating lease right of use asset				1,007,589
Intangible assets, net of accumulated amortization of $37,528				18,506
Total assets				1,542,391
Current Liabilities:
Accounts payable				871,313
Accrued expenses and other liabilities				514,783
Accrued interest— non-related parties				1,880,656
Convertible notes payable, current, net of debt discount of $946,291				9,507,228
Lease liability, current				120,162
Total current liabilities				12,894,142
Long-term Liabilities:
Lease liability, net of current portion				961,908
Convertible notes payable — net of debt discount of $49,078				50,000
Total Long-term Liabilities				1,011,908
Total liabilities				13,906,050
Commitments and Contingencies (Note 8)
Stockholders' Deficit:
Common stock, $.001 par value; 100,050,000 shares authorized; 36,918,882 shares issued and outstanding as of December 31, 2021				36,919
Additional paid-in capital				2,989,644
Accumulated deficit				(28,382,005)	$ (25,830,637)
Total shareholders' deficit				(25,355,442)		$ (23,288,229)
Total Liabilities and Shareholders' Deficit				1,542,391
As Previously Reported [Member] | Series A Redeemable Convertible Preferred Stock [Member]
Mezzanine Equity
Redeemable Convertible Preferred stock				7,020,992
As Previously Reported [Member] | Series B Redeemable Convertible Preferred Stock [Member]
Mezzanine Equity
Redeemable Convertible Preferred stock				5,970,791
Reclassifications [Member]
Current Liabilities:
Accrued interest— related parties				226,170
Accrued interest— non-related parties				(226,170)
Convertible notes payable— related parties, net of debt discount of $0				900,000
Convertible notes payable, current, net of debt discount of $946,291				(900,000)
Long-term Liabilities:
Commitments and Contingencies (Note 8)
Error Correction [Member]
Current Assets:
Intangible assets, net of accumulated amortization of $37,528				14,712
Total assets				14,712
Current Liabilities:
Convertible notes payable, current, net of debt discount of $946,291				(903,796)
Derivative liabilities				3,813,019
Total current liabilities				2,909,223
Long-term Liabilities:
Convertible notes payable — net of debt discount of $49,078				(49,078)
Derivative liabilities				33,300
Total Long-term Liabilities				(15,778)
Total liabilities				2,893,445
Commitments and Contingencies (Note 8)
Stockholders' Deficit:
Additional paid-in capital				170,847
Accumulated deficit				(4,392,451)
Total shareholders' deficit				(4,221,604)
Total Liabilities and Shareholders' Deficit				14,712
Error Correction [Member] | Series A Redeemable Convertible Preferred Stock [Member]
Mezzanine Equity
Redeemable Convertible Preferred stock				385,417
Error Correction [Member] | Series B Redeemable Convertible Preferred Stock [Member]
Mezzanine Equity
Redeemable Convertible Preferred stock				957,454
Stockholders' Deficit:
Accumulated deficit				$ (72,522)

Restatement and Correction of_4

Restatement and Correction of an Error - Schedule of Restated Balance Sheet (Parenthetical) (Detail) - USD ($)	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Mar. 31, 2022	Dec. 31, 2021
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Property and equipment, net of accumulated depreciation	$ 553,087	$ 530,116			$ 440,334
Intangible assets, net of accumulated amortization	$ 43,172	$ 42,044			$ 37,528
Preferred stock shares authorized			171,090,521
Common stock, par or stated value per share	$ 0.001	$ 0.001	$ 0.001		$ 0.001
Common stock shares authorized	240,000,000	240,000,000	240,000,000		100,050,000
Common stock shares issued	14,531,511	14,531,511			36,918,882
Common stock shares outstanding	14,531,511	14,531,511			36,918,882
Series A Redeemable Convertible Preferred Stock [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Preferred stock shares authorized	19,968,051	19,968,051	19,968,051		19,968,051
Preferred stock shares issued	19,968,051	19,968,051			19,968,051
Preferred stock shares outstanding	19,968,051	19,968,051		19,968,051	19,968,051
Preferred stock liquidation preference					$ 7,406,409
Series B Redeemable Convertible Preferred Stock [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Preferred stock shares authorized	34,622,470	34,622,470	34,622,470		34,772,230
Preferred stock shares issued	33,801,226	33,801,226			32,917,690
Preferred stock shares outstanding	33,801,226	33,801,226		32,917,690	32,917,690
Preferred stock liquidation preference					$ 6,928,245
Series C Redeemable Convertible Preferred Stock [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Preferred stock shares authorized					25,907,990
Preferred stock shares issued					0
Preferred stock shares outstanding					0
Convertible Debt [Member] | Related party [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Convertible notes payable, net of debt discount					$ 0
Convertible Debt [Member] | Non-related party [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Convertible notes payable, net of debt discount	$ 0	$ 0			946,291
Convertible notes payable, net of debt discount		$ 0			$ 49,078

Restatement and Correction of_5

Restatement and Correction of an Error - Schedule of Restated Operations (Detail) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021
Operating expenses:
Research and development	$ 740,325	$ 464,911	$ 2,196,063	$ 982,837
General and administrative expenses	510,445	462,432	3,217,280	863,333
Depreciation and amortization	24,101	23,414	94,298	94,162
Total operating expenses	1,274,871	950,757	5,507,641	1,940,332
Loss from operations	(1,274,871)	(950,757)	(5,507,641)	(1,940,332)
Other income (expense):
Gain on the forgiveness of loans payable			0	438,180
Other income	34,541	10,822	10,922	37,378
Change in fair value of derivative liabilities	(325,085)	337,497	1,259,287	(2,515,065)
Interest expense, related party	0	(17,753)	(52,471)	(72,000)
Interest expense, non-related party			(1,652,498)	(643,487)
Amortization of debt discount	(703)	(619,622)	(2,044,241)	(1,783,597)
Total other expense	(553,844)	(507,503)	(3,543,693)	(4,538,591)
Loss before provision for income taxes	(1,828,715)	(1,458,260)	(9,051,334)	(6,478,923)
Net Income (Loss)	(1,828,715)	(1,458,260)	(9,051,334)	(6,478,923)
Dividends on Series A preferred stock	(311,168)	(76,981)	(556,501)	(307,927)
Net loss attributable to common stockholders	$ (2,139,883)	$ (1,535,241)	$ (9,607,835)	$ (6,786,850)
Net loss per common share—basic	$ (0.12)	$ (0.04)	$ (0.34)	$ (0.29)
Net loss per common share—diluted	$ (0.12)	$ (0.04)	$ (0.34)	$ (0.29)
Weighted average shares outstanding—basic	18,303,103	40,096,825	28,546,036	23,139,165
Weighted average shares outstanding—diluted	18,303,103	40,096,825	28,546,036	23,139,165
As Previously Reported [Member]
Operating expenses:
Research and development				$ 982,837
General and administrative expenses				617,989
Depreciation and amortization				103,656
ROU amortization				145,846
Advertising and Marketing				8,015
Total operating expenses				1,858,343
Loss from operations				(1,858,343)
Other income (expense):
Gain on the forgiveness of loans payable				438,180
Other income				37,527
Interest expense, non-related party				(860,805)
Total other expense				(385,098)
Loss before provision for income taxes				(2,243,441)
Net Income (Loss)				(2,243,441)
Net loss attributable to common stockholders				$ (2,243,441)
Net loss per common share—basic				$ (0.16)
Net loss per common share—diluted				$ (0.16)
Weighted average shares outstanding—basic				13,698,060
Weighted average shares outstanding—diluted				13,698,060
Reclassifications [Member]
Operating expenses:
General and administrative expenses				$ 153,861
ROU amortization				(145,846)
Advertising and Marketing				(8,015)
Other income (expense):
Interest expense, related party				(72,000)
Interest expense, non-related party				125,686
Amortization of debt discount				(53,686)
Error Correction [Member]
Operating expenses:
General and administrative expenses				91,483
Depreciation and amortization				(9,494)
Total operating expenses				81,989
Loss from operations				(81,989)
Other income (expense):
Other income				(149)
Change in fair value of derivative liabilities				(2,515,065)
Interest expense, non-related party				91,632
Amortization of debt discount				(1,729,911)
Total other expense				(4,153,493)
Loss before provision for income taxes				(4,235,482)
Net Income (Loss)				(4,235,482)
Dividends on Series A preferred stock				(307,927)
Net loss attributable to common stockholders				$ (4,543,409)
Net loss per common share—basic				$ (0.13)
Net loss per common share—diluted				$ (0.13)
Weighted average shares outstanding—basic				9,441,105
Weighted average shares outstanding—diluted				9,441,105

Restatement and Correction of_6

Restatement and Correction of an Error - Schedule of Restated Stockholder's Equity (Detail) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Beginning Balance	$ (37,790,539)	$ (29,577,046)	$ (29,577,046)	$ (23,288,229)
Correction of accumulated error				13,878
Issuance of common stock		26,477	26,477	3,194
Exercise of stock options			$ 1,271	234,162
Exercise of stock options (Shares)			9,075
Stock-based compensation expense	180,509	172,183	$ 609,891	246,799
Net loss	(1,828,715)	(1,458,260)	(9,051,334)	(6,478,923)
Ending Balance	(39,743,801)	(30,504,144)	(37,790,539)	(29,577,046)
Series A Preferred Stock [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Accrued Series A preferred stock dividend	(75,084)	(76,981)	(307,927)	(307,927)
Common Stock [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Beginning Balance	$ 14,532	$ 36,919	$ 36,919	$ 2,922
Beginning Balance (in Shares)	14,531,511	36,918,882	36,918,882	2,922,284
Issuance of common stock		$ 204	$ 204	$ 31,940
Issuance of common stock (in Shares)		203,666	203,666	31,940,355
Exercise of stock options			$ 9	$ 2,057
Exercise of stock options (Shares)			9,075	2,056,243
Ending Balance	$ 14,532	$ 37,123	$ 14,532	$ 36,919
Ending Balance (in Shares)	14,531,511	37,122,548	14,531,511	36,918,882
Additional Paid-in Capital [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Beginning Balance	$ 4,577,220	$ 3,160,491	$ 3,160,491	$ 2,539,486
Correction of accumulated error				170,847
Issuance of common stock		26,273	26,273	(28,746)
Exercise of stock options			1,262	232,105
Stock-based compensation expense	180,509	172,183	609,891	246,799
Ending Balance	4,763,841	3,768,430	4,577,220	3,160,491
Accumulated Deficit [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Beginning Balance	(42,382,291)	(32,774,456)	(32,774,456)	(25,830,637)
Correction of accumulated error				(156,969)
Net loss	(1,828,715)	(1,458,260)	(9,051,334)	(6,478,923)
Ending Balance	(44,522,174)	(34,309,697)	(42,382,291)	(32,774,456)
Accumulated Deficit [Member] | Series A Preferred Stock [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Accrued Series A preferred stock dividend	$ (75,084)	(76,981)	(307,927)	(307,927)
As Previously Reported [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Beginning Balance		(25,355,442)	(25,355,442)	(23,288,229)
Issuance of common stock				3,194
Exercise of stock options				234,162
Stock-based compensation expense				246,799
Net loss				(2,243,441)
Ending Balance				(25,355,442)
As Previously Reported [Member] | Series A Preferred Stock [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Accrued Series A preferred stock dividend				(307,927)
As Previously Reported [Member] | Common Stock [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Beginning Balance		$ 36,919	$ 36,919	$ 2,922
Beginning Balance (in Shares)		36,918,882	36,918,882	2,922,284
Issuance of common stock				$ 31,940
Issuance of common stock (in Shares)				31,940,355
Exercise of stock options				$ 2,057
Exercise of stock options (Shares)				2,056,243
Ending Balance				$ 36,919
Ending Balance (in Shares)				36,918,882
As Previously Reported [Member] | Additional Paid-in Capital [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Beginning Balance		$ 2,989,644	$ 2,989,644	$ 2,539,486
Issuance of common stock				(28,746)
Exercise of stock options				232,105
Stock-based compensation expense				246,799
Ending Balance				2,989,644
As Previously Reported [Member] | Accumulated Deficit [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Beginning Balance		(28,382,005)	(28,382,005)	(25,830,637)
Net loss				(2,243,441)
Ending Balance				(28,382,005)
As Previously Reported [Member] | Accumulated Deficit [Member] | Series A Preferred Stock [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Accrued Series A preferred stock dividend				(307,927)
Error Correction [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Beginning Balance		$ (4,221,604)	$ (4,221,604)
Net loss				(4,235,482)
Ending Balance				(4,221,604)
Error Correction [Member] | Accumulated Deficit [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net loss				(4,235,482)
Revision of Prior Period, Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Beginning Balance				(23,274,351)
Revision of Prior Period, Adjustment [Member] | Common Stock [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Beginning Balance				$ 2,922
Beginning Balance (in Shares)				2,922,284
Revision of Prior Period, Adjustment [Member] | Additional Paid-in Capital [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Beginning Balance				$ 2,710,333
Revision of Prior Period, Adjustment [Member] | Accumulated Deficit [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Beginning Balance				$ (25,987,606)

Restatement and Correction of_7

Restatement and Correction of an Error - Schedule of Restated Cash Flow (Detail) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021
Cash Flows from Operating Activities:
Net income (loss)	$ (1,828,715)	$ (1,458,260)	$ (9,051,334)	$ (6,478,923)
Adjustments to reconcile net loss to net cash used in operating activities:
Gain on forgiveness of loans payable			0	(438,180)
Depreciation and amortization	24,099	23,415	94,298	94,162
Amortization of debt discount	703	619,622	2,044,241	1,783,597
Amortization of ROU assets	35,811	40,711	148,258	147,962
Change in fair value of derivative liabilities	325,085	(337,497)	(1,259,287)	2,515,065
Stock-based compensation	180,509	185,421	636,368	246,799
Changes in operating assets and liabilities:
Prepaid expenses and other current assets				9,918
Accounts payable	159,097	(768,539)	1,059,946	80,320
Accrued expenses and other liabilities	337,258	10,129	429,790	262,097
Lease liability	(31,413)	(34,268)	(124,840)	(115,132)
Accrued interest— related parties	0	17,753	52,471	72,000
Accrued interest -non related parties	262,598	181,410	1,004,378	643,486
Net cash used in operating activities	(475,959)	(1,597,658)	(3,428,707)	(1,176,829)
Cash flows from investing activities:
Purchase of property and equipment	0	(3,579)	(7,164)	(7,273)
Net cash used in investing activities				(7,273)
Cash Flows from Financing Activities:
Proceeds from convertible notes	0	2,612,514	2,745,974	906,839
Proceeds from PPP loan				217,460
Payment of offering costs			(20,332)	(166,342)
Proceeds from issuance of common stock				3,194
Proceeds from exercise of stock options			1,271	234,163
Net cash (used in) provided by financing activities	375,000	2,230,292	3,551,658	1,195,314
Net Change in Cash	(100,959)	629,055	115,787	11,212
Cash – beginning of period	128,149	12,362	12,362	1,150
Cash—end of period	27,190	641,417	128,149	12,362
Non-cash financing activity:
Accrued Series A preferred stock dividends	75,084	76,981	307,926	307,927
Initial recognition of derivative liabilities	$ 0	1,267,860	1,321,860	258,359
As Previously Reported [Member]
Cash Flows from Operating Activities:
Net income (loss)				(2,243,441)
Adjustments to reconcile net loss to net cash used in operating activities:
Gain on forgiveness of loans payable				(438,180)
Depreciation and amortization				103,656
Amortization of debt discount				53,686
Amortization of ROU assets				145,846
Stock-based compensation				246,799
Changes in operating assets and liabilities:
Prepaid expenses and other current assets				9,918
Accounts payable				80,320
Accrued expenses and other liabilities				262,098
Lease liability				(113,016)
Accrued interest -non related parties				715,486
Net cash used in operating activities				(1,176,828)
Cash flows from investing activities:
Purchase of property and equipment				(7,273)
Net cash used in investing activities				(7,273)
Cash Flows from Financing Activities:
Proceeds from convertible notes				906,839
Proceeds from PPP loan				217,460
Payment of offering costs				(166,342)
Proceeds from exercise of stock options				237,356
Net cash (used in) provided by financing activities				1,195,313
Net Change in Cash				11,212
Cash – beginning of period		$ 12,362	$ 12,362	1,150
Cash—end of period				12,362
Non-cash financing activity:
Accrued Series A preferred stock dividends				307,927
Reclassifications [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of ROU assets				2,116
Changes in operating assets and liabilities:
Accrued expenses and other liabilities				(1)
Lease liability				(2,116)
Accrued interest— related parties				72,000
Accrued interest -non related parties				(72,000)
Net cash used in operating activities				(1)
Cash Flows from Financing Activities:
Proceeds from issuance of common stock				3,194
Proceeds from exercise of stock options				(3,193)
Net cash (used in) provided by financing activities				1
Error Correction [Member]
Cash Flows from Operating Activities:
Net income (loss)				(4,235,482)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization				(9,494)
Amortization of debt discount				1,729,911
Change in fair value of derivative liabilities				2,515,065
Changes in operating assets and liabilities:
Net cash used in operating activities				0
Non-cash financing activity:
Initial recognition of derivative liabilities				$ 258,359

Restatement and Correction of_8

Restatement and Correction of an Error - Additional Information (Detail) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Jan. 01, 2021
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Amortization of debt discount	$ 703	$ 619,622	$ 2,044,241	$ 1,783,597
Increase (decrease) in accumulated deficit	(44,522,174)		(42,382,291)	(32,774,456)	$ (25,987,606)
Gain (loss) on the extinguishment			(1,064,692)	0
Fair value of the warrants	1,152,065		826,980	3,846,319
Amortization expense	$ 24,101	$ 23,414	$ 94,298	$ 94,162
Basic net loss per share	$ (0.12)	$ (0.04)	$ (0.34)	$ (0.29)
Diluted net loss per share	$ (0.12)	$ (0.04)	$ (0.34)	$ (0.29)
Net loss	$ (1,828,715)	$ (1,458,260)	$ (9,051,334)	$ (6,478,923)
Weighted average shares outstanding , Basic	18,303,103	40,096,825	28,546,036	23,139,165
Weighted average shares outstanding , Diluted	18,303,103	40,096,825	28,546,036	23,139,165
Error Correction [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Amortization of debt discount				$ 1,729,911
Increase (decrease) in accumulated deficit				(4,392,451)
Amortization expense				$ (9,494)
Basic net loss per share				$ (0.13)
Diluted net loss per share				$ (0.13)
Net loss				$ (4,235,482)
Weighted average shares outstanding , Basic				9,441,105
Weighted average shares outstanding , Diluted				9,441,105
Error Correction [Member] | Intangible Asset [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Increase (decrease) in accumulated deficit				$ (5,218)
Intangible assets carrying value				$ 78,009
Intangible asset estimated useful lives				10 years
Amortization expense				$ 9,494
As Previously Reported [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Increase (decrease) in accumulated deficit				(28,382,005)	$ (25,830,637)
Amortization expense				$ 103,656
Basic net loss per share				$ (0.16)
Diluted net loss per share				$ (0.16)
Net loss				$ (2,243,441)
Weighted average shares outstanding , Basic				13,698,060
Weighted average shares outstanding , Diluted				13,698,060
Derivative Liability [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Short-term derivative liabilities				$ 3,813,019
Long-term derivative liabilities				33,300
Loss on derivative				2,515,065
Related party convertible notes				995,369
Derivative Liability [Member] | Error Correction [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Increase (decrease) in accumulated deficit				1,351,531
Series A Preferred Stock [Member] | Error Correction [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Increase (decrease) in accumulated deficit				(98,325)
Additional paid-in capital				98,325
Series A Preferred Stock [Member] | As Previously Reported [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Gain (loss) on the extinguishment				(425,396)
Dividends				$ 39,979
Warrants issued				1,096,660
Series A Preferred Stock [Member] | As Previously Reported [Member] | Warrant [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Fair value of the warrants				$ 98,525
Series B Preferred Stock [Member] | Error Correction [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Increase (decrease) in accumulated deficit				(72,522)
Additional paid-in capital				72,522
Amortization of debt discount				957,454
Series B Preferred Stock [Member] | As Previously Reported [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Stockholders' equity, period increase (decrease)				1,029,976
Series B Preferred Stock [Member] | As Previously Reported [Member] | Warrant [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Fair value of the warrants				$ 72,522

IPO - Additional information (D

IPO - Additional information (Detail) - USD ($)				3 Months Ended	12 Months Ended
	Aug. 03, 2021	Jul. 29, 2021	Jul. 26, 2021	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period					9,075
Stock Issued During Period, Value, Stock Options Exercised					$ 1,271	$ 234,162
Alpha Healthcare Acquisition Corp. III [Member]
Shares Issued, Price Per Share				$ 10	$ 10		$ 10
Private Placement Warrants [Member] | Sponsor [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Class of warrants and rights issued during the period				455,000	455,000
Class Of Warrants and Rights Issued, Price Per Warrant				$ 10	$ 10
Proceeds from Issuance of Private Placement				$ 4,550,000	$ 4,550,000
IPO [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Shares Issued, Price Per Share		$ 10
Proceeds from Issuance Initial Public Offering		$ 154,441,030
Over-Allotment Option [Member] | Private Placement Warrants [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Class of warrants and rights issued during the period	8,882
Proceeds from Issuance of Private Placement	$ 88,820
Common Class A [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Stock shares issued during the period shares		15,000,000
Common Class A [Member] | IPO [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Stock shares issued during the period shares		15,000,000
Shares Issued, Price Per Share		$ 10
Proceeds from Issuance Initial Public Offering		$ 150,000,000
Exercise price of warrant		$ 11.5
Underwriting Agreement [Member] | Over-Allotment Option [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Stock shares issued during the period shares			2,250,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	444,103
Stock Issued During Period, Value, Stock Options Exercised	$ 4,441,030

Going Concern and Management'_2

Going Concern and Management's Liquidity Plans - Additional Information (Detail) - USD ($)		3 Months Ended		12 Months Ended
	Jul. 19, 2022	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Jan. 01, 2021
Debt Instrument [Line Items]
Cash		$ 27,190		$ 128,149	$ 12,362
Accumulated deficit		(44,522,174)		(42,382,291)	(32,774,456)	$ (25,987,606)
Loss from operations		(1,274,871)	$ (950,757)	(5,507,641)	(1,940,332)
Net cash used in operating activities		$ 475,959	$ 1,597,658	$ 3,428,707	$ 1,176,829
Percentage of increase in debt principal in case of event of default	25%
Minimum [Member]
Debt Instrument [Line Items]
Percentage of increase in debt interest rate in case of event of default	10%
Maximum [Member]
Debt Instrument [Line Items]
Percentage of increase in debt interest rate in case of event of default	18%

Property and Equipment - Schedu

Property and Equipment - Schedule of Property Plant and Equipment (Detail) - USD ($)	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 785,090	$ 785,090	$ 777,926
Less: accumulated depreciation	(553,087)	(530,116)	(440,334)
Property and equipment, net	232,003	254,974	337,592
Lab equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	666,178	666,178	662,593
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	115,333	115,333	$ 115,333
Furniture and fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 3,579	$ 3,579

Property and Equipment - Additi

Property and Equipment - Additional Information (Detail) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 22,971	$ 22,301	$ 89,782	$ 89,646

Accrued Expenses and Other Li_3

Accrued Expenses and Other Liabilities - Schedule Of Accrued Expenses and Other Liabilities (Detail) - USD ($)	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Accrued Liabilities and Other Liabilities [Abstract]
Accrued compensation	$ 1,234,660	$ 916,934	$ 489,794
Other	47,171	27,639	24,989
Accrued expenses and other liabilities	$ 1,281,831	$ 944,573	$ 514,783

Leases - Additional Information

Leases - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2022 Office
Lessee Disclosure [Abstract]
Number of leases	2
Lease expiration date	Dec. 31, 2028
Operating lease, weighted average remaining lease term	6 years
Operating lease weighted average incremental borrowing rate	8%

Leases - Schedule of Net Lease

Leases - Schedule of Net Lease Cost and Other Supplemental Lease (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Lease cost
Operating lease cost (cost resulting from lease payments)	$ 201,400	$ 204,499
Short term lease cost		31,500
Net lease cost	201,400	235,999
Operating lease – operating cash flows (fixed payments)	$ 200,980	$ 197,565

Leases - Schedule of Estimated

Leases - Schedule of Estimated Future Minimum Lease Payments, Excluding Non-lease Components (Detail)	Dec. 31, 2022 USD ($)
Lessee, Operating Lease, Liability, to be Paid [Abstract]
2023	$ 204,930
2024	204,930
2025	204,930
2026	204,930
2027	204,930
Thereafter	204,930
Total future minimum annual lease payments	1,229,580
Less: Imputed interest	(272,350)
Present value of lease liabilities	$ 957,230

Convertible Notes and Promiss_2

Convertible Notes and Promissory Notes - Additional Information (Detail) - USD ($)					3 Months Ended			5 Months Ended	6 Months Ended	11 Months Ended		12 Months Ended		21 Months Ended	40 Months Ended
	Dec. 31, 2022	Sep. 23, 2022	Jul. 19, 2022	Jan. 19, 2022	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2019	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2021	Dec. 31, 2021	Dec. 19, 2022	Jun. 24, 2020	Sep. 25, 2019	Sep. 08, 2018
Debt Disclosure [Line Items]
Amortization of debt discount					$ 703	$ 619,622						$ 2,044,241	$ 1,783,597
Principal amount of debt convertible into equity												15,665,171
Proceeds from convertible debt					0	2,612,514						2,745,974	906,839
Adjustment to additional paid in capital warrants issued					6,112	409,483						409,483
Convertible debt current	$ 2,777,778				2,777,778			$ 2,777,778	$ 7,703,432	$ 2,777,778	$ 7,703,432	2,777,778	$ 7,703,432	$ 7,703,432	$ 7,703,432
Interest expenses including late fees and accelerated payment					262,597
Pay check protection program loan one [member]
Debt Disclosure [Line Items]
Proceeds from other long term debt														$ 220,720
Pay check protection program loan one [member] | Gain loss on the forgiveness of debt [member]
Debt Disclosure [Line Items]
Debt instrument decrease forgiveness									$ 220,720
Pay check protection program loan two [member]
Debt Disclosure [Line Items]
Proceeds from other long term debt											217,460
Pay check protection program loan two [member] | Gain loss on the forgiveness of debt [member]
Debt Disclosure [Line Items]
Debt instrument decrease forgiveness											$ 217,460
Series one convertible notes [member]
Debt Disclosure [Line Items]
Long term debt bearing fixed interest rate percentage									8%		8%		8%	8%	8%
Convertible debt principal amount outstanding									$ 6,109,560		$ 6,109,560		$ 6,109,560	$ 6,109,560	$ 6,109,560
Unamortized debt discount									0		0		0	0	0
Interest expense on convertible debt					120,517							356,196	488,765
Amortization of debt discount					0							0	1,068,805
Interest payable current									1,473,699		1,473,699		1,473,699	1,473,699	1,473,699
Debt instrument conversion price per share		$ 0.1712
Fair value of shares issued upon conversion of convertible debt		$ 15,595,283
Fair value of derivative upon conversion of convertible debt									1,938,481		1,938,481		1,938,481	1,938,481	1,938,481
Series one convertible notes [member] | New series C two redeemable convertible preferred stock [member]
Debt Disclosure [Line Items]
Minimum proceeds from qualified financing															5,000,000
Debt instrument conversion price as a percentage of issue price of shares																			80%
Value considered for conversion of debt into shares									20,000,000		20,000,000		20,000,000	20,000,000	20,000,000
Series one convertible notes [member] | New series C two redeemable convertible preferred stock [member] | Principal Portion [Member]
Debt Disclosure [Line Items]
Principal amount of debt convertible into equity		$ 6,109,560
Debt intrument convertible number of equity instruments issued upon conversion		35,686,682
Series one convertible notes [member] | New series C two redeemable convertible preferred stock [member] | Interest Portion [Member]
Debt Disclosure [Line Items]
Principal amount of debt convertible into equity		$ 1,829,865
Debt intrument convertible number of equity instruments issued upon conversion		10,688,464
Series C two convertible notes [member]
Debt Disclosure [Line Items]
Long term debt bearing fixed interest rate percentage																		8%
Minimum proceeds from qualified financing							$ 5,000,000
Debt instrument conversion price as a percentage of issue price of shares																		80%
Value considered for conversion of debt into shares							$ 20,000,000
Convertible debt principal amount outstanding									3,440,163		3,440,163		3,440,163	3,440,163	3,440,163
Unamortized debt discount									946,291		946,291		946,291	946,291	946,291
Interest expense on convertible debt						75,560						222,906	226,749
Amortization of debt discount						304,367						1,099,770	714,163
Interest payable current									407,014		407,014		407,014	407,014	407,014
Fair value of shares issued upon conversion of convertible debt		$ 5,717,377
Fair value of derivative upon conversion of convertible debt		$ 1,122,002							1,122,002		1,122,002		1,122,002	1,122,002	1,122,002
Proceeds from convertible debt												523,752	906,839
Write off of debt issuance costs												57,921
Series C two convertible notes [member] | New series C two redeemable convertible preferred stock [member]
Debt Disclosure [Line Items]
Debt instrument conversion price per share		$ 0.1712
Fair value of derivative upon issuance of convertible debt												211,401	285,349
Series C two convertible notes [member] | New series C two redeemable convertible preferred stock [member] | Principal Portion [Member]
Debt Disclosure [Line Items]
Principal amount of debt convertible into equity		$ 3,965,455
Debt intrument convertible number of equity instruments issued upon conversion		23,162,704
Series C two convertible notes [member] | New series C two redeemable convertible preferred stock [member] | Interest Portion [Member]
Debt Disclosure [Line Items]
Principal amount of debt convertible into equity		$ 629,920
Debt intrument convertible number of equity instruments issued upon conversion		3,679,439
Other convertible notes [member]
Debt Disclosure [Line Items]
Long term maturity date																	Jun. 23, 2025
Convertible debt principal amount outstanding									50,000		50,000		50,000	50,000	50,000
Unamortized debt discount									49,078		49,078		49,078	49,078	49,078
Amortization of debt discount					301							1,206	629
Debt intrument convertible number of equity instruments issued upon conversion		343,157
Debt instrument conversion price per share		$ 0.1457
Write off of debt issuance costs												47,872
Debt instrument, face amount																	$ 50,000
Other convertible notes [member] | New series C two redeemable convertible preferred stock [member]
Debt Disclosure [Line Items]
Principal amount of debt convertible into equity		$ 50,000
Fair value of shares issued upon conversion of convertible debt		$ 73,092
Fair value of derivative upon conversion of convertible debt									$ 23,092		$ 23,092		$ 23,092	$ 23,092	$ 23,092
January 2022 convertible notes [member]
Debt Disclosure [Line Items]
Long term debt bearing fixed interest rate percentage			10%
Interest expense on convertible debt					125,000	40,123						332,253
Amortization of debt discount					703	$ 314,954						943,265
Fair value of derivative upon conversion of convertible debt	1,110,459							1,110,459		1,110,459		1,110,459
Write off of debt issuance costs								958,899
Long term debt fixed interest rate percentage in case of default			18%													18%
Long term debt percentage increase in outstanding principal due to default			25%
Convertible debt current	2,777,778				2,777,778			2,777,778		2,777,778		2,777,778
Interest expenses including late fees and accelerated payment												1,125,868
Late fees and penalties on convertible debt					$ 137,597							238,059
Accelerated payment amount.												555,556
January 2022 convertible notes [member] | Putian [Member]
Debt Disclosure [Line Items]
Convertible debt current	$ 1,627,749							$ 1,627,749		$ 1,627,749		$ 1,627,749				$ 1,610,413
Equity valuation minimum for consummation of business combination																$ 150,000,000
Number of freely transferrable shares withdrawn	25,000							25,000
Price per share of shares withdrawn																$ 10
January 2022 convertible notes [member] | Common stock [member]
Debt Disclosure [Line Items]
Long term debt bearing fixed interest rate percentage				10%
Debt instrument conversion price per share				$ 0.22
Long term debt fixed interest rate percentage in case of default				18%
Debt instrument date of first required payment			Jul. 19, 2022
Debt instrument monthly payment			$ 158,730	$ 158,730
Long term debt discount percentage				10%
Long term debt commission percentage				8%
Class of warrants or rights number of securities covered by warrants or rights				3,771,592
Class of warrants or rights exercise price of warrants or rights				$ 0.01
Class of warrants or rights term				5 years
Class of warrants or rights issued during the period fair value				$ 409,483
Debt instrument discount percentage on conversion price				25%
Debt instrument base conversion price	$ 0.11				$ 0.11			$ 0.11		$ 0.11		$ 0.11
Adjustment to additional paid in capital warrants issued								$ 409,483		$ 409,483
January 2022 convertible notes [member] | Common stock [member] | Tranche 1 [member]
Debt Disclosure [Line Items]
Debt instrument, face amount				$ 1,111,111
Class of warrants or rights number of securities covered by warrants or rights				1,885,796
January 2022 convertible notes [member] | Common stock [member] | Tranche 2 [member]
Debt Disclosure [Line Items]
Debt instrument, face amount				$ 1,111,111
Class of warrants or rights number of securities covered by warrants or rights				1,885,796
Two thousand and twenty three promissory notes [Member]
Debt Disclosure [Line Items]
Unamortized debt discount					$ 5,409
Amortization of debt discount					703
Debt instrument, face amount					$ 375,000
Class of warrants or rights exercise price of warrants or rights					$ 0.88
Class of warrants or rights term					5 years
Adjustment to additional paid in capital warrants issued					$ 6,112
Debt instrument, term					12 months
Debt conversion, converted instrument, warrants or options issued					117,646

Commitments & Contingencies - A

Commitments & Contingencies - Additional Information (Detail) - USD ($)						3 Months Ended		12 Months Ended
	Aug. 06, 2021	Aug. 03, 2021	Jul. 29, 2021	Jul. 26, 2021	Jan. 30, 2008	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Mar. 20, 2023	Jul. 14, 2021	Dec. 31, 2011
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period								9,075
Stock Issued During Period, Value, Stock Options Exercised								$ 1,271	$ 234,162
License Agreement [Member] | Carnegie Mellon University [Member]
Stock shares issued during the period shares					66,913
Warrants issued value					$ 2,000,000
Percentage of outstanding shares					8.20%
Common stock shares issued in exchnage of warrants												1,607,705
Royalities payable percentage					2.07%
Royalties payable exemption period					3 years
Sublicense fees payment percentage					25%
Payments due period					60 days
Overdue payments interest rate					4%
Accrued royalties						$ 0	$ 0	0	0
Payments for royalties						0	0	0	0
Reimbursment of expenses						0	0	0	0
Reimbursment of expenses payable						0	$ 0	0	0
Alpha Healthcare Acquisition Corp. III [Member]
Deferred Underwriting Fees Payable Noncurrent						$ 0		$ 5,405,436	$ 5,405,436	$ 5,405,436
NonRisk Incentive Private Shares [Member] | Maximum [Member] | Sponsor [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Percentage of ownership shares through initial Business Combination											10%
Risk Incentive Private Shares [Member] | Minimum [Member] | Sponsor [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Percentage of ownership shares through initial Business Combination											10%
Over-Allotment Option [Member] | Underwriting Agreement [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Stock shares issued during the period shares				2,250,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		444,103
Stock Issued During Period, Value, Stock Options Exercised		$ 4,441,030
Cash underwriting discount percent	2%		2%
Payment of underwriting discount	$ 88,820		$ 3,000,000
Deferred underwriting fee percent						3.50%		3.50%
Deferred underwriting commission						$ 5,405,436		$ 5,405,436

Shareholder's Equity - Addition

Shareholder's Equity - Additional Information (Detail) - $ / shares						3 Months Ended	11 Months Ended	12 Months Ended
	Sep. 30, 2021	Aug. 03, 2021	Jul. 29, 2021	Mar. 01, 2021	Jan. 25, 2021	Mar. 31, 2023	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Sep. 30, 2022
Class of Stock [Line Items]
Common stock par or stated value per share						$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001
Common stock shares authorized						240,000,000	100,050,000	240,000,000	100,050,000	240,000,000
Alpha Healthcare Acquisition Corp. III [Member]
Class of Stock [Line Items]
Preferred stock par or stated value per share						$ 0.0001		$ 0.0001
Preferred stock shares authorized						1,000,000		1,000,000
Preferred stock shares issued						0	0	0	0
Preferred stock shares outstanding						0	0	0	0
Stockholders' Equity Note, Stock Split						1:1.2		1:1.2
Volume weighted average price of shares						$ 9.2		$ 9.2
Proceeds from equity used for funding business combination as a percentage of the total						60%		60%
Notice period of redemption warrant						30 days		30 days
Initial Shareholders [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Class of Stock [Line Items]
Equity Method Investment, Ownership Percentage								50%
Warrant [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Class of Stock [Line Items]
Class of warrants or rights exercise price per unit						$ 11.5		$ 11.5
Warrants and rights outstanding term						5 years		5 years
Common Class A [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Class of Stock [Line Items]
Stock shares issued during the period shares			15,000,000
Common stock par or stated value per share				$ 0.0001		$ 0.0001		$ 0.0001
Common stock shares authorized				100,000,000		100,000,000		100,000,000
Common Class A [Member] | Founder [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Class of Stock [Line Items]
Percentage of common stock issued and outstanding						20%		20%
Common Class B [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Class of Stock [Line Items]
Common stock par or stated value per share				$ 0.0001		$ 0.0001		$ 0.0001
Common stock shares authorized				10,000,000		10,000,000		10,000,000
Stock Issued During Period, Shares, Stock Splits				4,312,500
Common Stock [Member]
Class of Stock [Line Items]
Stock shares issued during the period shares									31,940,355
Preferred Stock [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Class of Stock [Line Items]
Preferred stock par or stated value per share				$ 0.0001
Preferred stock shares authorized				1,000,000
Redemption of warrants equals or exceeds $18.00 [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Class of Stock [Line Items]
Adjusted exercise price of warrants as a percentage of newly issued price						180%		180%
Share price						$ 18		$ 18
Class of warrants or rights redemption price per unit						$ 0.01		$ 0.01
Securities for capital with closing of initial business combination						20 days	20 days	20 days
Third trading day prior to date on which company notice of redemption						30 days		30 days
Redemption of warrants equals or exceeds $18.00 [Member] | Common Class A [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Class of Stock [Line Items]
Notice period of redemption warrant						30 days		30 days
Redemption of warrants below $9.20 [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Class of Stock [Line Items]
Adjusted exercise price of warrants as a percentage of newly issued price						115%		115%
Share price						$ 9.2		$ 9.2
Over-Allotment Option [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Class of Stock [Line Items]
Number of additional shares purchased	444,103
Number of shares available for purchase		2,250,000
Number of shares lapsed		111,026
Number of founder shares forfeited		451,464
Over-Allotment Option [Member] | Common Class B [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Class of Stock [Line Items]
Common Stock Shares Subject To Forfeiture							562,500		562,500
Over-Allotment Option [Member] | Common Stock [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Class of Stock [Line Items]
Stock shares issued during the period shares					3,593,750
Common Stock Shares Subject To Forfeiture					468,750
Over-Allotment Option [Member] | Common Stock [Member] | Initial Shareholders [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Class of Stock [Line Items]
Equity Method Investment, Ownership Percentage					20%

Profit-Sharing Plan - Additiona

Profit-Sharing Plan - Additional Information (Detail) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021
Defined Benefit Plan [Abstract]
Profit sharing plan, employer contribution	$ 0	$ 0	$ 0	$ 0

Mezzanine Equity And Stockhol_3

Mezzanine Equity And Stockholders' Deficit - Schedule of Warrants Outstanding (Detail) - Common Stock Warrants [Member] - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Class of Warrant or Right [Line Items]
Beginning Outstanding and exercisable (Number of Warrants)	5,190,325	1,758,975
Warrants issued	117,646	3,771,592
Warrants exercised		(340,242)
Ending Outstanding and exercisable (Number of Warrants)	5,307,971	5,190,325	1,758,975
Beginning Outstanding and exercisable (Weighted Average Exercise Price)	$ 0.13	$ 0.46
Warrants issued	0.88	0.01
Warrants exercised		0.11
Ending Outstanding and exercisable (Weighted Average Exercise Price)	$ 0.14	$ 0.13	$ 0.46
(Weighted Average Remaining Contractual Life in Years)	3 years 1 month 13 days	3 years 3 months 25 days	2 years 4 months 17 days

Mezzanine Equity And Stockhol_4

Mezzanine Equity And Stockholders' Deficit - Additional Information (Detail)		1 Months Ended	3 Months Ended		12 Months Ended
	Sep. 23, 2022 USD ($) $ / shares shares	Sep. 30, 2021 USD ($) shares	Mar. 31, 2023 USD ($) $ / shares shares	Mar. 31, 2022 USD ($) shares	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares	Sep. 30, 2022 $ / shares shares	Jan. 19, 2022 $ / shares
Class of Warrant or Right [Line Items]
Proceeds from the exercise of warrants					$ 144,944
Share based compensation by share based award weighted average fair value per share of options granted | $ / shares			$ 0.12		$ 0.1	$ 0.09
Proceeds from issuance of common stock						$ 3,194
Payment for the repurchase of shares					$ 2,294
Common stock shares authorized | shares			240,000,000		240,000,000	100,050,000	240,000,000
Common stock par or stated value per share | $ / shares			$ 0.001		$ 0.001	$ 0.001	$ 0.001
Temporary equity stock shares authorized | shares							171,090,521
Issuance of common stock				$ 26,477	$ 26,477	$ 3,194
Common Stock [Member]
Class of Warrant or Right [Line Items]
Stock shares issued during the period shares | shares						31,940,355
Issuance of common stock (in Shares) | shares				203,666	203,666	31,940,355
Issuance of common stock				$ 204	$ 204	$ 31,940
Series A Redeemable Convertible Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Temporary equity stock shares authorized | shares			19,968,051		19,968,051	19,968,051	19,968,051
Temporary equity issue price per share | $ / shares			$ 0.2203		$ 0.2203
Temporary equity accrued dividends			$ 3,329,887		$ 3,254,803	$ 2,946,876
Temporary equity accretion of dividends during the period			$ 75,084	76,981	307,927
Series B Redeemable Convertible Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Proceeds from the exercise of warrants					$ 97,189
Percentage of distributions to be paid			70%
Temporary equity stock shares issued during the period shares | shares					883,536
Temporary equity stock shares authorized | shares			34,622,470		34,622,470	34,772,230	34,622,470
Series C1 Redeemable Convertibe Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Temporary equity stock shares issued during the period shares | shares	4,996,796
Temporary equity par or stated value per share | $ / shares							$ 0.001
Temporary equity stock shares authorized | shares							41,000,000
Temporary equity issue price per share | $ / shares			$ 0.213		$ 0.213
Temporary equity accrued dividends			$ 28,186		$ 9,470
Temporary equity accretion of dividends during the period			$ 18,716		$ 9,470
Series C2 Redeemable Convertible Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Temporary equity par or stated value per share | $ / shares							$ 0.001
Temporary equity stock shares authorized | shares			75,500,000		75,500,000	0	75,500,000
Temporary equity issue price per share | $ / shares			$ 0.1712		$ 0.1712
Temporary equity accrued dividends			$ 456,472		$ 239,104
Temporary equity accretion of dividends during the period			$ 217,368		$ 239,104
Series A, C1 And C2 Redeemable Convertible Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Temporary equity dividend rate percentage			7%		7%
Series C One Redeemable Convertible Preferred Stock And Related Warrants [Member]
Class of Warrant or Right [Line Items]
Proceeds from the exercise of redeemable convertible preferred stock and warrants	$ 1,064,317
Series C Redeemable Convertible Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Temporary equity par or stated value per share | $ / shares							$ 0.001
Temporary equity stock shares authorized | shares						25,907,990
Agreement With Angel Investors [Member]
Class of Warrant or Right [Line Items]
Proceeds from issuance of common stock		$ 3,194
Payment for the repurchase of shares					$ 2,294
Stock shares repurchased and retired during the period shares | shares					22,940,355
Agreement With Angel Investors [Member] | Tranche One [Member]
Class of Warrant or Right [Line Items]
Stock shares issued during the period shares | shares		15,970,178
Agreement With Angel Investors [Member] | Tranche Two [Member]
Class of Warrant or Right [Line Items]
Stock shares issued during the period shares | shares		15,970,177
Two Thousand And Nine Stock Incentive Plan [Member]
Class of Warrant or Right [Line Items]
Share based compensation by share based award number of shares authorized for issuance | shares			45,072,120		45,072,120
Share based compensation by share based award purchase of common stock percentage			100%		100%
Share based compensation by share based award contractual period			10 years		10 years
Share based compensation by share based award vesting period			4 years		4 years
Two Thousand And Nine Stock Incentive Plan [Member] | Share-Based Payment Arrangement, Tranche One [Member]
Class of Warrant or Right [Line Items]
Share based compensation by share based award vesting percentage			25%		25%
Two Thousand And Nine Stock Incentive Plan [Member] | Owners Holding Ten Percent Or More Of The Shares [Member]
Class of Warrant or Right [Line Items]
Share based compensation by share based award purchase of common stock percentage			110%		110%
Share based compensation by share based award contractual period			5 years		5 years
Share-Based Payment Arrangement, Option [Member]
Class of Warrant or Right [Line Items]
Allocated share based compensation expenses			$ 180,509	$ 172,183	$ 609,891	$ 246,799
Share based compensation options cost not yet recognized amount			$ 1,930,000		$ 2,000,000
Share based compensation options cost not yet recognized remaining period for recognition			2 years 2 months 12 days		2 years 4 months 6 days
January Two Thousand And Twenty Two Convertible Notes [Member] | Common Stock [Member]
Class of Warrant or Right [Line Items]
Class of warrants or rights exercise price per unit | $ / shares								$ 0.01
Exercise Of Warrants [Member] | Series C1 Redeemable Convertibe Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Proceeds from the exercise of warrants					$ 10,329
Temporary equity stock shares issued during the period shares | shares					93,897
Common Stock Warrants [Member]
Class of Warrant or Right [Line Items]
Class of warrants or rights exercise price per unit | $ / shares			$ 0.14		$ 0.13	$ 0.46
Class of warrants or rights outstanding aggregate intrinsic value			$ 565,739
Common Stock Warrants [Member] | January Two Thousand And Twenty Two Convertible Notes [Member]
Class of Warrant or Right [Line Items]
Class of warrants or rights exercise price per unit | $ / shares					$ 0.01
Class of warrants or rights issued during the period units | shares					3,771,592
Class of warrants or rights expiry date					5 years
Common Stock Warrants [Member] | One Time Warrant Special Exercise Offer [Member]
Class of Warrant or Right [Line Items]
Class of warrants or rights exercise price per unit | $ / shares					$ 0.11
Stock shares issued during the period shares | shares					340,243
Proceeds from the exercise of warrants					$ 37,426
Series B Redeemable Convertible Preferred Stock Warrants [Member]
Class of Warrant or Right [Line Items]
Class of warrants or rights exercise price per unit | $ / shares	$ 0.16		$ 0.22		$ 0.22	$ 0.22
Class of warrants or rights outstanding aggregate intrinsic value			$ 0
Percentage of distributions to be paid					70%
Series B Redeemable Convertible Preferred Stock Warrants [Member] | One Time Warrant Special Exercise Offer [Member]
Class of Warrant or Right [Line Items]
Class of warrants or rights exercise price per unit | $ / shares					$ 0.11
Proceeds from the exercise of warrants					$ 97,189
Class of warrants or rights issued during the period units | shares					883,536
Series C1 Redeemable Convertible Preferred Stock Warrants [Member]
Class of Warrant or Right [Line Items]
Class of warrants or rights exercise price per unit | $ / shares			$ 0.16		$ 0.16
Class of warrants or rights issued during the period units | shares	3,030,830
Class of warrants or rights expiry date	Sep. 22, 2032
Class of warrants or rights outstanding aggregate intrinsic value			$ 29,369
Temporary equity related warrants issuance costs	$ 312,088
Series C1 Redeemable Convertible Preferred Stock Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]
Class of Warrant or Right [Line Items]
Warrants or rights measurement input	0.07
Series C1 Redeemable Convertible Preferred Stock Warrants [Member] | One Time Warrant Special Exercise Offer [Member]
Class of Warrant or Right [Line Items]
Class of warrants or rights exercise price per unit | $ / shares					$ 0.11
Proceeds from the exercise of warrants					$ 10,329
Class of warrants or rights issued during the period units | shares					93,897

Mezzanine Equity And Stockhol_5

Mezzanine Equity And Stockholders' Deficit - Schedule of Series B preferred stock warrants (Detail) - Series B Redeemable Convertible Preferred Stock Warrants [Member] - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Class of Warrant or Right [Line Items]
Beginning Outstanding and exercisable (Number of Warrants)	821,253	1,704,789
Warrants exercised		(883,536)
Ending Outstanding and exercisable (Number of Warrants)	821,253	821,253	1,704,789
Beginning Outstanding and exercisable (Weighted Average Exercise Price)	$ 0.22	$ 0.22
Warrants exercised		0.11
Ending Outstanding and exercisable (Weighted Average Exercise Price)	$ 0.22	$ 0.22	$ 0.22
Weighted Average Remaining Contractual Life in Years	3 years 11 months 1 day	4 years 1 month 28 days	5 years 25 days

Mezzanine Equity And Stockhol_6

Mezzanine Equity And Stockholders' Deficit - Schedule of Series C-1 preferred stock warrants (Detail) - Series C One Redeemable Convertible Preferred Stock Warrants [Member] - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Class of Warrant or Right [Line Items]
Beginning Outstanding and exercisable (Number of Warrants)	2,936,933
Warrants issued		3,030,830
Warrants exercised		(93,897)
Ending Outstanding and exercisable (Number of Warrants)	2,936,933	2,936,933
Beginning Outstanding and exercisable (Weighted Average Exercise Price)	$ 0.16
Warrants issued		$ 0.16
Warrants exercised		0.11
Ending Outstanding and exercisable (Weighted Average Exercise Price)	$ 0.16	$ 0.16
Weighted Average Remaining Contractual Life in Years	9 years 5 months 26 days	9 years 8 months 23 days

Mezzanine Equity And Stockhol_7

Mezzanine Equity And Stockholders' Deficit - Schedule of the option activity (Detail) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Temporary Equity And Permanent Equity [Abstract]
Beginning (Number of Options)	36,320,980	34,990,469
Granted	1,250,000	4,350,000
Exercised		(9,075)
Expired/Cancelled	(200,000)	(3,010,414)
Ending (Number of Options)	37,370,980	36,320,980	34,990,469
Vested/Exercisable	16,163,949	14,578,490
Beginning (Weighted Average Exercise Price)	$ 0.13	$ 0.13
Granted	0.16	0.15
Exercised		0.14
Expired/Cancelled	0.11	0.13
Ending (Weighted Average Exercise Price)	0.13	0.13	$ 0.13
Vested/Exercisable	$ 0.12	$ 0.12
Weighted Average Remaining Life in Years	7 years 10 months 28 days	8 years 25 days	8 years 11 months 1 day
Vested/Exercisable	6 years 10 months 17 days	6 years 10 months 6 days
Beginning (Aggregate Intrinsic Value)	$ 1,083,492	$ 106,429
Ending (Aggregate Intrinsic Value)	1,073,492	1,083,492	$ 106,429
Vested/Exercisable	$ 569,604	$ 527,441

Mezzanine Equity And Stockhol_8

Mezzanine Equity And Stockholders' Deficit - Schedule of weighted average fair value of the options granted (Detail) - Share-Based Payment Arrangement, Option [Member]	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of expected volatility (Minimum)		76.30%
Range of expected volatility (Maximum)		82.40%
Expected term of option	6 years	6 years	6 years
Range of risk-free interest rate (Minimum)	3.55%	1.82%	0.74%
Range of risk-free interest rate (Maximum)	3.75%	3.04%	1.38%
Range of expected volatility	76.30%		82.40%

Income Taxes - Schedule of Inco

Income Taxes - Schedule of Income Tax Provision (Detail) - USD ($)	3 Months Ended		11 Months Ended	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Federal
Change in valuation allowance				$ 2,323,000	$ 1,481,000
Income tax provisions	$ 0	$ 0		0	$ 0
Alpha Healthcare Acquisition Corp. III [Member]
Federal
Current			$ 0	391,198
Deferred			(96,461)	(265,998)
Change in valuation allowance			96,461	265,998
Income tax provisions	$ 343,328	$ 0	$ 0	$ 391,198

Income Taxes - Schedule of Net

Income Taxes - Schedule of Net Deferred Tax Assets (Detail) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Deferred tax asset
Net operating loss carryforward	$ 7,642,000	$ 5,585,000
Accrued interest	747,000	543,000
Federal research and development tax credits	113,000	568,000
Amortization of research expense	585,000	0
Right of use asset	29,000	0
Non-qualified deferred compensation	263,000	132,000
Accrued compensation	271,000	142,000
Change in fair value of derivative liabilities	275,000	632,000
Total deferred tax assets	9,925,000	7,602,000
Valuation allowance	(9,925,000)	(7,602,000)
Net deferred income tax assets	0	0
Alpha Healthcare Acquisition Corp. III [Member]
Deferred tax asset
Net operating loss carryforward	0	33,531
Startup/Organization expenses	362,459	62,930
Total deferred tax assets	362,459	96,461
Valuation allowance	(362,459)	(96,461)
Net deferred income tax assets	$ 0	$ 0

Income Taxes - Schedule of Reco

Income Taxes - Schedule of Reconciliation of the Federal Income Tax Rate To The Company's Effective Tax Rate (Detail)	3 Months Ended		11 Months Ended	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Income Taxes [Line Items]
Statutory federal income tax rate				21%	21%
State taxes, net of federal tax benefit				7.90%	7.90%
Stock based compensation				(0.40%)	(1.10%)
Gain on loan forgiveness				(2.50%)	1.40%
Net operating loss true-up				2.60%
R&D expenses, net				0%	(0.60%)
R & D Credit				0.20%	2.20%
R & D True Up				(6.60%)	(1.90%)
Other permanent differences				(0.20%)	0%
Stock Compensation True up				0%	4.90%
Valuation allowance				(22.00%)	(33.80%)
Effective rate				0%	0%
Alpha Healthcare Acquisition Corp. III [Member]
Income Taxes [Line Items]
Statutory federal income tax rate	37.30%	0%	21%	21%
Change in fair value of overallotment liability			8.30%	0%
Effective tax rate			0%	65%
Valuation allowance			(29.30%)	44%
Effective rate	37.30%	0%	0%	65%

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended		11 Months Ended	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Income Tax Expense	$ 0	$ 0		$ 0	$ 0
Change in valuation allowance				2,323,000	1,481,000
Unrecognized tax benefits	0		$ 0	0	0
Unrecognized tax benefits income tax penalties and interest accrued	0		0	$ 0	$ 0
Effective Income Tax Rate Reconciliation, Percent				0%	0%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent				21%	21%
Tax Year 2028 [Member]
Net operating loss carryovers				$ 7,000,000
Operating loss carryforwards, limitations on use				operating loss carryforwards, which expire after twenty years and begin to expire starting in 2028
Non Expirable [Member]
Net operating loss carryovers				$ 18,900,000
Tax Year 2022 [Member] | Research Tax Credit Carryforward [Member]
Tax credit carryforward, amount				113,000
Alpha Healthcare Acquisition Corp. III [Member]
Income Tax Expense	$ 343,328	$ 0	0	391,198
Change in valuation allowance			96,461	265,998
Unrecognized tax benefits			0	0	$ 0
Unrecognized tax benefits income tax penalties and interest accrued			$ 0	$ 0	0
Effective Income Tax Rate Reconciliation, Percent	37.30%	0%	0%	65%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	37.30%	0%	21%	21%
U.S. federal and state [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21%	21%
Domestic Tax Authority [Member]
Net operating loss carryovers				$ 25,700,000
Net operating loss recognized during the year				5,400,000
Domestic Tax Authority [Member] | Research Tax Credit Carryforward [Member]
Tax credit carryforward, amount				$ 13,000
Tax credit carryforward, limitations on use				federal research and development credit carryovers, which expire after twenty years and begin to expire starting in 2042
Domestic Tax Authority [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Net operating loss carryovers			$ 159,673	$ 0	$ 159,673
State and Local Jurisdiction [Member]
Net operating loss carryovers				29,900,000
Net operating loss recognized during the year				$ 6,300,000

Stock-based Compensation - Addi

Stock-based Compensation - Additional Information (Detail) - Alpha Healthcare Acquisition Corp. III [Member] - USD ($)		3 Months Ended		11 Months Ended	12 Months Ended
	Jul. 27, 2021	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2022
Disclosure Of Compensation Related Costs Share Based Payments [Line Items]
Share based compensation		$ 0	$ 0	$ 0
Fair value of founder shares on the grant date		$ 5.26			$ 5.26
Number of awards granted					0
Number of awards exercised					0
Number of awards cancelled					0
Three Independent Director Nominees [Member] | Common Class B [Member] | Sponsor [Member]
Disclosure Of Compensation Related Costs Share Based Payments [Line Items]
Stock Issued During Period, Shares, New Issues	25,000
Founder Shares [Member]
Disclosure Of Compensation Related Costs Share Based Payments [Line Items]
Founder shares non vested shares					75,000
Founder shares non vested grant date fair value		$ 394,000			$ 394,000

Related Party Transactions - Sc

Related Party Transactions - Schedule of Related Party Transactions (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Mar. 31, 2023
Board [Member]
Related Party Transaction [Line Items]
Preferred stock, Dollars	$ 19,924		$ 38,036
Board [Member] | Series 1 Convertible Notes [Member]
Related Party Transaction [Line Items]
Interest Expense	46,641	$ 64,000
Debt instrument, face amount		800,000
Accrued Interest		202,740
Related Party [Member]
Related Party Transaction [Line Items]
Preferred stock, Dollars	22,378		42,721
Related Party [Member] | Series 1 Convertible Notes [Member]
Related Party Transaction [Line Items]
Interest Expense	52,471	72,000
Debt instrument, face amount		900,000
Accrued Interest		226,170
Immediately Family Member 1 [Member]
Related Party Transaction [Line Items]
Preferred stock, Dollars	1,234		2,355
Immediately Family Member 1 [Member] | Series 1 Convertible Notes [Member]
Related Party Transaction [Line Items]
Interest Expense	2,915	4,000
Debt instrument, face amount		50,000
Accrued Interest		12,066
Immediate Family Member 2 [Member]
Related Party Transaction [Line Items]
Preferred stock, Dollars	1,220		2,330
Immediate Family Member 2 [Member] | Series 1 Convertible Notes [Member]
Related Party Transaction [Line Items]
Interest Expense	2,915	4,000
Debt instrument, face amount		50,000
Accrued Interest		11,364
Series A Preferred Stock [Member] | Board [Member]
Related Party Transaction [Line Items]
Preferred stock, Dollars	$ 877,054	$ 877,054	$ 877,054
Shares	4,222,223	4,222,223	4,222,223
Series A Preferred Stock [Member] | Related Party [Member]
Related Party Transaction [Line Items]
Preferred stock, Dollars	$ 1,555,748	$ 1,490,637	$ 1,570,945
Dividends Earned To Date, Dollars	$ 678,694	$ 613,583	693,891
Shares	4,222,223	4,222,223
Series B Preferred Stock [Member] | Board [Member]
Related Party Transaction [Line Items]
Preferred stock, Dollars	$ 887,049	$ 857,089	$ 887,049
Shares	5,094,537	4,822,181	5,094,537
Series B Preferred Stock [Member] | Related Party [Member]
Related Party Transaction [Line Items]
Preferred stock, Dollars	$ 990,293	$ 960,333	$ 990,293
Shares	5,875,504	5,603,148	5,875,504
Series B Preferred Stock [Member] | Immediately Family Member 1 [Member]
Related Party Transaction [Line Items]
Preferred stock, Dollars	$ 103,244	$ 103,244	$ 103,244
Shares	780,967	780,967	780,967
Series C One Preferred Stock [Member] | Related Party [Member]
Related Party Transaction [Line Items]
Preferred stock, Dollars	$ 50,010		$ 50,873
Dividends Earned To Date, Dollars	$ 10		873
Shares	234,742
Series C One Preferred Stock [Member] | Immediately Family Member 1 [Member]
Related Party Transaction [Line Items]
Preferred stock, Dollars	$ 50,000		$ 50,000
Shares	234,742		234,742
Series C Two Preferred Stock [Member] | Board [Member]
Related Party Transaction [Line Items]
Preferred stock, Dollars	$ 1,049,381		$ 1,049,381
Shares	6,129,561		6,129,561
Series C Two Preferred Stock [Member] | Related Party [Member]
Related Party Transaction [Line Items]
Preferred stock, Dollars	$ 1,178,641		$ 1,178,641
Shares	6,884,585		6,884,585
Series C Two Preferred Stock [Member] | Immediately Family Member 1 [Member]
Related Party Transaction [Line Items]
Preferred stock, Dollars	$ 64,981		$ 64,981
Shares	379,560		379,560
Series C Two Preferred Stock [Member] | Immediate Family Member 2 [Member]
Related Party Transaction [Line Items]
Preferred stock, Dollars	$ 64,279		$ 64,279
Shares	375,464		375,464

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($)							3 Months Ended		11 Months Ended	12 Months Ended
	Aug. 03, 2021	Jul. 29, 2021	Jul. 27, 2021	Jul. 26, 2021	Jan. 25, 2021	Jan. 21, 2021	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Sep. 30, 2022	Jun. 30, 2021	Mar. 01, 2021
Common stock par or stated value per share							$ 0.001		$ 0.001	$ 0.001	$ 0.001		$ 0.001
Stock Issued During Period, Value, Issued for Services								$ 26,477		$ 26,477	$ 3,194
Common stock shares outstanding							14,531,511		36,918,882	14,531,511	36,918,882
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period										9,075
Other liabilities							$ 47,171		$ 24,989	$ 27,639	$ 24,989
Debt conversion, converted instrument, amount										$ 15,665,171
Number of share options granted during the period							1,250,000			4,350,000
Alpha Healthcare Acquisition Corp. III [Member]
Stock Issued During Period, Value, Issued for Services									$ 25,000
Shares Issued, Price Per Share							$ 10			$ 10				$ 10
Shares Issued, Shares, Share-based Payment Arrangement, Forfeited									451,474
Other liabilities current							$ 71,024		$ 2,275	$ 31,979	2,275
Share-based payment arrangement, expense							0	0	0
Founder Shares [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Common Stock, Shares Subscribed but Unissued						3,593,750
Common stock par or stated value per share						$ 0.0001
Stock Issued During Period, Value, Issued for Services					$ 25,000	$ 25,000
Shares Issued, Price Per Share					$ 0.00696
Stock Issued During Period, Shares, Issued for Services					3,593,750
Working Capital Loan [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Debt Instrument, Convertible, Warrants issued							$ 1,500,000			$ 1,500,000
Warrants issued price per warrant							$ 1.5			$ 1.5
Administrative Service [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Administrative fees							$ 30,000	0
Sponsor [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Administrative fees							$ 30,000	30,000	51,000	$ 120,000
Sponsor [Member] | Darlene DeRemer [Member] | Founder Shares [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Stock shares issued during the period shares			25,000
Sponsor [Member] | Eugene Podsiadlo [Member] | Founder Shares [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Stock shares issued during the period shares			25,000
Sponsor [Member] | William Woodward [Member] | Founder Shares [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Stock shares issued during the period shares			25,000
Sponsor [Member] | Private Placement Warrants [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Class of warrants and rights issued during the period							455,000			455,000
Proceeds from Issuance of Private Placement							$ 4,550,000			$ 4,550,000
Immediately Family Member 1 [Member] | Preferred Series C1 Warrants [Member]
Class of warrant or right issued during the period										117,371
Fair value of warrants issued										$ 13,099
Related Party [Member] | Conversion of Debt Principal to Preferred Series C2 [Member]
Debt conversion, original debt, amount										$ 900,000
Debt conversion, converted instrument, shares issued										5,257,009
Debt conversion, converted instrument, amount										$ 1,119,743
Related Party [Member] | Conversion of Debt Accrued Interest to Preferred Series C2 [Member]
Debt conversion, original debt, amount										$ 278,641
Debt conversion, converted instrument, shares issued										1,627,576
Debt conversion, converted instrument, amount										$ 346,674
Related Party [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Other liabilities current							71,024		2,275	31,979	2,275
Selling, general and administrative expense							11,024			1,979
Related Party [Member] | Office Space Administrative And Support Services [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Operating costs and expenses							10,000			10,000
Related Party [Member] | Working Capital Loan [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Other liabilities current									0	0	0
Related Party [Member] | Administrative Service [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Other liabilities							60,000		$ 0	30,000	0
Immediate Family Member 2 [Member]
Number of share options granted during the period												148,854
Share based compensation arrangement by share based payment award, options, granted in period, fair value												$ 12,925
Share-based payment arrangement, expense							$ 796	$ 796		$ 3,229	$ 3,229
Over-Allotment Option [Member] | Founder Shares [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Common Stock forfeiture provisions lapsed	111,026
Shares Issued, Shares, Share-based Payment Arrangement, Forfeited	451,464
Overallotment option vesting period	45 days
Over-Allotment Option [Member] | Private Placement Warrants [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Class of warrants and rights issued during the period	8,882
Proceeds from Issuance of Private Placement	$ 88,820
IPO [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Shares Issued, Price Per Share		$ 10
Underwriting Agreement [Member] | Founder Shares [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Stock shares issued during the period shares	2,250,000
Underwriting Agreement [Member] | Over-Allotment Option [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	444,103
Stock shares issued during the period shares				2,250,000
Forward Purchase Agreement [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Option granted to direct anchor investors to subscribe to agreement as percentage of aggregate securities sold in one or multiple private placements							60%			60%
Option granted to direct anchor investors to subscribe to agreement percentage of as aggregate securities sold in one or multiple private placements per each direct anchor investor							10%			10%
Common Class A [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Common stock par or stated value per share							$ 0.0001			$ 0.0001					$ 0.0001
Common stock shares outstanding							463,882			463,882
Stock shares issued during the period shares		15,000,000
Common Class A [Member] | Sponsor [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Share price							$ 12			$ 12
Number of trading days for determining the share price							20 days			20 days
Number of consecutive trading days for determining the share price							30 days			30 days
Waiting period after which the share trading days are considered							150 days			150 days
Common Class A [Member] | IPO [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Shares Issued, Price Per Share		$ 10
Stock shares issued during the period shares		15,000,000
Overallotment option vesting period		45 days
Common Class B [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Common stock par or stated value per share							$ 0.0001			$ 0.0001					$ 0.0001
Stock Issued During Period, Shares, Issued for Services										25,000
Common stock shares outstanding							3,861,026		4,312,500	3,861,026	4,312,500				4,312,500
Shares Issued, Shares, Share-based Payment Arrangement, Forfeited									451,474
NonRisk Incentive Private Shares [Member] | Sponsor [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Sale of Stock, Consideration Received on Transaction		$ 1,186,448
NonRisk Incentive Private Shares [Member] | IPO [Member] | Sponsor [Member] | Founder Shares [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Stock shares issued during the period shares		225,000
Sale of Stock, Consideration Received on Transaction		$ 1,186,448
Sale of Stock, Price Per Share		$ 5.27
Risk Incentive Private Shares [Member] | IPO [Member] | Sponsor [Member] | Founder Shares [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Stock shares issued during the period shares		600,900
Sale of Stock, Percentage of Ownership before Transaction		9.90%
Preferred Series C1 [Member] | Immediately Family Member 1 [Member]
Temporary equity stock issued during period shares new issues										234,742
Temporary equity stock issued during period value new issues										$ 50,000

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - USD ($)				3 Months Ended	12 Months Ended
	May 01, 2023	Apr. 01, 2023	Jan. 01, 2023	Mar. 31, 2023	Dec. 31, 2022	Jan. 04, 2023	Sep. 30, 2022	Dec. 31, 2021
Subsequent Event [Line Items]
Common stock, par or stated value per share				$ 0.001	$ 0.001		$ 0.001	$ 0.001
Number of share options granted during the period				1,250,000	4,350,000
Weighted average per share				$ 0.16	$ 0.15
Subsequent Event [Member]
Subsequent Event [Line Items]
Number of share options granted during the period			950,000
Weighted average per share			$ 0.16
Subsequent Event [Member] | Three Zero Coupon Promissory Notes [Member]
Subsequent Event [Line Items]
Common stock, par or stated value per share				$ 0.001
Debt instrument, face amount				$ 250,000
Debt instrument, term				12 months
Debt conversion, converted instrument, warrants or options issued				78,431
Class of warrants or rights exercise price per unit				$ 0.88
Subsequent Event [Member] | Four Zero Coupon Promissory Notes [Member]
Subsequent Event [Line Items]
Debt instrument, face amount		$ 283,500
Debt instrument, term		12 months
Debt conversion, converted instrument, warrants or options issued		88,941
Class of warrants or rights exercise price per unit		$ 0.88
Subsequent Event [Member] | Business Combination Agreement [Member]
Subsequent Event [Line Items]
Common stock, par or stated value per share						$ 0.0001
Entity equity value						$ 150,000,000
Sandstone Asset Management [Member] | Subsequent Event [Member] | Alpha Healthcare Acquisition Corp. III [Member]
Subsequent Event [Line Items]
Stock issued during period, shares, new issues	1,020,520
Class of warrant or right issued during the period	285,875
Amount of funds retained after business combination	$ 10,400,000